Use of immunomodulating targeted polynucleotide conjugates for use with immune honing agent

Targeted polyneucleotide conjugates address the limitations of immunostimulating polynucleotides by enhancing specific immune responses and reducing toxicity, improving treatment outcomes for proliferative and infectious diseases.

WO2024238558A1PCT designated stage expired Publication Date: 2024-11-21TALLAC THERAPEUTICS INC

Patent Information

Application Number
PCT/US2024/029295
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-01
Filing Date
2024-05-14
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current immunostimulating polynucleotides, such as CpG ODNs, face challenges due to susceptibility to degradation in serum and uneven tissue distribution, leading to off-target activity and local toxicity, which limits their therapeutic potential in treating proliferative and infectious diseases.

Method used

Development of targeted polyneucleotide conjugates comprising a targeting moiety, like antibodies, covalently linked to immunomodulating oligonucleotides and an immune-honing agent, to specifically bind to immune cells, enhancing antigen-specific responses and immune cell activation.

Benefits of technology

The conjugate approach results in higher antigen-specific antibody titers, longer-lasting immune responses, and improved immune cell activation, reducing off-target effects and enhancing therapeutic efficacy against diseases like cancer and infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000007_0001
    Figure IMGF000007_0001
  • Figure IMGF000008_0001
    Figure IMGF000008_0001
  • Figure IMGF000008_0002
    Figure IMGF000008_0002
Patent Text Reader

Abstract

Provided are methods of treating, delaying progression, or preventing a proliferative disease or an infectious disease in an individual, comprising administering to the individual an effective amount of a conjugate comprising an antibody or antigen-binding fragment thereof that binds to an antigen expressed on the surface of an immune cell such as an NK cell or B-cell (e.g., CD22) and one or more immunomodulating oligonucleotides, and an immune honing agent (IHA).
Need to check novelty before this filing date? Find Prior Art

Description

USE OF IMMUNOMODULATING TARGETED POLYNUCLEOTIDE CONJUGATES FOR USE WITH IMMUNE HONING AGENT CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of United States provisional patent application serial No. 63 / 502,384, filed May 15, 2023, United States provisional patent application serial No. 63 / 504,697, filed May 26, 2023, United States provisional patent application serial No. 63 / 588,969, filed October 9, 2023, and United States provisional patent application serial No.63 / 560,570, filed March 1, 2024, the contents of each of which are hereby incorporated by reference herein in their entirety for all purposes. REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The content of the electronic sequence listing (186492001140seqlist.xml; Size: 386,796 bytes; and Date of Creation: May 7, 2024) is herein incorporated by reference in its entirety. FIELD OF INVENTION

[0003] The present disclosure relates generally to methods of treating, delaying progression, or preventing a proliferative disease or an infectious disease in an individual. BACKGROUND

[0004] Pathogen-associated molecular patterns (PAMPs) are molecules associated with various pathogens and are recognized by toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) activating innate immune responses. The ability of PAMPs to recruit immune system in the absence of pathogens provides a strategy for treating a variety of diseases involving cell destruction (e.g., anticancer therapy) through the use of innate immune system response. One class of PAMPs that has been investigated for a variety of therapeutic applications is immunostimulating polynucleotides, such as unmethylated cytosine-guanine dinucleotide (CpG)-containing oligodeoxynucleotides (CpG ODNs) (e.g., agatolimod). It is thought that CpG ODNs mediate TLR9 dimerization in immune cells (e.g., B cells, monocytes and plasmacytoid dendritic cells (pDCs)) to upregulate cytokines (e.g., type I interferon and interleukins), thereby activating natural killer cells.

[0005] Toll-like receptor 9 (TLR9), also designated as CD289, is an important receptor expressed in immune system cells including dendritic cells (DCs), B lymphocytes, macrophages, natural killer cells, and other antigen presenting cells. TLR9 activation triggers intracellular signaling cascades, leading to activation, maturation, proliferation and cytokine productions in these immune cells, thus bridges the innate and adaptive immunity. Martinez- Campos et al., Viral Immunol. 2016, 30, 98-105; Notley et al., Sci. Rep. 2017, 7, 42204. Natural TLR-9 agonists include unmethylated cytosine-guanine dinucleotide (CpG)-containing oligodeoxynucleotides (CpG ODNs).^^

[0006] CpG ODNs may include, for example, oligodeoxynucleotides comprising poly-G tails with phosphorothioate backbones at 3'- and 5'-termini and a central palindromic sequence including a phosphate backbone and a CpG within its central palindrome sequence, or oligodeoxynucleotides having a fully phosphorothioate backbone, and a sequence at the 5' end for TLR9 activation, or oligodeoxynucleotides having a fully phosphorothioate backbone with a 3'-end sequence enabling formation of a duplex. However, CpG ODNs are often susceptible to degradation in serum and thus pharmacokinetics of CpG ODNs may be one of the limiting factors in their development as therapeutics. Also, CpG ODNs often exhibit uneven tissue distribution in vivo, with primary sites of accumulation being in liver, kidney, and spleen. Such distribution can elicit off-target activity and local toxicity associated with PAMPs. BRIEF SUMMARY

[0007] Provided herein are methods of treatment comprising administering to a subject (a) an effective amount of a conjugate comprising a targeting moiety that is capable of binding to the surface of an immune cell covalently linked to one or more immunomodulating oligonucleotides, and (b) an immune-honing agent (IHA). In some embodiments, the immune cell is a lymphocyte. In some embodiments, the lymphocyte is a B cell or an NK cell. In some embodiments, the immune cell is a myeloid cell. In some embodiments, the myeloid cell is a monocyte, a dendritic cell, or a macrophage. In some embodiments, the myeloid cell is a dendritic cell. In some embodiments, the targeting moiety comprises an antibody or an antigen binding fragment thereof.

[0008] In some embodiments, the IHA comprises an antigen or a nucleic acid encoding an antigen. In some embodiments, the IHA comprises nucleic acid and the nucleic acid comprises DNA, RNA or a combination thereof. In some embodiments, the IHA comprises a peptide or a cell. In some embodiments, the IHA is derived from a mammalian antigen. In someembodiments, the IHA induces an immune response against a tumor cell or a cell in the tumor microenvironment. In some embodiments, the IHA is derived from a tumor cell or a cell in the tumor microenvironment from the subject. In some embodiments, the IHA is a tumor associated antigen. In some embodiments, the IHA is derived from a tumor cell line. In some embodiments, the IHA comprises an amino acid or nucleic acid sequence derived computationally. In some embodiments, the IHA is derived from a pathogen. In some embodiments, the pathogen is a virus, a bacterium, a protozoon, a worm, a prion or a fungus. In some embodiments, the pathogen is a virus and the IHA comprises a viral protein, a viral particle or a portion thereof. In some embodiments, the pathogen is a virus and the IHA comprises a nucleic acid encoding a viral protein, a viral particle or a portion thereof. In some embodiments, the pathogen is a bacterium and the IHA comprises a bacterial protein or a portion thereof. In some embodiments, the pathogen is a bacterium and the IHA comprises a nucleic acid encoding a bacterial protein or a portion thereof. In some embodiments, the pathogen agent is a fungus and the IHA comprises a fungal protein or a portion thereof. In some embodiments, the pathogen is a fungus and the IHA comprises a nucleic acid encoding a fungal protein or a portion thereof. In some embodiments, the IHA comprises a metabolite or derivative thereof. In some embodiments, the IHA comprises a virus, bacterium or fungal cell. In some embodiments, the virus, bacterial cell, or fungal cell is inactivated, attenuated or replication deficient.

[0009] In some embodiments, the treatment prevents a disease, or ameliorates the severity of a disease, in the subject. In some embodiments, treatment delays or prevents the progression of a disease in the subject. In some embodiments, treatment prevents recurrence of a disease in the subject. In some embodiments, treatment delays recurrence of a disease in the subject. In some embodiments, the disease is an infectious disease. In some embodiments, the infectious disease is caused by a virus, a bacterium, a protozoon, a worm, a prion, a parasite, or a fungus. In some embodiments, the disease is a cancer. In some embodiments, the cancer is selected from the group consisting of head and neck squamous cell carcinoma (HNSCC), non-small- cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), gastric cancer, hepatocellular carcinoma (HCC), esophageal cancer, cervical cancer, cervical squamous cell carcinoma, Merkle cell carcinoma, endometrial cancer, ovarian cancer, pancreatic cancer, melanoma, cutaneous melanoma, sarcoma, colorectal cancer, breast cancer, small cell lung cancer (SCLC), cutaneous squamous cell carcinoma, and urothelial carcinoma, leukemia, lymphoma, myeloma, acute lymphoblastic leukemia (ALL), hairy cell leukemia, and diffuse large B celllymphoma (DLBCL). In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a liquid tumor. In some embodiments, the IHA comprises an allergen or portion thereof. In some embodiments, the treatment induces tolerance to the allergen. In some embodiments, the treatment reduces or ameliorates a symptom or severity of an allergic reaction of the subject.

[0010] In some embodiments of any of the embodiments, the method further comprises a step of administering a therapeutic agent to the subject. In some embodiments of any of the embodiments, the IHA is administered concurrently with an adjuvant. In some embodiments, the method further comprises a step of administering a therapeutic agent to the subject and the IHA is administered concurrently with an adjuvant. In some embodiments, the adjuvant is selected from the group consisting of Aluminum (Alum), AS01B (MPL), AS04 (MPL), MatrixMTM, and MF59. In some embodiments, the conjugate and the IHA are administered concurrently. In some embodiments, the conjugate and the IHA are administered as a single composition. In some embodiments, the conjugate and the IHA are administered separately. In some embodiments, the conjugate is administered prior to the IHA. In some embodiments, the IHA is administered prior to the conjugate. In some embodiments, the conjugate and the IHA are administered multiple times. In some embodiments, the conjugate and the IHA are administered prior to the onset or diagnosis of disease in the subject. In some embodiments, the conjugate and the IHA are administered subsequent to the onset or diagnosis of disease in the subject. In some embodiments, the IHA is re-administered to the subject subsequent to the administration of the conjugate and the IHA.

[0011] In some embodiments, administration of the conjugate and the IHA produces a higher antigen-specific antibody titer as compared to administration of the IHA without the conjugate. In some embodiments, the duration of an antibody response following administration of the conjugate and the IHA is longer as compared to the duration of an antibody response following administration of the IHA without the conjugate. In some embodiments, the B-cell response is improved following administration of the conjugate and the IHA as compared to the B-cell response following administration of the IHA without the conjugate. In some embodiments, the B-cell response is a memory B-cell response. In some embodiments, administration of the conjugate and the IHA produces a higher antigen-specific antibody titer as compared to administration of the IHA and an unconjugated immunomodulating oligonucleotide. In some embodiments, the duration of an antibody response following administration of the conjugate and the IHA is longer as compared to theduration of an antibody response following administration of the IHA and an unconjugated immunomodulating oligonucleotide. In some embodiments, the B-cell response is improved following administration of the conjugate and the IHA as compared to the B-cell response following administration of the IHA and an unconjugated immunomodulating oligonucleotide. In some embodiments, the B-cell response is a memory B-cell response. In some embodiments, the antibody response is an IgG response. In some embodiments, the antibody response is an IgM response. In some embodiments, the antibody titer is an IgG titer. In some embodiments, the antibody titer is an IgM titer. In some embodiments, the duration or magnitude of an immune cell response following administration of the conjugate and the IHA is increased as compared to the duration or magnitude of an immune cell response following administration of the IHA and an unconjugated immunomodulating oligonucleotide. In some embodiments, the duration or magnitude of an immune cell response following administration of the conjugate and the IHA is increased as compared to the duration or magnitude of an immune cell response following administration of the IHA without the conjugate. In some embodiments, the immune cell response is mediated by an immune cell selected from the group consisting of T-cell, an NK cell, a dendritic cell, a myeloid cell and any combination thereof. In some embodiments, the immune cell response comprises at least one of activation, maturation, proliferation and cytokine production. In some embodiments, the immune cell response comprises at least one of antigen cross-presentation, up-regulation of a co-stimulatory molecule, enhanced production of a pro-inflammatory dendritic cell-derived cytokine, and an increase in interferon ^. In some embodiments, the co-stimulatory molecule is CD40 or CD86. In some embodiments, the pro-inflammatory dendritic cell-derived cytokine is IFN^2 or IL- 12. In some embodiments, a T-cell response is improved following administration of the conjugate and the IHA as compared to a T-cell response following administration of the IHA without the conjugate. In some embodiments, the T-cell response comprises an activation or priming of T-cells. In some embodiments, administration of the conjugate and the IHA to an elderly subject provides a rejuvenated immune response in the elderly subject. In some embodiments, the immune response is improved following administration of the conjugate and the IHA in an elderly subject as compared to the immune response following administration of the IHA without the conjugate. In some embodiments, the elderly subject is at least 65 years old. In some embodiments, administration of the conjugate and the IHA provides a robust immune response in a subject with a compromised or aged immune system. In some embodiments, the immune response is improved following administration of the conjugate and the IHA in a subject with a compromised or aged immune system as compared to the immuneresponse following administration of the IHA without the conjugate. In some embodiments, the methods further comprise administering an adjuvant.

[0012] In some embodiments, the subject is a mammal. In some embodiments, the subject is human.

[0013] In some embodiments, the antibody or the antigen-binding fragment thereof is linked to one or more Q-tag peptides (Q) comprising at least one glutamine residue, and wherein each immunomodulating oligonucleotide (P) is linked to a Q-tag peptide via an amide bond with the glutamine residue of the Q-tag peptide and a linker (L) as shown in Formula (A):wherein indicates the point of attachment of each Q to the antibody or antigen binding fragment thereof. In some embodiments, the Q tag peptide comprises: (a) a sequence selected from RPQGF (SEQ ID NO:47), RPQGFPP (SEQ ID NO:48), or RPQGFGPP (SEQ ID NO:49), (b) a peptide sequence comprising between 5 and 15 amino acid residues, (c) a Q-tag sequence naturally occurring within the antibody or antigen binding fragment, or (d) a sequence selected from the group consisting of SEQ ID NOs:39-55. In some embodiments, the Q-tag peptide is linked or fused to the C-terminus of the heavy chain(s) of the antibody. In some embodiments, the antibody comprises two antibody heavy chains and two antibody light chains, and wherein one Q-tag is attached to one or both light chain(s) of the antibody. In some embodiments, the Q-tag is within the Fc domain of the heavy chain(s) of the antibody. In some embodiments, the one or more immunomodulating oligonucleotides comprises one or more CpG sites. In some embodiments, the one or more immunomodulating oligonucleotides comprises at least 3 CpG sites. In some embodiments, the conjugate has a DAR of 1 or 2. In some embodiments, the one or more immunomodulating oligonucleotides comprises the structure of Formula I( ) wherein and ** indicate the points of attachment within the oligonucleotide, and whereinindicates the point of attachment to the linker L; each T1is independently O or S; each T2is S-;, wherein indicates the point of attachment to alinker and whereinindicates the point of attachment to the rest of the oligonucleotide; Z is O or S; U5’is –H or halogen; R5’is -H or methoxy; Rc1is -H or methoxy;Rg1, Rg2, Rg3, and Rg4are H; R3’is methoxy; R1is -(CH2)3-OH; R2is -H or methyl; and n is an integer from 0 to 2.

[0014] In some embodiments, the linker comprises a polyethylene glycol moiety or has a structure comprisingwherein m is an integer ranging from about 0 to about 50, and wherein † indicates the point of attachment to T3or P, and indicates the point of attachment to the rest of the conjugate. In some embodiments, Z is S. In some embodiments, Formula I comprises at least one pair of geminal T1and T2wherein T1is S and T2is S-. In some embodiments, each immunomodulating oligonucleotide independently comprises an oligonucleotide selected from Table 1:.

[0015] In some embodiments, the antibody or antigen binding fragment thereof is a monoclonal antibody or antigen binding fragment thereof. In some embodiments, the antigen binding fragment of the antibody is a Fab, F(ab’)2, Fab’-SH, Fv, scFv, single domain, single heavy chain, or single light chain antibody or antigen binding fragment thereof. In some embodiments, the antibody or antigen binding fragment thereof is a humanized, human, or chimeric antibody or antigen binding fragment thereof.

[0016] In some embodiments, the antibody or antigen binding fragment thereof comprises an Fc region. In some embodiments, the Fc region is a human Fc region selected from the group consisting of an IgG1 Fc region, an IgG2 Fc region, and an IgG4 Fc region. In some embodiments, the Fc region is a wild-type human IgG1, IgG2, or IgG4 Fc region.

[0017] In some embodiments, the conjugate induces activation of TLR9. In some embodiments, the antibody or antigen binding fragment of the conjugate binds to an antigen expressed on the surface of a B cell selected from the group consisting of B220 / CD45R, B7- 1 / CD80, B7-2 / CD86, BCMA / TNFRSF17, BLIMP1 / PRDM1, C1q R1 / CD93, CD117 / c-kit, CD11b / Integrin alpha M, CD19, CD1c / BDCA-1, CD1d, CD20, CD21 / CD35, CD22, CD23 / Fcepsilon RII, CD24, CD25 / IL-2 R alpha, CD27 / TNFRSF7, CD30, CD34, CD37, CD38, CD40 / TNFRSF5, CD1, CD2, CD5, CD9, CD11, CD17, CD18, CD43, CD69, CD70, CD72, CD78, CD79a (Ig^), CD79b (Ig^), CD80, CD83, CD86, CD93 (C1Rqp), CD137 / 4-1BB, CD138, CD252 / OX40L, CD267, CD268 / BAFF-R, CD279 / PD1, CD319, CXCR4, CXCR5, DEP-1 / CD148, EMMPRIN / CD147, FCRL3 / FcRH3, Flt-3 / Flk-2, HLA-DR, IgM, IL-10, IL-12 R beta 2, IL-12 / IL-35 p35, IL-21, IL-21 R, IL-27 R alpha / WSX-1 / TCCR, IL-27 / IL-35 EBI3 Subunit, IL-3 R alpha / CD123, IL-4 R alpha, IL-7 R alpha / CD127, IRF4, MHC class II (I-A / I- E), Neprilysin / CD10, Pax5 / BSAP, Sca-1 / Ly6, Siglec-2 / CD22, STAT1, STAT3, Syndecan- 1 / CD138, TACI / TNFRSF13B, TGF-beta, TIM-1 / KIM-1 / HAVCR, PDL-2, Pax-5, IgD, IgM, Notch 2, and TLR4. In some embodiments, the antigen expressed on the surface of a B cell is human CD22 (hCD22) or CD79b.

[0018] Further provided herein is a composition for treating, delaying progression, ameliorating or preventing a proliferative disease or an infectious disease in a subject comprising: (a) an effective amount of a conjugate comprising a targeting moiety that is capable of binding to the surface of an immune cell covalently linked to one or more immunomodulating oligonucleotides, and (b) an immune-honing agent (IHA). In some embodiments, the immune cell is a B cell. In some embodiments, the immune cell is a myeloid cell. In some embodiments, the myeloid cell is a monocyte, a dendritic cell, a macrophage, or an NK cell. In some embodiments, the myeloid cell is a dendritic cell. In some embodiments, the targeting agent is an antibody or an antigen binding fragment. In some embodiments, the antibody or antigen binding fragment of the conjugate binds to an antigen expressed on the surface of a B cell selected from the group consisting of B220 / CD45R, B7-1 / CD80, B7- 2 / CD86, BCMA / TNFRSF17, BLIMP1 / PRDM1, C1q R1 / CD93, CD117 / c-kit, CD11b / Integrin alpha M, CD19, CD1c / BDCA-1, CD1d, CD20, CD21 / CD35, CD22, CD23 / Fc epsilon RII, CD24, CD25 / IL-2 R alpha, CD27 / TNFRSF7, CD30, CD34, CD37, CD38, CD40 / TNFRSF5, CD1, CD2, CD5, CD9, CD11, CD17, CD18, CD43, CD69, CD70, CD72, CD78, CD79a (Ig^), CD79b (Ig^), CD80, CD83, CD86, CD93 (C1Rqp), CD137 / 4-1BB, CD138, CD252 / OX40L, CD267, CD268 / BAFF-R, CD279 / PD1, CD319, CXCR4, CXCR5, DEP-1 / CD148, EMMPRIN / CD147, FCRL3 / FcRH3, Flt-3 / Flk-2, HLA-DR, IgM, IL-10, IL-12 R beta 2, IL- 12 / IL-35 p35, IL-21, IL-21 R, IL-27 R alpha / WSX-1 / TCCR, IL-27 / IL-35 EBI3 Subunit, IL-3 R alpha / CD123, IL-4 R alpha, IL-7 R alpha / CD127, IRF4, MHC class II (I-A / I-E), Neprilysin / CD10, Pax5 / BSAP, Sca-1 / Ly6, Siglec-2 / CD22, STAT1, STAT3, Syndecan-1 / CD138, TACI / TNFRSF13B, TGF-beta, TIM-1 / KIM-1 / HAVCR, PDL-2, Pax-5, IgD, IgM, Notch 2, and TLR4.

[0019] In some embodiments, the antibody or antigen binding fragment of the conjugate binds to human CD22 (hCD22) or CD79b. In some embodiments, the antibody or antigen binding fragment of the conjugate binds to human SIRPα. In some embodiments, the antibody or the antigen-binding fragment thereof is linked to one or more Q-tag peptides (Q) comprising at least one glutamine residue, and wherein each immunomodulating oligonucleotide (P) is linked to a Q-tag peptide via an amide bond with the glutamine residue of the Q-tag peptide and a linker (L) as shown in Formula (A):wherein indicates the point of attachment of each Q to the antibody or antigen binding fragment thereof.

[0020] In some embodiments, the Q tag peptide comprises: (a) a sequence selected from RPQGF (SEQ ID NO:47), RPQGFPP (SEQ ID NO:48), or RPQGFGPP (SEQ ID NO:49), (b) a peptide sequence comprising between 5 and 15 amino acid residues, (c) a Q-tag sequence naturally occurring within the antibody or antigen binding fragment, or (d) a sequence selected from the group consisting of SEQ ID NOs:39-55. In some embodiments, the Q-tag peptide is linked or fused to the C-terminus of the heavy chain(s) of the antibody. In some embodiments, the antibody comprises two antibody heavy chains and two antibody light chains, and wherein one Q-tag is attached to one or both light chain(s) of the antibody. In some embodiments, the Q-tag is within the Fc domain of the heavy chain(s) of the antibody. In some embodiments, the one or more immunomodulating oligonucleotides comprises one or more CpG sites. In some embodiments, the one or more immunomodulating oligonucleotides comprises at least 3 CpG sites. In some embodiments, the conjugate has a DAR of 1 or 2.

[0021] In some embodiments, the one or more immunomodulating oligonucleotides comprises the structure of Formula Iwhereinandindicate the points of attachment within the oligonucleotide, and wherein† indicates the point of attachment to the linker L; each T1is independently O or S; each T2is S-;g p , wherein † indicates the point of attachment to a linker and wherein # indicates the point of attachment to the rest of the oligonucleotide; Z is O or S; U5’is –H or halogen; R5’is -H or methoxy; Rc1is -H or methoxy;Rg1, Rg2, Rg3, and Rg4are H; R3’is methoxy; R1is -(CH2)3-OH; R2is -H or methyl; and n is an integer from 0 to 2.

[0022] In some embodiments, the linker comprises a polyethylene glycol moiety or has a structure comprisingwherein m is an integer ranging from about 0 to about 50, and wherein † indicates the point of attachment to T3or P, and indicates the point of attachment to the rest of the conjugate

[0023] In some embodiments, Z is S. In some embodiments, Formula I comprises at least one pair of geminal T1and T2wherein T1is S and T2is S-. In some embodiments, each immunomodulating oligonucleotide independently comprises an oligonucleotide selected from Table 1:

[0024] In some embodiments, the antibody or antigen binding fragment thereof is a monoclonal antibody or antigen binding fragment thereof. In some embodiments, the antigen binding fragment of the antibody is a Fab, F(ab’)2, Fab’-SH, Fv, scFv, single domain, single heavy chain, or single light chain antibody or antigen binding fragment thereof. In some embodiments, the antibody or antigen binding fragment thereof is a humanized, human, or chimeric antibody or antigen binding fragment thereof. In some embodiments, the antibody or antigen binding fragment thereof comprises an Fc region. In some embodiments, the Fc region is a human Fc region selected from the group consisting of an IgG1 Fc region, an IgG2 Fc region, and an IgG4 Fc region. In some embodiments, the Fc region is a wild-type human IgG1, IgG2, or IgG4 Fc region. In some embodiments, the IHA comprises an antigen or a nucleic acid encoding an antigen. In some embodiments, the IHA comprises nucleic acid and the nucleic acid comprises DNA, RNA or a combination thereof. In some embodiments, the IHA comprises an amino acid or nucleic acid sequence derived computationally. In some embodiments, the IHA is derived from a mammalian antigen. In some embodiments, the IHA is derived from a tumor cell or a cell in the tumor microenvironment from the subject. In some embodiments, the IHA is a tumor associated antigen. In some embodiments, the IHA is derivedfrom a tumor cell line. In some embodiments, the IHA is derived from a pathogen. In some embodiments, the pathogen is a virus, a bacterium, a protozoon, a worm, a prion, a parasite, or a fungus. In some embodiments, the pathogen is a virus and the IHA comprises a viral protein, a viral particle or a portion thereof. In some embodiments, the pathogen is a virus and the IHA comprises a nucleic acid encoding a viral protein, a viral particle or a portion thereof. In some embodiments, the pathogen is a bacterium and the IHA comprises a bacterial protein or a portion thereof. In some embodiments, the pathogen is a bacterium and the IHA comprises a nucleic acid encoding a bacterial protein or a portion thereof. In some embodiments, the pathogen agent is a fungus and the IHA comprises a fungal protein or a portion thereof. In some embodiments, the pathogen is a fungus and the IHA comprises a nucleic acid encoding a fungal protein or a portion thereof. In some embodiments, the IHA comprises a metabolite or derivative thereof. In some embodiments, the IHA comprises a virus, bacterium or fungal cell. In some embodiments, the virus, bacterial cell, or fungal cell is inactivated, attenuated or replication deficient.

[0025] In some embodiments, the composition further comprises an adjuvant. In some embodiments, the adjuvant is selected from the group consisting of Aluminum (Alum), AS01B (MPL), AS04 (MPL), MatrixMTM, and MF59.

[0026] Further provided herein is the composition described in the preceding embodiments for use in the treatment of a disease, wherein the composition prevents or ameliorates the severity of the disease in the subject. BRIEF DESCRIPTION OF THE FIGURES

[0027] The present application can be understood by reference to the following description taken in conjunction with the accompanying figures.

[0028] FIG. 1 provides a schematic of the immunization and antigen challenge schedules described in Example 2.

[0029] FIG.2 provides results from experiments that were performed to assess the titer of antigen-specific IgG antibodies 14 days after mice were immunized with (a) Nectin-4 (N4) antigen and adjuvant (MPL), (b) N4 antigen, MPL, and CpG conjugated anti-CD22 antibody (CD22TRAAC), (c) N4, MPL, and unconjugated oligonucleotide (CpG), or (d) N4, MPL, and unconjugated anti-CD22 antibody (anti-CD22)

[0030] FIG.3 provides results from experiments that were performed to assess the titer of antigen-specific IgG antibodies 21 days after mice were immunized with (a) Nectin-4 (N4)antigen and MPL adjuvant (Adj), (b) N4, Adj, and CpG conjugated anti-CD22 antibody (CD22TRAAC), (c) N4, Adj, and unconjugated oligonucleotide (CpG), or (d) N4, Adj, and unconjugated anti-CD22 antibody (anti-CD22).

[0031] FIG.4 provides results from experiments that were performed to assess the titer of antigen-specific IgG antibodies 29 and 42 days after mice were immunized with (a) Nectin-4 (N4)antigen and MPL adjuvant (Adj), (b) N4, Adj, and CpG conjugated anti-CD22 antibody (CD22TRAAC), (c) N4, Adj, and unconjugated oligonucleotide (CpG), or (d) N4, Adj, and unconjugated anti-CD22 antibody (anti-CD22).

[0032] FIG.5 provides results from experiments that were performed to assess reciprocal EC50 titer of antigen-specific IgG antibodies on days 14, 21, 29, 42, 67 and 77 providing an overview of the IgG response for the entirety of the study. Groups shown are mice immunized with (a) N4 antigen and adjuvant (MPL); (b) N4, MPL, and CpG conjugated anti-CD22 antibody (CD22TRAAC); (c) N4, MPL, and unconjugated oligonucleotide (CpG); and (d) N4, MPL, and unconjugated anti-CD22 antibody (anti-CD22).

[0033] FIG.6 provides a schematic of the immunization schedule described in Example 3.

[0034] FIG.7 provides results from experiments that were performed to assess the titer of human Nectin-4-specific IgG antibodies 21 days after mice were immunized with (a) human Nectin-4 (hN4) only, (b) hN4 and CpG-conjugated anti-CD22 antibody (CD22TRAAC), (c) hN4 and CpG-conjugated anti-CD79b antibody (CD79bTRAAC), (d) hN4 and unconjugated oligonucleotide (CpG), (e) hN4 and unconjugated anti-CD79b antibody (anti-CD79b), (f) CpG-conjugated anti-CD22 antibody alone (CD22TRAAC) or (g) CpG-conjugated anti- CD79b antibody alone (CD79bTRAAC).

[0035] FIG.8 provides results from experiments that were performed to assess the titer of mouse Nectin-4-specific IgG antibodies 21 days after mice were immunized with (a) mouse Nectin-4 (mN4) only, (b) mN4 and CpG-conjugated anti-CD22 antibody (CD22TRAAC), (c) v mN4 and CpG-conjugated anti-CD79b antibody (CD79bTRAAC), (d) mN4 and unconjugated oligonucleotide (CpG), (e) mN4 and unconjugated anti-CD79b antibody (anti- CD79b), (f) CpG-conjugated anti-CD22 antibody alone (CD22TRAAC) or (g) CpG- conjugated anti-CD79b antibody alone (CD79bTRAAC).

[0036] FIG.9 provides results from experiments that were performed to assess IgG2a and IgG2b response 14 days after Balb / c (top panel) or FVB (bottom panel) mice were immunized with (a) human Nectin-4 (hNectin-4) and MPL adjuvant (Adj), (b) hNectin-4, Adj, and CpG-conjugated anti-CD22 antibody (CD22TRAAC), (c) hNectin-4, Adj, and unconjugated oligonucleotide (CpG), or (d) hNectin-4, and unconjugated anti-CD22 antibody (anti-CD22).

[0037] FIG.10 provides results from experiments that were performed to assess IgG2a and IgG2b response 21 days after Balb / c (top panel) or FVB (bottom panel) mice were immunized with (a) human Nectin-4 (hNectin-4) and MPL adjuvant (Adj), (b) hNectin-4, Adj, and CpG- conjugated anti-CD22 antibody (CD22TRAAC), (c) hNectin-4, Adj, and unconjugated oligonucleotide (CpG), or (d) hNectin-4, and unconjugated anti-CD22 antibody (anti-CD22).

[0038] FIG.11 provides results from experiments that were performed to assess IgG2a and IgG2b response 29 days after Balb / c mice were immunized with (a) human Nectin-4 (hNectin- 4) and MPL adjuvant (Adj), (b) hNectin-4, Adj, and CpG-conjugated anti-CD22 antibody (CD22TRAAC), (c) hNectin-4, Adj, and unconjugated oligonucleotide (CpG), or (d) hNectin- 4, and unconjugated anti-CD22 antibody (anti-CD22).

[0039] FIG.12 provides results from experiments that were performed to assess IgG2a and IgG2b response 42 days after Balb / c (top panel) or FVB (bottom panel) mice were immunized with (a) human Nectin-4 (hNectin-4) and MPL adjuvant (Adj), (b) hNectin-4, Adj, and CpG- conjugated anti-CD22 antibody (CD22TRAAC), (c) hNectin-4, Adj, and unconjugated oligonucleotide (CpG), or (d) hNectin-4, and unconjugated anti-CD22 antibody (anti-CD22). Bars are in order: (a), (c), and (b) (top panel) or (a), (c), (b), and (d) (bottom panel).

[0040] FIG. 13A provides results of experiments that were performed to measure total titers of antigen-specific IgG antibodies before antigen challenge (on day 74) in mice immunized with (a) human Nectin-4 (hNectin-4) and adjuvant (Adj), (b) hNectin-4, Adj, and CpG-conjugated anti-CD22 antibody (CD22TRAAC), (c) hNectin-4, Adj, and unconjugated oligonucleotide (CpG), or (d) hNectin-4, Adj, and unconjugated anti-CD22 antibody (anti- CD22) 9 weeks prior.

[0041] FIG.13B provides results of experiments that were performed to measure titers of antigen-specific IgG antibodies 3 days post antigen challenge (on day 74) in mice immunized with (a) human Nectin-4 (hNectin-4) and adjuvant (Adj), (b) hNectin-4, Adj, and CpG- conjugated anti-CD22 antibody (CD22TRAAC), (c) hNectin-4, Adj, and unconjugated oligonucleotide (CpG), or (d) hNectin-4, Adj, and unconjugated anti-CD22 antibody (anti- CD22) 9 weeks prior.

[0042] FIG. 13C provides results of experiments that were performed to assess the pre- and post-challenged antibody titers in FIG.13A and FIG.13B.

[0043] FIG. 13D provides results of experiments that were performed to assess the levels of splenic plasma cells 3 days post antigen challenge in mice immunized with (a) human Nectin-4 (hNectin-4) and adjuvant (Adj), (b) hNectin-4, Adj, and CpG-conjugated anti-CD22 antibody (CD22TRAAC), (c) hNectin-4, Adj, and unconjugated oligonucleotide (CpG), or (d) hNectin-4, Adj, and unconjugated anti-CD22 antibody (anti-CD22) 9 weeks prior.

[0044] FIG.14A provides results from experiments that were performed to assess the titer of antigen-specific IgG antibodies 28 days after mice were immunized with (a) a trimer of SARS-CoV-2 Spike Protein (SpikeWT) and unconjugated anti-CD22 antibody, (b) SpikeWT, and non-targeted CpG-conjugated anti-hCD22 antibody (NB TRAAC), (c) SpikeWT, and adjuvant (MPL), (d) SpikeWT, adjuvant (MPL), and targeted CpG-conjugated anti-CD22 antibody (CD22TRAAC), or (e) SpikeWT and targeted CpG conjugated antibody (CD22TRAAC).

[0045] FIG. 14B provides reciprocal EC50 titer of antigen-specific IgG antibodies from FIG14A.

[0046] FIG. 15 provides results from experiments that were performed to assess the subtype titer of antigen-specific IgG antibodies 14 days after mice were immunized with (a) a trimer of SARS-CoV-2 Spike Protein (SpikeWT) and unconjugated anti-CD22 antibody (anti- CD22), (b) SpikeWT, and non-targeted CpG-conjugated anti-hCD22 antibody (NB TRAAC), (c) SpikeWT, and adjuvant (MPL), (d) SpikeWT, and targeted CpG-conjugated anti-CD22 antibody (CD22TRAAC), or (e) SpikeWT, adjuvant (MPL), and targeted CpG-conjugated anti-CD22 antibody (CD22TRAAC).

[0047] FIGS. 16A-16C provide results from experiments that were performed to assess antigen-specific IgG antibodies as a titer (FIG. 16A), as fold change over vaccine response (FIG.16B), and as a titer retention ratio displayed as a ratio of signal of elderly titer over signal of its youth counterpart (FIG.16C). Elderly and youth cohorts assessed were immunized with either (a) a trimer of SARS-CoV-2 Spike Protein (SpikeWT) and PBS, (b) SpikeWT and unconjugated oligonucleotide (CpG), (c) SpikeWT and adjuvant (MPL), (d) SpikeWT and anti- CD22 antibody-CpG conjugate (CD22TRAAC), or (e) SpikeWT, adjuvant (MPL) and anti- CD22 antibody-CpG conjugate (CD22TRAAC).

[0048] FIG. 17 provides results from experiments that were performed to assess the subtype titer of antigen-specific IgG antibodies 29 days after elderly and youth cohort mice were immunized with (a) a trimer of SARS-CoV-2 Spike Protein (SpikeWT) and PBS, (b)SpikeWT and unconjugated oligonucleotide (CpG), (c) SpikeWT and adjuvant (MPL), (d) SpikeWT and anti-CD22 antibody-CpG conjugate (CD22TRAAC), or (e) SpikeWT, adjuvant (MPL) and anti-CD22 antibody-CpG conjugate (CD22TRAAC).

[0049] FIG. 18 provides results from experiments that were performed to assess the neutralization titer of spike-specific IgG antibodies 29 days after elderly and youth cohort mice were immunized with (a) a trimer of SARS-CoV-2 Spike Protein (SpikeWT) and PBS, (b) SpikeWT and unconjugated oligonucleotide (CpG), (c) SpikeWT and adjuvant (MPL), (d) SpikeWT and anti-CD22 antibody-CpG conjugate (CD22TRAAC), or (e) SpikeWT, adjuvant (MPL) and anti-CD22 antibody-CpG conjugate (CD22TRAAC).

[0050] FIG. 19A and FIG. 19B provide results from experiments that were performed to assess reciprocal EC50 titer of wildtype spike-specific IgG antibodies (FIG.19A) and Omicron spike variant-specific IgG antibodies (FIG. 19B) pre and post challenge, days 59 and 67 respectively. Groups assessed are elderly and youth cohort mice that were immunized with (a) a trimer of SARS-CoV-2 Spike Protein (SpikeWT) and PBS, (b) SpikeWT and unconjugated oligonucleotide (CpG), (c) SpikeWT and adjuvant (MPL), (d) SpikeWT and anti-CD22 antibody-CpG conjugate (CD22TRAAC), or (e) SpikeWT, adjuvant (MPL) and anti-CD22 antibody-CpG conjugate (CD22TRAAC).

[0051] FIG. 19C provides results from experiments that were performed to assess reciprocal EC50 titer of wildtype spike-specific IgG antibodies on days 14, 29, 59 and 67 providing an overview of the IgG response for the entirety of the study. Groups shown are elderly and youth cohort mice immunized with (a) a trimer of SARS-CoV-2 Spike Protein (SpikeWT) and PBS, (b) SpikeWT and unconjugated oligonucleotide (CpG), (c) SpikeWT and adjuvant (MPL), (d) SpikeWT and anti-CD22 antibody-CpG conjugate (CD22TRAAC), or (e) SpikeWT, adjuvant (MPL) and anti-CD22 antibody-CpG conjugate (CD22TRAAC).

[0052] FIG. 20 provides results from experiments that were performed to assess the post challenge neutralization titer of spike-specific IgG antibodies 67 days after elderly (left panel) and youth (right panel) cohort mice were immunized with (a) a trimer of SARS-CoV-2 Spike Protein (SpikeWT) and PBS, (b) SpikeWT and unconjugated oligonucleotide (CpG), (c) SpikeWT and adjuvant (MPL), (d) SpikeWT and anti-CD22 antibody-CpG conjugate (CD22TRAAC), or (e) SpikeWT, adjuvant (MPL) and anti-CD22 antibody-CpG conjugate (CD22TRAAC).

[0053] FIG. 21 provides results from experiments that were performed to assess the titer at 1 / 2,700 dilution of variant-specific (alpha, beta, gamma, delta, eta, kappa, lambda, omicron or wildtype) IgG antibodies 28 days after mice were immunized with (a) a trimer of SARS- CoV-2 Spike Protein (SpikeWT)and unconjugated anti-mCD22 antibody (anti-CD22), (b) Spike WT and non-targeted CpG-conjugated anti-hCD22 antibody (NB TRAAC), (c) SpikeWT and adjuvant (MPL), (d) SpikeWT and targeted CpG-conjugated anti-mCD22 antibody (CD22TRAAC), or (e) SpikeWT, adjuvant (MPL), and targeted CpG-conjugated anti-mCD22 antibody (CD22TRAAC).

[0054] FIG. 22 provides results from experiments that were performed to assess the survival probability of mice post tumor implantation that were immunized with (a) PBS, (b) 50 µg human Nectin-4 (TNT175) and 25 µg mouse Nectin-4 (TNT176) (N4), (c) N4 and CpG- conjugated anti-mCD22 antibody (CD22TRAAC), (d) N4 with adjuvant (MPL), (e) CpG- conjugated anti-mCD22 antibody (CD22TRAAC) alone, or (f) N4 and unconjugated oligonucleotide (CpG).

[0055] FIG. 23 provides a schematic of the immunization and implantation schedule to determine the prophylactic anti-tumor activity of a B-cell targeting conjugate in combination with a tumor-associated antigen, human Nectin-4 (N4). Days of immunization (Days 0, 7, and 14) are indicated by arrows. Days of blood draws (Days 21, 68, 84, 152, and 193) are indicated by droplets. Tumor cell implants on Days 70 (CT26(+ / - N4) and 176 (4T1(+ / - N4) are indicated by circles.

[0056] FIG. 24 provides results from experiments performed to assess the suppression of tumor growth of CT26 cells (CT26 parental) or CT26 cells transduced to express human Nectin-4 (CT26-N4) in Balb / c Mice following immunization with human Nectin-4 (N4) alone or in combination with CD22TRAAC, CpG, or MPL.

[0057] FIG. 25 provides results from experiments performed to assess the suppression of tumor growth of 4T1 parental tumor cells (4T1) or 4T1 cells transduced to express human Nectin-4 (4T1N4) in mice that previously eliminated CT26-N4 tumor growth following immunization with human Nectin-4 (N4) in combination with CD22TRAAC, CpG, or MPL. Tumor growth in age-matched, non-immunized, animals implanted with parental 4T1 or with 4T1N4 were also assessed as a control.

[0058] FIG. 26 provides the tumor volumes of individual mice on Day 20 post tumor implant from experiments performed to assess the suppression of tumor growth of 4T1 parentaltumor cells (4T1) or 4T1 cells transduced to express human Nectin-4 (4T1N4) in mice that previously eliminated CT26-N4 tumor growth following immunization with human Nectin-4 (N4) in combination with CD22TRAAC, CpG, or MPL and in age-matched, non-immunized, control animals.

[0059] FIG. 27 provides the ratio of 4T1N4 / parental 4T1 tumor volumes in mice that previously eliminated CT26-N4 tumor growth following immunization with human Nectin-4 (N4) in combination with CD22TRAAC, CpG, or MPL and in age-matched, non-immunized, control animals.

[0060] FIG. 28 provides results of experiments that were performed to measure titers of total antigen-specific IgG antibodies in serum, on study Day 21, after immunization with (a) human Nectin-4 (N4) (b) human Nectin-4 and CpG-conjugated anti-CD22 antibody (N4 + CD22TRAAC (1) and N4 + CD22TRAAC (2)), (c) human Nectin-4 and unconjugated oligonucleotide (N4 + CpG), or (d) human Nectin-4 and MPL (N4 + MPL). Two sub-groups of mice immunized with N4 + CD22TRAAC were evaluated, those to be implanted with CT26 (N4+CD22TRAAC [1]) and those to be implanted with CT26-N4 (N4+CD22TRAAC [2]).

[0061] FIGS.29A-29D provide results from experiments that were performed to measure the titers of antigen-specific IgG1 (FIG.29A), IgG2a (FIG.29B), IgG2b (FIG.29C), and IgM (FIG.29D) antibodies, at 1 / 2,700 serum dilution, on Day 21, after immunization with (a) human Nectin-4 (N4) (b) human Nectin-4 and CpG-conjugated anti-CD22 antibody (N4 + CD22TRAAC (1) and N4 + CD22TRAAC (2)), (c) human Nectin-4 and unconjugated oligonucleotide (N4 + CpG), or (d) human Nectin-4 and MPL (N4 + MPL). Two sub-groups of mice immunized with N4 + CD22TRAAC were evaluated, those to be implanted with CT26 (TRAAC [1]) and those to be implanted with CT26-N4 (TRAAC [2]).

[0062] FIG.30 provides results of experiments that were performed to measure total titers of antigen-specific IgG antibodies in mouse serum following immunization with human Nectin-4 (N4); human Nectin-4 and CpG-conjugated anti-CD22 antibody (N4 + CD22TRAAC – CT26 Parental and N4 + CD22TRAAC – CT26-N4); human Nectin-4 and unconjugated oligonucleotide (N4 + CpG); or human Nectin-4 and MPL (N4 + MPL) on Day 21, prior to CT26 (+ / - N4) cell implantation, Day 68 (two days prior to CT26 (+ / - N4) cell implantation); Day 84, after CT26 (+ / - N4) cell implantation; Day 152, prior to 4T1 (+ / - N4) cell implantation in CT26-N4 tumor resistant mice, and Day 193 after 4T1 (+ / - N4) cell implantation in CT26-N4 tumor resistant mice. Days of CT26(+ / -N4) and 4T1(+ / -N4) tumor cell implantation are indicated by dashed lines on Days 68 and 176, respectively.

[0063] FIG.31 provides results of experiments that were performed to measure total titers of antigen-specific IgG antibodies on study Day 193, in mouse serum, 17 days after challenge with 4T1(+ / -N4) and 123 days after resisting growth of CT26-N4 tumor cells, following immunization with hNectin-4 and CpG-conjugated anti-CD22 antibody (N4 + CD22TRAAC), human Nectin-4 and unconjugated oligonucleotide (N4 + CpG), or human Nectin-4 and MPL (N4 + MPL). Total IgG titers in non-immunized, age-matched, control mice, challenged with 4T1 (+ / -N4), were also measured for comparison.

[0064] FIGS.32A-32C provide results from experiments that were performed to measure the titers of antigen-specific IgG1 (FIG. 32A), IgG2a (FIG. 32B), and IgG2b (FIG. 32C) antibodies, at 1 / 2,700 serum dilution, on study Day 193, in mice, 17 days after challenge with 4T1(+ / -N4) and 123 days after resisting growth of CT26-N4 tumor cells following immunization with hNectin-4 and CpG-conjugated anti-CD22 antibody (N4 + CD22TRAAC), hNectin-4 and unconjugated oligonucleotide (N4 + CpG), or hNectin-4 and MPL (N4 + MPL). Antibody subtype titers were also measured in non-immunized, age-matched, control mice, challenged with 4T1 (+ / -N4), for comparison.

[0065] FIGS. 33A & 33B show total IgG titer (FIG. 33A) and IgG subtype titers (FIG. 33B) at Day 42 from mice administered vehicle, GP2-P4 antigen, GP2-P4 + CD22TRAAC, and GP2-P4+CpG.

[0066] FIGS. 34A & 34B show intracellular IFNγ detected in lymphocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4). FIG.34A shows data obtained from CD8+ T cells; FIG.34B shows data obtained from CD4+ T cells.

[0067] FIGS. 35A & 35B show intracellular TNFα detected in lymphocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4). FIG.35A shows data obtained from CD8+ T cells; FIG.35B shows data obtained from CD4+ T cells.

[0068] FIGS. 36A & 36B show intracellular Granzyme B detected in lymphocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4). FIG.36A shows data obtained from CD8+ T cells; FIG.36B shows data obtained from CD4+ T cells.

[0069] FIGS. 37A & 37B show intracellular IFNγ detected in splenocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2 + GP2-P4). FIG. 37A shows data obtained from CD8+ T cells; FIG.37B shows data obtained from CD4+ T cells.

[0070] FIGS. 38A & 38B show intracellular TNFα detected in splenocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2 + GP2-P4). FIG. 38A shows data obtained from CD8+ T cells; FIG.38B shows data obtained from CD4+ T cells.

[0071] FIGS. 39A & 39B show intracellular Granzyme B detected in splenocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2 + GP2-P4). FIG. 39A shows data obtained from CD8+ T cells; FIG.39B shows data obtained from CD4+ T cells.

[0072] FIGS. 40A-40D show total IFNγ (FIG. 40A), TNFα (FIG. 40B), IL-17A (FIG. 40C), and GM-CSF (FIG. 40D) detected in lymphocyte culture media supernatant for each treatment condition, without (baseline) and with peptide ex vivo peptide stimulation (GP2-P4).

[0073] FIGS. 41A-41F show total IFNγ (FIG. 41A), TNFα (FIG. 41B), IL-17A (FIG. 41C), GM-CSF (FIG. 41D), IL-2 (FIG. 41E), and IL-4 (FIG. 41F) detected in splenocyte culture media supernatant for each treatment condition, without (baseline) and with peptide ex vivo peptide stimulation (GP2+ GP2-P4).

[0074] FIG. 42 shows an overview of the cytokine responses in media following ex vivo antigenic peptide stimulation (i.e., antigen recall).

[0075] FIG.43 provides results from experiments that were performed to assess dendritic cell activation in PBMC cultures. CD40 (middle), CD86 (right), and HLADR (left) expression on dendritic cells were analyzed following no treatment (white; media), 24 hr. treatment with anti-hSIRP^ antibody (gray), or hSIRP^ TRAAC (black; SIRP^ TRAAC).

[0076] FIG. 44 provides results from experiments that were performed to assess cytokine production in PBMC cultures. IFN^2 (left), IFNγ (right) and IL-12 (middle) levels in cell culture supernatant were analyzed following no treatment (white; media), 24 hr. treatment with anti-hSIRP^ antibody (gray), or hSIRP^ TRAAC (black; SIRP^ TRAAC).

[0077] FIG. 45 provides results from an experiment performed to assess the combination treatment of SIRPα TRAAC and exemplary checkpoint inhibitor, anti-PD-1 antibody, on CT26tumor growth immune competent syngeneic mice (BALB / c). Tumor growth was measured following treatment with phosphate-buffered saline (PBS; open triangles); anti-PD-1 antibody at 10 mg / kg, two times, three days apart (2q3d) (open circles); hSIRP^ TRAAC at 0.3 mg / kg, 2q3d (closed squares); or hSIRP^ TRAAC at 0.3 mg / kg and anti-PD-1 antibody at 10 mg / kg, 2q3d (closed diamonds) (n=5 / group). Days of hSIRP^ TRAAC administration are indicated by solid arrows, and days of anti-PD-1 antibody administration are indicated by dashed arrows.

[0078] FIGS. 46A & 46B show total IgG titer (FIG. 46A) and IgG subtype titers (FIG. 46B) at Day 42 from mice administered vehicle, GP2-P4 antigen, GP2-P4 + SIRPαTRAAC, and GP2-P4 + CpG.

[0079] FIGS. 47A & 47B show intracellular IFNγ detected in lymphocytes from mice immunized with peptide only, peptide + SIRPαTRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4). FIG.47A shows data obtained from CD8+ T cells; FIG.47B shows data obtained from CD4+ T cells.

[0080] FIGS. 48A & 48B show intracellular Granzyme B detected in lymphocytes from mice immunized with peptide only, peptide + SIRPαTRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4). FIG.48A shows data obtained from CD8+ T cells; FIG.48B shows data obtained from CD4+ T cells.

[0081] FIGS. 49A & 49B show intracellular IFNγ detected in lymphocytes from mice immunized with peptide only, peptide + SIRPαTRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4). FIG.49A shows data obtained from CD8+ T cells; FIG.49B shows data obtained from CD4+ T cells.

[0082] FIGS. 50A & 50B show intracellular Granzyme B detected in lymphocytes from mice immunized with peptide only, peptide + SIRPαTRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4). FIG.50A shows data obtained from CD8+ T cells; FIG.50B shows data obtained from CD4+ T cells.

[0083] FIGS. 51A-51C show total IFNγ (FIG. 51A), IL17A (FIG. 51B), and GM-CSF (FIG.51C) detected in lymphocyte culture media supernatant for each treatment condition (as indicated), without (baseline) and with peptide ex vivo peptide stimulation (GP2-P4).

[0084] FIG. 52 shows total IL17A detected in splenocyte culture media supernatant for each treatment condition (as indicated), without (baseline) and with peptide ex vivo peptide stimulation (GP2 + GP2-P4).

[0085] FIG. 53 shows an overview of cytokine responses in media following ex vivo antigenic peptide stimulation (i.e., antigen recall).

[0086] FIGS. 54A-54D show levels of IFNγ (FIG. 54A), TNFα (FIG. 54B), IL-17A (FIG. 54C), or GM-CSF (FIG. 54D) in the media of splenocytes in response to the AH1 peptide.

[0087] FIGS. 55A & 55B show levels of intracellular IFNγ (FIG. 55A) or Granzyme B (GZMB; FIG.54B) in CD8+ T cells in response to the AH1 peptide.

[0088] FIGS. 56A-56C show CD86 (FIG. 56A), MHCII (FIG. 56B), and CD40 (FIG. 56C) expression on purified CD19+ B cells from naïve mouse splenocytes at increasing concentrations of CD22TRAAC, CpG or media only.

[0089] FIG. 57 shows that CD22TRAAC in combination with the exemplary mRNA immune-honing agent, LNP-mRNA-OVA, induced specific MHC I-restricted antigen presentation in B220+B cells to a greater extent than CpG or media controls. DETAILED DESCRIPTION

[0090] The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.

[0091] The present application is based on the discovery that administration of (a) an effective amount of a conjugate comprising an antibody or antigen-binding fragment thereof that binds to an antigen expressed on the surface of a B-cell (Ab) and one or more immunomodulating oligonucleotides (P), and (b) an immune honing agent (IHA) to an individual results in a higher antigen-specific IgG titer, a longer and more robust IgG2 response, a more robust and longer lasting primary B-cell response, a more robust and longer lasting memory B-cell response, a higher neutralizing antibody response than the administration of the IHA without the conjugate and (c) B-cell responses as described are also observed in elderly subjects with expected weaker immune responses. The present application is also based on the discovery that administration of (a) an effective amount of a conjugate comprising an antibody or antigen-binding fragment thereof that binds to an antigen expressed on the surface of a dendritic cell (Ab) and one or more immunomodulating oligonucleotides (P), and (b) an immune honing agent (IHA) to an individual results in a greater antigenicimmune response than the administration of the IHA without the conjugate or administration of the conjugate alone. I. Definitions

[0092] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications and other publications referred to herein are incorporated by reference in their entireties. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in a patent, application, or other publication that is herein incorporated by reference, the definition set forth in this section prevails over the definition incorporated herein by reference.

[0093] It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to particular method steps, reagents, or conditions are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed.

[0094] As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

[0095] Throughout this application, unless the context indicates otherwise, references to a conjugate which can include ionic forms, polymorphs, pseudopolymorphs, amorphous forms, solvates, co-crystals, chelates, isomers, tautomers, oxides (e.g., N-oxides, S-oxides), esters, prodrugs, isotopes and / or protected forms thereof.

[0096] The term "immunomodulating polynucleotide" or “immunomodulating oligonucleotide” as used herein, represents a polynucleotide construct containing a total of from 6 to 50 contiguous nucleosides. The immunomodulating polynucleotides are capable of modulating an innate immune response, as determined by, e.g., a change in the activation of intracellular signaling pathway(s) including but not limited to NF^B, a change in the expressionof an activation marker or a change in the secretion of at least one inflammatory cytokine or at least one type I interferon in an immune cell (e.g., antigen-presenting cell) to which an immunomodulating polynucleotide was delivered (e.g., in comparison to another immune cell (e.g., antigen-presenting cell) to which an immunomodulating polynucleotide was not delivered) or in an immune cell that interacts with an immune cell (e.g., antigen-presenting cell) to which an immunomodulating polynucleotide was delivered (including direct cell-to- cell interactions as well as indirect stimulation, e.g., from one or more cytokines secreted by the cell to which an immunomodulating polynucleotide was delivered).

[0097] The term "immunostimulating polynucleotide" or “immunostimulating oligonucleotide” as used herein, represents an immunomodulating polynucleotide capable of activating an immune response, as determined by, e.g., an increase in the activation of intracellular signaling pathway(s) such as NF^B or an increase in levels of cell surface marker(s) of activation or function or an increase in the secretion of at least one inflammatory cytokine or at least one type I interferon in an immune cell (e.g., antigen-presenting cell) to which an immunostimulating polynucleotide was delivered (e.g., in comparison to another immune cell (e.g., antigen-presenting cell) to which an immunostimulating polynucleotide was not delivered) or in an immune cell that interacts with an immune cell (e.g., antigen-presenting cell) to which an immunomodulating polynucleotide was delivered (including direct cell-to- cell interactions as well as indirect stimulation, e.g., from one or more cytokines secreted by the cell to which an immunomodulating polynucleotide was delivered). In some embodiments, the immunostimulating polynucleotide contains at least one cytidine-p-guanosine (CpG) sequence, in which p is an internucleoside phosphodiester (e.g., phosphate or phosphorothioate) or an internucleoside phosphotriester or phosphothiotriester. As used herein, the CpG-containing immunostimulating polynucleotide can be naturally existing, such as CpG ODNs of bacterial or viral origins, or synthetic. For example, in some embodiments, the CpG sequence in the immunostimulating polynucleotide contains 2’-deoxyribose. In some embodiments, the CpG sequence in the immunostimulating oligonucleotide is unmethylated.

[0098] It is to be understood that the terms “polynucleotide” and “oligonucleotide” may be used interchangeably herein. In addition, the terms “free,” “naked,” and “unconjugated” referring to immunomodulating polynucleotides, immunostimulating polynucleotides, and / or oligonucleotides (e.g., CpG oligonucleotides) may be used interchangeably herein.

[0099] As used herein, the term "amino acid" refers to any amino acid (both standard and non-standard amino acids), including, but not limited to, ^-amino acids, ^-amino acids, ^-amino acids and ^-amino acids. Examples of suitable amino acids include, but are not limited to, alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Additional examples of suitable amino acids include, but are not limited to, ornithine, hypusine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, citrulline, beta-alanine, alpha-ethyl-glycine, alpha-propyl-glycine and norleucine.

[0100] The terms “antibody,” “immunoglobulin,” and “Ig” are used interchangeably herein, and are used in the broadest sense and specifically cover, for example, individual monoclonal antibodies (including agonist, antagonist, neutralizing antibodies, full length or intact monoclonal antibodies), antibody compositions with polyepitopic or monoepitopic specificity, polyclonal or monovalent antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies so long as they exhibit the desired biological activity), formed from at least two intact antibodies, single chain antibodies, and fragments of antibodies. An antibody can be human, humanized, chimeric and / or affinity matured as well as an antibody from other species, for example, mouse and rabbit. Antibodies also include, but are not limited to, synthetic antibodies, monoclonal antibodies, recombinant antibodies, multispecific antibodies (including bi-specific antibodies), human antibodies, humanized antibodies, camelized antibodies, chimeric antibodies, intrabodies, anti-idiotypic (anti-Id) antibodies, and functional fragments thereof, which refers a portion of an antibody heavy or light chain polypeptide that retains some or all of the binding activity of the antibody from which the fragment is derived. Non-limiting examples of functional fragments of an antibody include single-chain Fvs (scFv) (e.g., including monospecific or bispecific), Fab fragments, F(ab’) fragments, F(ab)2 fragments, F(ab’)2 fragments, disulfide-linked Fvs (sdFv), Fd fragments, Fv fragments, scRv-Fc, nanobody, diabody, triabody, tetrabody, and minibody. In some embodiments, the antibody comprises an Fc variant that has reduced or ablated effector function. In particular, antibodies provided herein include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, for example, antigen-binding domains or molecules that contain an antigen-binding site that binds to the antigen (e.g., one or more complementarity determining regions (CDRs) of an anti-CD22 antibody). Such antibody fragments are described in, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989); Myers (ed.), Molec. Biology and Biotechnology: A Comprehensive Desk Reference, New York: VCH Publisher, Inc.; Huston et al., Cell Biophysics 1993, 22, 189-224; Plückthun and Skerra, Meth. Enzymol. 1989, 178,497-515; and Day, Advanced Immunochemistry, Second Ed., Wiley-Liss, Inc., New York, NY (1990). The antibodies provided herein can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or any subclass (e.g., IgG2a and IgG2b) of an immunoglobulin molecule.

[0101] The term “antigen” refers to a predetermined target to which an antibody can selectively bind. A target antigen can be a polypeptide, carbohydrate, nucleic acid, lipid, hapten, or fragment thereof, or other naturally occurring or synthetic compound. In one embodiment, the target antigen is a polypeptide.

[0102] The terms “antigen-binding fragment,” “antigen-binding domain,” and “antigen- binding region” refer to a portion of an antibody that comprises the amino acid residues that interact with an antigen (e.g., a polypeptide, carbohydrate, nucleic acid, lipid, hapten, or fragment thereof, or other naturally occurring or synthetic compound) and confer on the binding agent its specificity and affinity for the antigen (e.g., complementarity determining regions (CDRs)).

[0103] The term “specific binding,” “specifically binds to,” or “specific for” a particular polypeptide or an epitope on a particular polypeptide target can be exhibited, for example, by a molecule (e.g., an antibody) having a dissociation constant (Kd) for the target of at least about 10-4M, at least about 10-5M, at least about 10-6M, at least about 10-7M, at least about 10-8M, at least about 10-9M, at least about 10-10M, at least about 10-11M, or at least about 10-12M. In one embodiment, the term “specific binding” refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

[0104] A 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. In the case of IgGs, the 4-chain unit is generally about 150,000 Daltons. Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable domain (VH) followed by three constant domains (CH) for each of the ^ and ^ chains and four CH domains for ^ and ^ isotypes. Each L chain has at the N-terminus, a variable domain (VL) followed by a constant domain (CL) at its other end. The VL is aligned with the VH and the CL is aligned with the first constant domain of the heavy chain (CH1). Particular amino acid residues are believed toform an interface between the light chain and heavy chain variable domains. The pairing of a VH and VL together forms a single antigen-binding site. For the structure and properties of the different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th edition, Stites et al. (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6.

[0105] The term “variable region” or “variable domain” refers to a portion of the light or heavy chains of an antibody that is generally located at the amino-terminal of the light or heavy chain and has a length of about 120 to 130 amino acids in the heavy chain and about 100 to 110 amino acids in the light chain, and are used in the binding and specificity of each particular antibody for its particular antigen. The variable region of the heavy chain may be referred to as “VH.” The variable region of the light chain may be referred to as “VL.” The term “variable” refers to the fact that certain segments of the variable regions differ extensively in sequence among antibodies. The V region mediates antigen binding and defines specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the 110-amino acid span of the variable regions. Instead, the V regions consist of less variable (e.g., relatively invariant) stretches called framework regions (FRs) of about 15-30 amino acids separated by shorter regions of greater variability (e.g., extreme variability) called “hypervariable regions” that are each about 9-12 amino acids long. The variable regions of heavy and light chains each comprise four FRs, largely adopting a ^ sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the ^ sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991)). The constant regions are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). The variable regions differ extensively in sequence between different antibodies. The variability in sequence is concentrated in the CDRs while the less variable portions in the variable region are referred to as framework regions (FR). The CDRs of the light and heavy chains are primarily responsible for the interaction of the antibody with antigen. In specific embodiments, the variable region is a human variable region.

[0106] The term “variable region residue numbering as in Kabat” or “amino acid position numbering as in Kabat”, and variations thereof, refers to the numbering system used for heavychain variable regions or light chain variable regions of the compilation of antibodies in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable domain. For example, a heavy chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g., residues 82a, 82b, and 82c, etc., according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence. The Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g., Kabat et al., Sequences of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The “EU numbering system” or “EU index” is generally used when referring to a residue in an immunoglobulin heavy chain constant region (e.g., the EU index reported in Kabat et al., supra). The “EU index as in Kabat” refers to the residue numbering of the human IgG1 EU antibody. Other numbering systems have been described, including, for example, by AbM, Chothia, Contact, IMGT and AHo.

[0107] An “intact” antibody is one comprising an antigen-binding site as well as a CL and at least heavy chain constant regions, CH1, CH2 and CH3. The constant regions may include human constant regions or amino acid sequence variants thereof. Preferably, an intact antibody has one or more effector functions.

[0108] The term “antibody fragment” refers to a portion of an intact antibody, preferably the antigen-binding or variable region of the intact antibody. Examples of antibody fragments include, without limitation, Fab, Fab’, F(ab’)2, and Fv fragments; diabodies and di-diabodies (see, e.g., Holliger et al., Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6444-8; Lu et al., J. Biol. Chem. 2005, 280, 19665-72; Hudson et al., Nat. Med. 2003, 9, 129-134; WO 93 / 11161; and U.S. Pat. Nos.5,837,242 and 6,492,123); single-chain antibody molecules (see, e.g., U.S. Pat. Nos. 4,946,778; 5,260,203; 5,482,858 and 5,476,786); dual variable domain antibodies (see, e.g., U.S. Pat. No. 7,612,181); single variable domain antibodies (SdAbs) (see, e.g., Woolven et al., Immunogenetics 1999, 50, 98-101 Streltsov et al., Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 12444-12449); and multispecific antibodies formed from antibody fragments.

[0109] The term “functional fragment,” “binding fragment,” or “antigen-binding fragment” of an antibody refers to a molecule that exhibits at least one of the biological functions attributed to the intact antibody, the function comprising at least binding to the target antigen.

[0110] The term “heavy chain” when used in reference to an antibody refers to a polypeptide chain of about 50-70 kDa, wherein the amino-terminal portion includes a variable region of about 120 to 130 or more amino acids and a carboxyl-terminal portion that includes a constant region. The constant region can be one of five distinct types, (e.g., isotypes) referred to as alpha (^), delta (^), epsilon (^), gamma (^) and mu (µ), based on the amino acid sequence of the heavy chain constant region. The distinct heavy chains differ in size: ^, ^ and ^ contain approximately 450 amino acids, while µ and ^ contain approximately 550 amino acids. When combined with a light chain, these distinct types of heavy chains give rise to five well known classes (e.g., isotypes) of antibodies, IgA, IgD, IgE, IgG and IgM, respectively, including four subclasses of IgG, namely IgG1, IgG2, IgG3, and IgG4. A heavy chain can be a human heavy chain.

[0111] The term “light chain” when used in reference to an antibody refers to a polypeptide chain of about 25 kDa, wherein the amino-terminal portion includes a variable region of about 100 to about 110 or more amino acids and a carboxyl-terminal portion that includes a constant region. The approximate length of a light chain is 211 to 217 amino acids. There are two distinct types, referred to as kappa (^) of lambda (^) based on the amino acid sequence of the constant domains. Light chain amino acid sequences are well known in the art. A light chain can be a human light chain.

[0112] “Humanized” forms of nonhuman (e.g., murine) antibodies are chimeric antibodies that include human immunoglobulins (e.g., recipient antibody) in which the native CDR residues are replaced by residues from the corresponding CDR of a nonhuman species (e.g., donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, one or more FR region residues of the human immunoglobulin are replaced by corresponding nonhuman residues. Furthermore, humanized antibodies can comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. A humanized antibody heavy or light chain can comprise substantially all of at least one or more variable regions, in which all or substantially all of the CDRs correspond to those of a nonhuman immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulinsequence. In certain embodiments, the humanized antibody will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see, Jones et al., Nature 1986, 321, 522-525; Riechmann et al., Nature 1988, 332, 323-329; Presta, Curr. Opin. Biotechnol.1992, 3, 394-398; Carter et al., Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4285-4289; and U.S. Pat. Nos: 6,800,738, 6,719,971, 6,639,055, 6,407,213, and 6,054,297.

[0113] A “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human and / or has been made using any of the techniques for making human antibodies as disclosed herein. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage-display libraries (Hoogenboom and Winter, J. Mol. Biol. 1991, 227, 381; Marks et al., J. Mol. Biol. 1991, 222, 581) and yeast display libraries (Chao et al., Nature Protocols 2006, 1, 755-768). Also available for the preparation of human monoclonal antibodies are methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p.77 (1985); Boerner et al., J. Immunol.1991, 147, 86-95. See also van Dijk and van de Winkel, Curr. Opin. Pharmacol.2001, 5, 368-374. Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., mice (see, e.g., Jakobovits, Curr. Opin. Biotechnol. 1995, 6, 561-566; Brüggemann and Taussing, Curr. Opin. Biotechnol. 1997, 8, 455-458; and U.S. Pat. Nos. 6,075,181 and 6,150,584 regarding XENOMOUSETMtechnology). See also, for example, Li et al., Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 3557-3562 regarding human antibodies generated via a human B-cell hybridoma technology.

[0114] A “CDR” refers to one of three hypervariable regions (H1, H2, or H3) within the non-framework region of the immunoglobulin (Ig or antibody) VH ^-sheet framework, or one of three hypervariable regions (L1, L2, or L3) within the non-framework region of the antibody VL ^-sheet framework. Accordingly, CDRs are variable region sequences interspersed within the framework region sequences. CDR regions are well known to those skilled in the art and have been defined by, for example, Kabat as the regions of most hypervariability within the antibody variable (V) domains. Kabat et al., J. Biol. Chem.1977, 252, 6609-6616; Kabat, Adv. Protein Chem. 1978, 32, 1-75. CDR region sequences also have been defined structurally by Chothia as those residues that are not part of the conserved ^-sheet framework, and thus areable to adapt different conformations. Chothia and Lesk, J. Mol. Biol. 1987, 196, 901-917. Both terminologies are well recognized in the art. CDR region sequences have also been defined by AbM, Contact and IMGT. The positions of CDRs within a canonical antibody variable region have been determined by comparison of numerous structures. Al-Lazikani et al., J. Mol. Biol. 1997, 273, 927-948; Morea et al., Methods.2000, 20, 267-279. Because the number of residues within a hypervariable region varies in different antibodies, additional residues relative to the canonical positions are conventionally numbered with a, b, c and so forth next to the residue number in the canonical variable region numbering scheme. Al- Lazikani et al., supra (1997). Such nomenclature is similarly well known to those skilled in the art.

[0115] The term “hypervariable region”, “HVR”, or “HV”, when used herein refers to the regions of an antibody variable region that are hypervariable in sequence and / or form structurally defined loops. Generally, antibodies comprise six hypervariable regions; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). A number of hypervariable region delineations are in use and are encompassed herein. The Kabat Complementarity Determining Regions (CDRs) are based on sequence variability and are the most commonly used (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). Chothia refers instead to the location of the structural loops. See, e.g., Chothia and Lesk, J. Mol. Biol.1987, 196, 901-917. The end of the Chothia CDR-H1 loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops and are used by Oxford Molecular’s AbM antibody modeling software (see, e.g., Martin, in Antibody Engineering, Vol. 2, Chapter 3, Springer Verlag). The “contact” hypervariable regions are based on an analysis of the available complex crystal structures. The residues from each of these hypervariable regions or CDRs are noted below.

[0116] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain, including, for example, native sequence Fc regions, recombinant Fc regions, and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is often definedto stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl- terminus thereof. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during production or purification of the antibody, or by recombinantly engineering the nucleic acid encoding a heavy chain of the antibody. Accordingly, a composition of intact antibodies may comprise antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue.

[0117] The term “DAR” refers to a drug-antibody ratio of an oligonucleotide-antibody conjugate, more specifically an immunomodulating polynucleotide-antibody ratio. In some instances, for example, an oligonucleotide-antibody conjugate may be described herein as having a DAR of 1 or as a DAR1 conjugate, wherein the oligonucleotide-antibody ratio is 1- to-1. In other instances, an oligonucleotide-antibody conjugate may be described herein as having a DAR of 2 or as a DAR2 conjugate, wherein the oligonucleotide-antibody ratio is 2- to-1.

[0118] The term “immune honing agent (IHA)” as used herein, means an agent capable of inducing an immune response when administered to a subject, alone, in combination with an adjuvant or in combination with a conjugate described herein. In some embodiments, an IHA comprises an antigen, such as a peptide, protein or portion thereof, a polysaccharide or other biological molecule. In some embodiments, an IHA comprises a foreign organism, such as a pathogen, a virus, a microorganism or a portion thereof. In some embodiments, an IHA comprises an agent capable of producing or inducing the host to produce an antigen, such as a nucleic acid that encodes a protein or portion thereof. In some cases, a vaccine is an IHA or an IHA in combination with one or more adjuvants.

[0119] An “immune cell” is a cell that is part of the immune system of a subject. Exemplary immune cells include lymphocytes and myeloid cells. Exemplary lymphocytes include T cells, B cells, and NK cells. Exemplary myeloid cells that are immune cells include eosinophils, basophils, monocytes, and neutrophils. Monocytes differentiate into immune cells that are dendritic cells and macrophages.

[0120] As used herein, the terms “including,” “containing,” and “comprising” are used in their open, non-limiting sense. It is also understood that aspects and embodiments of the invention described herein may include “consisting of” and / or “consisting essentially of” aspects and embodiments.

[0121] It is understood that, whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and / or measurement conditions for such given value.

[0122] As used herein, a “carrier” includes pharmaceutically acceptable carriers, excipients, or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Non-limiting examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt- forming counterions such as sodium; and / or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

[0123] As used herein, the term “effective amount” or “therapeutically effective amount” of a substance is at least the minimum concentration required to bring about a measurable improvement or prevention of a particular disorder. An effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the substance to elicit a desired response in the individual. An effective amount is also one in which any toxic or detrimental effects of the treatment are outweighed by the therapeutically beneficial effects. In reference to cancer, an effective amount comprises an amount sufficient to cause a tumor to shrink and / or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation in cancer. In some embodiments, an effective amount is an amount sufficient to delay development of cancer. In some embodiments, an effective amount is an amount sufficient to prevent or delay recurrence. In some embodiments, an effective amount is an amount sufficient to reduce recurrence rate in the individual. An effective amount can be administered in one or more administrations. The effective amount of the drug or composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and preferably stop)tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and / or recurrence of tumor; (vii) reduce recurrence rate of tumor, and / or (viii) relieve to some extent one or more of the symptoms associated with the cancer. An effective amount can be administered in one or more administrations. For purposes of this disclosure, an effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. As is understood in the clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective amount” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.

[0124] The terms "protein," "polypeptide" and "peptide" are used herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Typically, a protein for use herein will have a molecular weight of at least about 5-20 kDa, alternatively at least about 20-100 kDa, or at least about 100 kDa. Also included within the definition are, for example, proteins containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.

[0125] A “pharmaceutically acceptable salt” is a salt form that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See generally Berge et al.(1977) J. Pharm. Sci.66, 1. Particular pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of subjects without undue toxicity, irritation, or allergic response. Pharmaceutically acceptable salts include, without limitation, acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like. These salts may be derived from inorganic or organic acids. Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates,metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, besylates, xylenesulfonates, naphthalene-1-sulfonates, naphthalene-2- sulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, ^- hydroxybutyrates, glycolates, tartrates, and mandelates. In some embodiments, pharmaceutically acceptable salts are formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. Salts derived from pharmaceutically acceptable organic non-toxic bases include, without limitation, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, tromethamine, trimethylamine, dicyclohexylamine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N- ethylglucamine, N-methylglucamine, theobromine, purines, piperazine, piperidine, N- ethylpiperidine, polyamine resins, amino acids such as lysine, arginine, histidine, and the like. Examples of pharmaceutically acceptable base addition salts include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. In some embodiments, the organic non-toxic bases are L-amino acids, such as L-lysine and L- arginine, tromethamine, N-ethylglucamine and N-methylglucamine. Acceptable inorganic bases include, without limitation, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. Lists of other suitable pharmaceutically acceptable salts are found in Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton, Pa., 1985.

[0126] A “subject,” “patient” or “individual” includes a mammal, such as a human or other animal, and typically is human. In some embodiments, the subject, e.g., patient, to whom the therapeutic agents and compositions are administered, is a mammal, typically a primate, such as a human. In some embodiments, the primate is a monkey or an ape. The subject can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, andgeriatric subjects. In some embodiments, the subject is a non-primate mammal, such as a rodent, a dog, a cat, a farm animal, such as a cow or a horse, etc.

[0127] The term “proliferative disease,” refers to the presence of cells possessing characteristics such as uncontrolled and / or unwanted proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features. An exemplary proliferative disease is cancer. Cancer cells are often in the form of a solid tumor, which is detectable on the basis of tumor mass, e.g., by procedures such as CAT scan, MR imaging, X-ray, ultrasound or palpation, and / or which is detectable because of the expression of one or more cancer-specific antigens in a sample obtainable from a patient. In some embodiments, a solid tumor does not need to have measurable dimensions. Cancer cells may also in the form of a liquid tumor, which cancer cells may exist alone or disseminated within an animal. As used herein, the terms “disseminated tumor” and “liquid tumor” are used interchangeably, and include, without limitation, leukemia and lymphoma and other blood cell cancers.

[0128] As used herein, the term “cancer” includes premalignant as well as malignant cancers, and also includes primary tumors (e.g., those whose cells have not migrated to sites in the subject's body other than the site of the original tumor) and secondary tumors (e.g., those arising from metastasis, the migration of tumor cells to secondary sites that are different from the site of the original tumor), recurrent cancer and refractory cancer.

[0129] The terms “cancer recurrence” and “cancer relapse” are used interchangeably and refer to the return of a sign, symptom or disease after a remission. The recurrent cancer cells may re-appear in the same site of the primary tumor or in another location, such as in secondary cancer. The cancer cells may re-appear in the same diseased form as the primary cancer or a different diseased form. For example, in some embodiments, a primary cancer is a solid tumor, and the recurrent cancer is a liquid tumor. In other embodiments, a primary cancer is a liquid tumor, and the recurrent cancer is a solid tumor. In yet other embodiments, the primary cancer and the recurrent cancer are both solid tumors, or both liquid tumors. In some embodiments, the recurrent tumor expresses at least one tumor-associated antigen that is also expressed by the primary tumor.

[0130] The term “refractory cancer” as used herein refers to a cancer that does not respond to a treatment, for example, a cancer that is resistant at the beginning of treatment (e.g., treatment with an immunotherapy) or a cancer that may become resistant during treatment. Theterms “respond,” “response” or “responsiveness” refer to an anti-cancer response, e.g. in the sense of reduction of tumor size or inhibiting tumor growth. The terms can also refer to an improved prognosis, for example, as reflected by an increased time to recurrence, which is the period to first recurrence censoring for second primary cancer as a first event or death without evidence of recurrence, or an increased overall survival, which is the period from treatment to death from any cause. To respond or to have a response means there is a beneficial endpoint attained when exposed to a stimulus. Alternatively, a negative or detrimental symptom is minimized, mitigated or attenuated on exposure to a stimulus. It will be appreciated that evaluating the likelihood that a tumor or subject will exhibit a favorable response is equivalent to evaluating the likelihood that the tumor or subject will not exhibit favorable response (i.e., will exhibit a lack of response or be non-responsive).

[0131] In some embodiments, “at risk” means that the individual may or may not have detectable proliferative disease or symptoms of a proliferative disease and may or may not have displayed detectable disease or symptoms of disease prior to the methods described herein. In some embodiments, “at risk” means that an individual has one or more risk factors, which are measurable parameters that correlate with development of a proliferative disease, as known in the art. An individual having one or more of these risk factors has a higher probability of developing a proliferative disease, than an individual without one or more of these risk factors.

[0132] As used herein, cancers include, but are not limited to, melanomas, breast cancer, lung cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, cancer of hematologic tissues, B cell cancer, e.g., multiple myeloma, Waldenström's macroglobulinemia, the heavy chain diseases, such as, for example, alpha chain disease, gamma chain disease, and mu chain disease, benign monoclonal gammopathy, and immunocytic amyloidosis, and the like. Other non-limiting examples of types of cancers applicable to the methods encompassed by the present invention include human sarcomas and carcinomas, e.g., fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, liver cancer, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, bone cancer, brain tumor, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma; leukemias, e.g., acute lymphocytic leukemia and acute myelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström’s macroglobulinemia, and heavy chain disease. In some embodiments, cancers are epithelial in nature and include but are not limited to, bladder cancer, breast cancer, cervical cancer, colon cancer, gynecologic cancers, renal cancer, laryngeal cancer, lung cancer, oral cancer, head and neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, or skin cancer. In other embodiments, the cancer is breast cancer, prostate cancer, lung cancer, or colon cancer. In still other embodiments, the epithelial cancer is non-small-cell lung cancer, nonpapillary renal cell carcinoma, cervical carcinoma, ovarian carcinoma (e.g., serous ovarian carcinoma), or breast carcinoma. The epithelial cancers may be characterized in various other ways including, but not limited to, serous, endometrioid, mucinous, clear cell, Brenner, or undifferentiated.

[0133] The term “cancer therapy” or “cancer therapeutic agent” as used herein, refers to those therapies or agents that can exert anti-tumor effect or have an anti-tumor activity. Such anti-tumor effect or anti-tumor activity can be exhibited as a reduction in the rate of tumor cell proliferation, viability, or metastatic activity. A possible way of showing anti-tumor activity is to show a decline in growth rate of abnormal cells that arises during therapy or tumor size stability or reduction. Such activity can be assessed using accepted in vitro or in vivo tumor models, including but not limited to xenograft models, allograft models, MMTV models, and other known models known in the art to investigate anti-tumor activity.

[0134] The term “infectious disease” is meant to include diseases or conditions that can be transmitted from one individual to another (e.g., from human to human, from animal to human,from bird to human and the like) and includes agents such as bacteria, fungi, protozoa, and virus.

[0135] The terms “treat,” “treating,” and “treatment” are meant to include alleviating or abrogating a condition, disorder, or disease, or one or more of the symptoms associated with the condition, disorder, or disease; or alleviating or eradicating the cause(s) of the condition, disorder, or disease itself.

[0136] The terms “prevent,” “preventing,” and “prevention” are meant to include a method of delaying and / or precluding the onset of a condition, disorder, or disease, and / or its attendant symptoms; barring a subject from acquiring a condition, disorder, or disease; or reducing a subject’s risk of acquiring a condition, disorder, or disease.

[0137] In some embodiments, “preventing” a proliferative (e.g., cancer) disease refers to providing prophylaxis with respect to occurrence or recurrence of the proliferative disease. In some embodiments, preventing a proliferative disease (e.g., cancer) refers to causing the clinical symptoms of the proliferative disease not to develop in a patient that does not yet have or has not yet experienced or displayed symptoms of the proliferative disease. In some embodiments treating or delaying the progression of a proliferative disease (e.g., cancer) refers to approach for obtaining beneficial or desired results including clinical results. For example, beneficial or desired clinical results in treating or delaying progression of a proliferative disease include, but are not limited to, one or more of the following: alleviating one or more symptoms resulting from the proliferative disease, diminishing the extent of the proliferative disease, stabilizing the proliferative disease ( e.g., preventing or delaying the worsening of the proliferative disease), preventing or delaying the spread (e.g., metastasis) of the proliferative disease, preventing or delaying the recurrence of the proliferative disease, delay or slowing the progression of the proliferative disease, ameliorating the disease state of the proliferative disease, providing a remission (partial or total) of the proliferative disease, decreasing the dose of one or more other medications required to treat the proliferative disease, delaying the progression of the proliferative disease, increasing or improving the quality of life, increasing weight gain, and / or prolonging survival. In some embodiments, treatment refers to a reduction of pathological consequence of proliferative disease (for example, tumor volume, wherein the proliferative disease is cancer).

[0138] In some embodiments, “preventing” an infectious disease refers to providing prophylaxis with respect to occurrence or recurrence of the infectious disease. In someembodiments, preventing an infectious disease refers to causing the clinical symptoms of the infectious disease not to develop in a patient that does not yet have or has not yet experienced or displayed symptoms of the infectious disease. In some embodiments, treating or delaying an infectious disease in an individual refers to an intervention designed to alter the natural course of the individual being treated during the course of clinical pathology. Desirable effects of treating an infectious disease include decreasing the rate of progression, ameliorating or palliating the pathological state, and remission or improved prognosis of a particular disease, disorder, or condition. An individual is successfully “treated”, for example, if one or more symptoms associated with a particular infectious disease are mitigated or eliminated.

[0139] By "optional" or "optionally" is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined herein. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible, and / or inherently unstable. It will also be understood that where a group or moiety is optionally substituted, the disclosure includes both embodiments in which the group or moiety is substituted and embodiments in which the group or moiety is unsubstituted. II. Methods of treatment

[0140] Provided herein are methods of treating, delaying progression, or preventing a proliferative disease or an infectious disease in an individual that comprise administering to the individual (a) an effective amount of a conjugate comprising a targeting moiety (such as an antibody or antigen binding fragment thereof) that is capable of binding to the surface of an immune cell, such as a myeloid cell or a lymphoid cell, such as a monocyte, a T cell (e.g., a cytotoxic T cell), a B cell, an NK cell, a dendritic cell, or a macrophage, wherein the targeting moiety is covalently linked to one or more immunomodulating oligonucleotides (e.g., CpG oligonucleotide), and (b) an effective amount of an immune honing agent. In some embodiments, an immune honing agent (IHA) is one or more antigens, one or more pathogens, or portion thereof, expressing or exposing one or more antigens, one or more agents presenting an antigen, one or more agents capable of producing an antigen, or agent capable of inducing the host to produce an antigen. In some embodiments, the IHA is a vaccine.

[0141] In any of the embodiments, the provided methods can further include administering an additional component, such as an additional therapeutic agent. In any of the embodiments, the therapeutic agent is a treatment for a disease or condition, such as a proliferative disease, an infectious disease, or an allergic response. In some embodiments, the provided methods include administering a cancer therapeutic agent. In some embodiments the cancer therapeutic agent includes but is not limited to an immunotherapy (e.g., a checkpoint inhibitor immunotherapy, such as an anti-PD-1, anti-PD-L1, or anti-CTLA4 therapy), a chemotherapy, a radiation therapy, a hormone therapy, a hyperthermia therapy, a photodynamic therapy, a surgery, or another targeted therapy. In some embodiments, the provided methods include administering a therapeutic agent that is an antiviral, antibiotic, antimicrobial, antiparasitic, or antifungal agent.

[0142] In any of the embodiments, the individual is a human or non-human primate. In some embodiments, the targeting moiety is an antibody, such an immune cell-targeted antibody or antigen binding fragment, such as an antibody or antigen binding fragment targeting a myeloid cell or a lymphoid cell, such as a monocyte, a T cell (e.g., a cytotoxic T cell), a B cell, an NK cell, a dendritic cell, or a macrophage.

[0143] In some embodiments, the provided methods enhance the immune response to an antigen, such as an antigen associated with a proliferative disease, an infectious disease, or an allergic response. Such enhancement may include an improved level, duration or earlier initiation of a response as compared to methods administering an effective amount of an immune honing agent alone or administering the conjugate alone. In some aspects, the provided methods enhance the immune response to an antigen associated with a disease, such as a proliferative disease, an infectious disease, or an allergic response, compared to methods administering an effective amount of an immune honing agent (IHA) in combination with a corresponding unconjugated CpG oligonucleotide. In some aspects, the provided methods enhance the immune response to an antigen associated with a disease, such as a proliferative disease, an infectious disease, or an allergic response, compared to methods administering an effective amount of an immune honing agent in combination with a corresponding unconjugated (e.g., naked) antibody.

[0144] In some embodiments, the enhanced immune response in a subject is an enhanced proinflammatory response. In some embodiments, an enhanced immune response is an enhanced antibody response in the subject. In some embodiments, an enhanced antibody response results in increased antibody titers in a subject, such as IgG and / or IgM antibody titersin the subject. In some embodiments, an enhanced antibody response is an enhanced antigen- specific immune response, such as an enhanced antibody response to an antigen associated with a disease or condition (e.g., a proliferative disease or an infectious disease). In some embodiments of the provided methods, the enhanced immune response results in increased numbers of immune cells to a site of a proliferative disease (e.g., a tumor) or site of an infection. In some embodiments of the provided methods, the enhanced immune response includes stimulation of immune cells to proliferate and / or to become activated in the subject.

[0145] In some embodiments, the enhanced immune response in a subject is an enhanced response of one or more immune cells. In some embodiments, the enhanced immune response in a subject is an enhanced antigen-specific T-cell response. In some embodiments, the enhanced immune response in a subject is an enhanced macrophage response. In some embodiments, the enhanced immune response in a subject is an enhanced dendritic cell response.

[0146] In some embodiments, the provided methods result in increased immune cell activities within a subject compared to the immune cell activities within a subject following administration of an immune honing agent alone, a conjugate described herein alone, a combination of the immune honing agent and a corresponding unconjugated CpG oligonucleotide, or a combination of the immune honing agent and a corresponding unconjugated antibody. In some embodiments, the provided methods result in increased immune cell activities within a subject compared to the immune cell activities within a subject following administration of a therapeutic agent. In some embodiments, the provided methods result in increased immune cell activities within a subject compared to the immune cell activities within a subject following administration of an immune honing agent and a therapeutic agent, a conjugate described herein and a therapeutic agent, a combination of the immune honing agent and a corresponding unconjugated CpG oligonucleotide and a therapeutic agent, or a combination of the immune honing agent and a corresponding unconjugated antibody and a therapeutic agent. Enhanced immune cell activities can include activities related to an immune response, for example such as the exemplary immune cell activities described herein. A. B-Cell-Targeted Methods of Treatment

[0147] Provided herein are methods of treating, delaying progression, or preventing a proliferative disease or an infectious disease in an individual that comprise administering tothe individual (a) an effective amount of a conjugate comprising a targeting moiety (such as an antibody or antigen binding fragment thereof) that is capable of binding to the surface of a B- cell, wherein the targeting moiety is covalently linked to one or more immunomodulating oligonucleotides (e.g., CpG oligonucleotide), and (b) an effective amount of an immune honing agent. In some embodiments, an immune honing agent (IHA) is one or more antigens, one or more pathogens, or portion thereof, expressing or exposing one or more antigens, one or more agents presenting an antigen, one or more agents capable of producing an antigen, or agent capable of inducing the host to produce an antigen. In some embodiments, the IHA is a vaccine. In any of the embodiments, the individual is a human or non-human primate. In some embodiments, the targeting moiety is an antibody, such as B-cell-targeted antibody or antigen binding fragment.

[0148] In some embodiments, the provided methods enhance the immune response to an antigen, such as an antigen associated with a proliferative disease, an infectious disease, or an allergic response. Such enhancement may include an improved level, duration or earlier initiation of a response as compared to methods administering an effective amount of an immune honing agent alone or administering the conjugate alone. In some aspects, the provided methods enhance the immune response to an antigen associated with a disease, such as a proliferative disease, an infectious disease, or an allergic response, compared to methods administering an effective amount of an immune honing agent in combination with a corresponding unconjugated CpG oligonucleotide. In some aspects, the provided methods enhance the immune response to an antigen associated with a disease, such as a proliferative disease, an infectious disease, or an allergic response, compared to methods administering an effective amount of an immune honing agent in combination with a corresponding unconjugated (e.g., naked) antibody.

[0149] In some embodiments, the enhanced immune response in a subject is an enhanced proinflammatory response. In some embodiments, an enhanced immune response is an enhanced antibody response in the subject. In some embodiments, an enhanced antibody response results in increased antibody titers in a subject, such as IgG and / or IgM antibody titers in the subject. In some embodiments, an enhanced antibody response is an enhanced antigen- specific immune response, such as an enhanced antibody response to an antigen associated with a disease or condition (e.g., a proliferative disease or an infectious disease). In some embodiments of the provided methods, the enhanced immune response results in increased numbers of immune cells to a site of a proliferative disease (e.g., a tumor) or site of an infection.In some embodiments of the provided methods, the enhanced immune response includes stimulation of immune cells to proliferate and / or to become activated in the subject.

[0150] In some embodiments of the provided methods, the enhanced immune response results in enhanced cell-mediated immunity (CMI). In some embodiments, the enhanced immune response includes an increased type 1 helper (Th1) cell response. In some embodiments, an increased Th1 response results in increased levels of cytokines, such as interferon-gamma (IFNγ), interleukin-2 (IL-2), and / or tumor necrosis factor-beta (TNF-β), which activate macrophages and contribute to CMI and phagocyte-dependent protective responses. In some embodiments, an enhanced Th1 response results in increased stimulation of B cells and / or increased B cell production of antibodies, such as IgG and / or IgM antibodies.

[0151] In some embodiments, the provided methods yield a higher antibody titer in the blood of a subject compared with an antibody titer produced in a subject following administration of an immune honing agent alone, a conjugate described herein alone, a combination of the immune honing agent and a corresponding unconjugated CpG oligonucleotide, or a combination of the immune honing agent and a corresponding unconjugated antibody. Antibody titers can be measured by any method known in the art, such as antibody endpoint titration, enzyme-linked immunosorbent assay (ELISA), or spectrophotometry. Exemplary antibody measurements can include measurements of IgG and or IgM antibodies, such as one or more of IgG1, IgG2a, IgG2b, IgG3, and IgM antibodies. Methods of measuring antibody isotypes are routine and can be used to determine isotype antibody titers in response to the provided methods.

[0152] In some embodiments, the provided methods yield a higher antigen-specific antibody titer in the blood of a subject compared with an antigen-specific antibody titer produced in a subject following administration of an immune honing agent alone, a conjugate described herein alone, a combination of the immune honing agent and a corresponding unconjugated CpG oligonucleotide, or a combination of the immune honing agent and a corresponding unconjugated antibody. In some embodiments, the higher titer of antigen- specific antibodies includes a higher titer or antigen-specific neutralizing antibodies.

[0153] In some embodiments, the duration of an antibody response when employing the provided methods to a subject is of longer duration as compared with the antibody response produced in a subject following administration of an immune honing agent alone, a conjugate described herein alone, a combination of the immune honing agent and a correspondingunconjugated CpG oligonucleotide, or a combination of the immune honing agent and a corresponding unconjugated antibody.

[0154] In some embodiments, the provided methods result in increased neutralizing antibody activity of the antigen compared with the neutralizing antibody activity produced in a subject following administration of an immune honing agent alone, a conjugate described herein alone, a combination of the immune honing agent and a corresponding unconjugated CpG oligonucleotide, or a combination of the immune honing agent and a corresponding unconjugated antibody. Neutralizing antibodies bind antigens, expressed on the surface of a pathogen, an infectious particle or agent, such as a virus, or a toxin in such a manner to neutralize biological effects of the pathogen or infectious particle or agent and block infection and / or toxic activity. Antigen neutralization activity of the serum of subjects can be tested using known immunoassays, such as ELISA.

[0155] In some embodiments, the provided methods result in an increased B-cell response in the subject compared to the B-cell response in a subject following administration of an immune honing agent alone, a conjugate described herein alone, a combination of the immune honing agent and a corresponding unconjugated CpG oligonucleotide, or a combination of the immune honing agent and a corresponding unconjugated antibody. Techniques for measuring B cell responses are well-known and include enzyme-linked immunosorbent spot (ELISpot), flow cytometry, mass cytometry, and fluorescence microscopy to identify and / or isolate B cells. Specific B cells, such as antigen-specific B cells can also be isolated using these methods. Enrichment protocols can be used in combination with such techniques to improve analysis. In some embodiments, isolated B cells can be subjected to sequencing, such as single cell sequencing. In some embodiments, increased B-cell response includes increased B-cell proliferation. In some embodiments, increased B-cell response includes increased B-cell activation. Markers of B cell activation and signaling. In some embodiments, increased B-cell response includes increased persistence of antigen-specific B-cells.

[0156] In some embodiments, the increased B-cell response is an increased memory B-cell response. In some embodiments, memory B-cell response is measured by increased or prolonged recall of an antigen of the disease, infectious agent or particle, allergen, or toxin. In some embodiments, antibodies can be harvested from cultured B cells isolated from treated subjects and analyzed for activity. In some embodiments, antibodies, isolated from serum or collected from isolated B cells, from subjects treated using the provided methods exhibit ACE- 2 receptor blocking activity.

[0157] Any of such responses indicate increased immunity as a result of applying the provided methods. B. Dendritic Cell-Targeted Methods of Treatment

[0158] Provided herein are methods of treating, delaying progression, or preventing a proliferative disease or an infectious disease in an individual that comprise administering to the individual (a) an effective amount of a conjugate comprising a targeting moiety (such as an antibody or antigen binding fragment thereof) that is capable of binding to the surface of a dendritic cell, wherein the targeting moiety is covalently linked to one or more immunomodulating oligonucleotides (e.g., CpG oligonucleotide), and (b) an effective amount of an immune honing agent. In some embodiments, an immune honing agent (IHA) is one or more antigens, one or more pathogens, or portion thereof, expressing or exposing one or more antigens, one or more agents presenting an antigen, one or more agents capable of producing an antigen, or agent capable of inducing the host to produce an antigen. In some embodiments, the IHA is a vaccine. In any of the embodiments, the individual is a human or non-human primate. In some embodiments, the targeting moiety is an antibody, such as a dendritic cell- targeted antibody or antigen binding fragment.

[0159] In some embodiments, the provided methods enhance the immune response to an antigen, such as an antigen associated with a proliferative disease, an infectious disease, or an allergic response. Such enhancement may include an improved level, duration or earlier initiation of a response as compared to methods administering an effective amount of an immune honing agent alone or administering the conjugate alone. In some aspects, the provided methods enhance the immune response to an antigen associated with a disease, such as a proliferative disease, an infectious disease, or an allergic response, compared to methods administering an effective amount of an immune honing agent (IHA) in combination with a corresponding unconjugated CpG oligonucleotide. In some aspects, the provided methods enhance the immune response to an antigen associated with a disease, such as a proliferative disease, an infectious disease, or an allergic response, compared to methods administering an effective amount of an immune honing agent in combination with a corresponding unconjugated (e.g., naked) antibody.

[0160] In some embodiments, the provided methods result in increased T cell priming and / or T cell activation, such as antigen-specific T cell priming and / or activation, within a subject compared to within a subject following administration of an immune honing agentalone, a conjugate described herein alone, a combination of the immune honing agent and a corresponding unconjugated CpG oligonucleotide, or a combination of the immune honing agent and a corresponding unconjugated antibody. In some embodiments, the increased T cell priming and / or activation results in increased interferon gamma (IFNγ) secretion.

[0161] In some embodiments, the provided methods result in increased dendritic cell activities within a subject compared to within a subject following administration of an immune honing agent alone, a conjugate described herein alone, a combination of the immune honing agent and a corresponding unconjugated CpG oligonucleotide, or a combination of the immune honing agent and a corresponding unconjugated antibody. In some embodiments, the increased dendritic cell activities include enhanced antigen presentation, such as by increased HLA-DR expression. In some embodiments, the increased dendritic cell activities include upregulation of co-stimulatory molecules on dendritic cells. In some embodiments, the increased dendritic cell activities include upregulation of CD40 and / or CD86 co-stimulatory molecules on dendritic cells. In some embodiments, the increased dendritic cell activities include increased secretion of pro-inflammatory cytokines. In some embodiments the increased dendritic cell activities include secretion of IFNα2 and / or IL-12 pro-inflammatory cytokines. III. Exemplary diseases and conditions for treatment A. Proliferative Disease

[0162] In some embodiments, the individual to be treated has a proliferative disease, is predisposed to developing a proliferative disease or is at risk of developing a proliferative disease. In some embodiments, the methods and treatments described herein treat, reduce, prevent, or ameliorate one or more symptoms of a proliferative disease. In some embodiments, the proliferative disease is a cancer. In some embodiments, the cancer is a tumor, e.g., a primary tumor, an advanced or metastatic solid tumor, or a liquid tumor. In some embodiments, the cancer to be treated is head and neck squamous cell carcinoma (HNSCC), non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), gastric cancer, hepatocellular carcinoma (HCC), esophageal cancer, cervical cancer, cervical squamous cell carcinoma, Merkle cell carcinoma, endometrial cancer, ovarian cancer, pancreatic cancer, melanoma, cutaneous melanoma, sarcoma, colorectal cancer, breast cancer, small cell lung cancer (SCLC), cutaneous squamous cell carcinoma, and urothelial carcinoma, leukemia, lymphoma, myeloma, acute lymphoblastic leukemia (ALL), hairy cell leukemia, and diffuse large B cell lymphoma (DLBCL). In some embodiments, the cancer to be treated is triple negative breast cancer, melanoma,ovarian cancer or colon cancer. In some embodiments, the cancer to be treated is a blood cancer, such as a leukemia, a lymphoma, or a myeloma. B. Infectious Disease

[0163] In some embodiments, the methods and treatments described herein treat, reduce, prevent, or ameliorate one or more symptoms of an infectious disease. In some embodiments, the individual has an infectious disease. In some embodiments, the infectious disease is a virus. In some embodiments, the virus is from the viral family Retroviridae (e.g. human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV- III / LAV, or HIV-III; and other isolates, such as HIV-LP); Picornaviridae (e.g., polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis viruses, rubella viruses); Flaviridae (e.g., dengue viruses, encephalitis viruses, yellow fever viruses); Coronoviridae (e.g., coronaviruses); Rhabdoviradae (e.g., vesicular stomatitis viruses, rabies viruses); Filoviridae (e.g., ebola viruses); Paramyxoviridae (e.g., parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g., influenza viruses); Bungaviridae (e.g., Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses); Arena viridae (hemorrhagic fever viruses); Reoviridae (e.g., reoviruses, arboviruses and rotaviruses); Birnaviridae; Hepadnaviridae (Hepatitis B virus); Parvovirida (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae (herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes virus); Poxviridae (variola viruses, vaccinia viruses, pox viruses); and Iridoviridae (e.g., African swine fever virus); and unclassified viruses (e.g., the etiological agents of Spongiform encephalopathies, the agent of delta hepatitis (thought to be a defective satellite of hepatitis B virus), the agents of non-A, non-B hepatitis (class 1=internally transmitted; class 2=parenterally transmitted (i.e., hepatitis C virus); Norwalk and related viruses, and astroviruses). In some embodiments, the virus is Respiratory Syncytial Virus (RSV), Herpes Simplex Virus 1 (HSV1), Herpes Simplex Virus 2 (HSV2), Human Immunodeficiency Virus-1 (HIV1), or HIV2.

[0164] In some embodiments, the infectious disease is bacterial. In some embodiments, the bacterial infectious disease is caused by Pasteurella species, Staphylococci species, or Streptococcus species. In some embodiments, the bacterial infectious disease is caused by a gram-negative bacteria including, but not limited to, Escherichia coli, Pseudomonas species,or Salmonella species. In some embodiments, the bacterial infectious disease is caused by Helicobacter pylori, Borrelia burgdorferi, Legionella pneumophilia, Mycobacteria sps. (e.g., M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae (Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (anaerobic sps.), Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasteurella multocida, Bacteroides sp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidum, Treponema pertenue, Leptospira, Rickettsia, and Actinomyces israelli. In some embodiments, the bacterial infectious disease is caused by a bacterium that causes dental caries, for example Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguinis, Lactobacillus acidophilus, or Actinomyces viscosus. In other embodiments, a bacterium is one that causes periodontal disease, for example Porphyromonas gingivalis or Actinobacillus actinomycetemcomitans.

[0165] In some embodiments, the infectious disease is fungal. In some embodiments, the fungus is Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans.

[0166] In some embodiments, the infectious disease is caused by other organisms than viruses or bacteria (i.e., protists) including Plasmodium spp. such as Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax and Toxoplasma gondii. Blood- borne and / or tissues parasites include Plasmodium spp., Babesia microti, Babesia divergens, Leishmania tropica, Leishmania spp., Leishmania braziliensis, Leishmania donovani, Trypanosoma gambiense and Trypanosoma rhodesiense (African sleeping sickness), Trypanosoma cruzi (Chagas' disease), and Toxoplasma gondii. In some embodiments, a parasite is one associated with malaria. Other medically relevant microorganisms have been described extensively in the literature, e.g., see C. G. A Thomas, Medical Microbiology, Bailliere Tindall, Great Britain 1983. Plasmodium falciparum, Toxoplasma gondii, Entamoeba hystolitica, Trypanosoma brucei, Leishmania promastigotes, Giardia lamblia, Trichomonas vaginalis, Cryptosporidium. C. Allergies and Allergic Reactions

[0167] In some embodiments, the individual has an allergy or an allergic reaction, or is at risk of an allergy or allergic reaction. In some embodiments, the methods and treatments described herein treat, reduce, prevent, or ameliorate one or more symptoms or the severity of an allergic reaction in the individual. An allergen is a substance that can induce an allergic or asthmatic response in a susceptible subject. Allergens include, for example, pollens, insect venoms, animal dander dust, fungal spores and drugs (e.g., penicillin). Examples of natural, animal and plant allergens include proteins specific to the following genera: Canine (Canis familiaris); Dermatophagoides (e.g. Dermatophagoides farinae); Felis (Felis domesticus); Ambrosia (Ambrosia artemiisfolia); Lolium (e.g. Lolium perenne or Lolium multiflorum); Cryptomeria (Cryptomeria japonica); Alternaria (Alternaria alternata); Alder; Alnus (Alnus gultinosa); Betula (Betula verrucosa); Quercus (Quercus alba); Olea (Olea europa); Artemisia (Artemisia vulgaris); Plantago (e.g. Plantago lanceolata); Parietaria (e.g. Parietaria officinalis or Parietaria judaica); Blattella (e.g. Blattella germanica); Apis (e.g. Apis multiflorum); Cupressus (e.g. Cupressus sempervirens, Cupressus arizonica and Cupressus macrocarpa); Juniperus (e.g. Juniperus sabinoides, Juniperus virginiana, Juniperus communis and Juniperus ashei); Thuya (e.g. Thuya orientalis); Chamaecyparis (e.g. Chamaecyparis obtusa); Periplaneta (e.g. Periplaneta americana); Agropyron (e.g. Agropyron repens); Secale (e.g. Secale cereale); Triticum (e.g. Triticum aestivum); Dactylis (e.g. Dactylis glomerata); Festuca (e.g. Festuca elatior); Poa (e.g. Poa pratensis or Poa compressa); Avena (e.g. Avena sativa); Holcus (e.g. Holcus lanatus); Anthoxanthum (e.g. Anthoxanthum odoratum); Arrhenatherum (e.g. Arrhenatherum elatius); Agrostis (e.g. Agrostis alba); Phleum (e.g. Phleum pratense); Phalaris (e.g. Phalaris arundinacea); Paspalum (e.g. Paspalum notatum); Sorghum (e.g. Sorghum halepensis); and Bromus (e.g. Bromus inermis). The term “allergy” refers to acquired hypersensitivity to a substance (allergen). An “allergic reaction” is the response of an immune system to an allergen in a subject allergic to the allergen. Allergic conditions include eczema, allergic rhinitis or coryza, hay fever, bronchial asthma, urticaria (hives) and food allergies, and other atopic conditions. IV. Exemplary Conjugates

[0168] In the methods herein, immunomodulating polynucleotides (e.g., CpG ODNs) are conjugated to an immune cell-targeting moiety, such as an antibody or antigen-binding fragment thereof (Ab) that binds to an antigen expressed on the surface of an immune cell, such as a B-cell or myeloid cell (e.g., a dendritic cell), and such conjugates are administered in conjunction with an immune honing agent to provide the treatments described herein.

[0169] Exemplary targeting moieties and immunomodulating oligonucleotides are described herein. The targeting moiety can be conjugated to the immunomodulating oligonucleotide using any method well-known in the art. In some embodiments, the targeting moiety that binds to the surface of an immune cell is conjugated to the immunomodulating oligonucleotide using a method described in, e.g., WO 2010 / 132622; US 2007 / 0212337; WO 2020 / 081744; US 2018 / 0312536; US 2008 / 0031887; WO 2011 / 097384; WO 2018 / 189382, WO 2021 / 174091 , WO 2022 / 040173, and others. In some embodiments, the immunomodulating polynucleotides (e.g., CpG ODNs) can be conjugated via a transglutaminase-mediated reaction to the targeting moiety. A. Exemplary immunomodulating polynucleotides

[0170] In some embodiments, the conjugate comprises a CpG ODN attached via a linking moiety to an antibody or antigen-binding fragment thereof that binds to an antigen expressed on the surface of an immune cell. In some embodiments, one antibody (or antigen binding fragment thereof) can be conjugated to one or more CpG ODNs. In some embodiments, the oligonucleotide-antibody conjugate is a conjugate comprising an antibody or antigen-binding fragment thereof and one or more immunomodulating oligonucleotides (P) (CpG ODN), wherein the antibody or antigen-binding fragment is linked to one or more Q-tag peptides (Q) comprising at least one glutamine residue, wherein each immunomodulating oligonucleotide is linked to a Q-tag peptide via an amide bond with the glutamine residue of the Q-tag peptide and a linker (L) as shown in Formula (A):or a stereoisomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; wherein: indicates the point of attachment of each Q to the antibody or antigen-binding fragment thereof (Ab); each Q is independently a Q-tag peptide sequence comprising at least one glutamine residue;each L is independently a bond or a linker moiety connected to Q via an amide bond with the glutamine residue; and each P is independently an immunomodulating oligonucleotide.

[0171] In some embodiments, the oligonucleotide-antibody conjugate has a DAR ranging from about 1 to about 20, from about 1 to about 10, from about 1 to about 8, from about 1 to about 4, or from about 1 to about 2. In another embodiment, the oligonucleotide-antibody conjugate has a DAR of about 1, about 2, about 3, about 4, about 5, about 6, about 7, or about 8.

[0172] In some embodiments, the conjugate comprises one or more Q-tag peptides. In some embodiments, the conjugate has 2 Q-tag peptides. In some embodiments, the conjugate comprises one or more or two or more immunomodulating oligonucleotides. In some embodiments, the conjugate has one immunomodulating oligonucleotide.

[0173] In certain embodiments, the conjugate comprises an immunostimulating polynucleotide that comprises one or more phosphotriesters (e.g., internucleoside phosphotriesters) and / or phosphorothioates (e.g., from about 1 to about 6 or from about 1 to about 4), e.g., at one or both termini (e.g., within the six 5’-terminal nucleosides or the six 3’- terminal nucleosides). The inclusion of one or more internucleoside phosphotriesters and / or phosphorothioates can enhance the stability of the polynucleotide by reducing the rate of exonuclease-mediated degradation.

[0174] In certain embodiments, the conjugate comprises an immunostimulating polynucleotide that comprises a phosphotriester or a terminal phosphodiester, where the phosphotriester or the terminal phosphodiester comprises a linker bonded to a targeting moiety or a conjugating group and optionally to one or more (e.g., from about 1 to about 6) auxiliary moieties. In certain embodiments, the immunostimulating polynucleotide comprises only one linker. In certain embodiments, the immunostimulating polynucleotide comprises only one conjugating group.

[0175] In one aspect, the oligonucleotide of the oligonucleotide-antibody conjugate comprises one or more CpG sites. In some embodiments, the oligonucleotide comprises at least 1, at least 2, or at least 3 CpG sites.

[0176] In some embodiments, the conjugate comprises an oligonucleotide that comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, atleast 11, at least 12, at least 13, at least 14, or at least 15 phosphorothioate linkages. In some embodiments, the phosphorothioate internucleoside linkages or phosphorodithioate internucleoside linkages are between the nucleotides at positions 1-3, 2-4, 3-5, 4-6, 4-5, 6-8, 7- 9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, 18-20 or 19-21 from the 5' end of the oligonucleotide. In some embodiments, the oligonucleotide comprises one or more modified nucleotides and one or more modified internucleoside linkages.

[0177] In some embodiments, the conjugate comprises an oligonucleotide that is about 10- 30, about 10-15, about 15-20, about 20-25, about 25-30, about 15-25 nucleotides in length. In some embodiments, the oligonucleotide is about 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length.

[0178] In some embodiments, the conjugate comprises an oligonucleotide structure set forth in PCT application WO2018 / 189382, incorporated herein by reference in its entirety.

[0179] In some embodiments, the conjugate comprises an oligonucleotide that has the structure: X5’-(XN)b-YP-(XN)c-X3’or a stereoisomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; wherein each XNis independently a nucleotide; X3'is a 3' terminal nucleotide; X5'is a 5' terminal nucleotide; YPis an internucleoside phosphotriester; and b and c are each an integer ranging from about 0 to about 25; with the proviso that their sum is no less than 5; wherein the oligonucleotide comprises a nucleotide with a modified nucleobase. In some aspects, each XNis independently a 2'-deoxyribonucleotide. In some aspects, X3' is a 2'- deoxyribonucleotide. In some aspects, X3' is 2'-deoxyadenosine, 2'-deoxyguanosine, 2'- deoxycytidine, a 5-halo-2'-deoxycytidine, T-deoxythymidine, 2'-deoxyuridine, or a 5-halo-2'- deoxyuridine. In some aspects, X3' is 2'-deoxythymidine. In some aspects, X3' is a 2'-modified ribonucleotide. In some aspects, X3' is a 2'-methoxy ribonucleotide or 2'-ethoxymethoxy ribonucleotide. In some aspects, X5'is a 2'-deoxyribonucleotide. In some aspects, X5'is 2'- deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, a 5-halo-2'-deoxycytidine, T- deoxythymidine, 2'-deoxyuridine, or a 5-halo-2'-deoxyuridine. In some aspects, X5'is a 2'- deoxyribonucleotide with a substituted pyrimidine base. In some aspects, X5'is a 2'- deoxyribonucleotide with a 5-substituted pyrimidine base. In some aspects, X5'is 2'- deoxythymidine, a 5-halo-2'-deoxycytidine, or a 5-halo-2'deoxyuridine. In some aspects, X5'is a 5-halo-2'-deoxycytidine. In some aspects X5' is a 5-halo-2'-deoxyuridine. In some aspects, X5'is 2'-deoxythymidine, 5-bromo-2'-deoxycytidine, 5-iodo-2'-deoxycytidine, 5-bromo-2'- deoxyuridine, or 5-iodo-2'-deoxyuridine. In some aspects X5' is 2'-deoxythymidine, 5-bromo-2'-deoxyuridine, or 5-iodo-2'-deoxyuridine. In some aspects, X5'has a 3'-phosphorothioate group. In some aspects YPis:wherein Z is O or S; and d is an integer ranging from about 0 to about 50. In some aspects YPis:wherein Z is O or S; and d is an integer ranging from about 0 to about 50.

[0180] In some embodiments, the conjugate comprises an oligonucleotide that has the structure set forth in PCT / US2021 / 20039 (published as WO2021 / 174091).

[0181] In some embodiments, the conjugate comprises an oligonucleotide that has the structure:whereinandindicate the points of attachment within the oligonucleotide; each T1is independently O or S; each T2is O- or S-; T3is a gp wherein † indicates the point of attachment to L and wherein # indicates the point of attachment to the rest of the oligonucleotide; Z is O or S; U5’is –H or halogen; R5’is -H or methoxy; Rc1is -H or methoxy;Rg1, Rg2, Rg3, and Rg4are H or oxo, wherein if one of Rg1, Rg2, Rg3, and Rg4is oxo, then the carbon to which the oxo is attached has a single bond to the ring nitrogen at the 7- position; R3’is methoxy; R1is C1-4-alkylene-hydroxy; R2is -H or methyl; and n is an integer from 0 to 2.

[0182] In other embodiments, the conjugate comprises an oligonucleotide that has the structurewhereinindicate the points of attachment within the oligonucleotide; each T1is independently O or S;each T2is O- or S-; T3is a group , wherein† indicates the point of attachment to L and wherein # indicates the point of attachment to the rest of the oligonucleotide; Z is O or S; R5’is -H or methoxy; Rc1is -H or methoxy; Rg1, Rg2, Rg3, and Rg4are H or oxo, wherein if one of Rg1, Rg2, Rg3, and Rg4is oxo, then the carbon to which the oxo is attached has a single bond to the ring nitrogen at the 7- position; R3’is methoxy; R1is C1-4-alkylene-hydroxy; R2is -H or methyl; and n is an integer from 0 to 2.

[0183] In still other embodiments, the conjugate comprises an oligonucleotide that has the structurewhereinindicate the points of attachment within the oligonucleotide; each T1is independently O or S; each T2is O- or S-; T3is a group , wherein † indicates the point of attachment to L and wherein # indicates the point of attachment to the rest of the oligonucleotide; Z is O or S; R5’is -H or methoxy; Rc1is -H or methoxy;Rg1, Rg2, Rg3, and Rg4are H or oxo, wherein if one of Rg1, Rg2, Rg3, and Rg4is oxo, then the carbon to which the oxo is attached has a single bond to the ring nitrogen at the 7- position; R3’is methoxy; R1is C1-4-alkylene-hydroxy; R2is -H or methyl; and n is an integer from 0 to 2.

[0184] In still other embodiments, the conjugate comprises an oligonucleotide that has one of the structures in Table 1. Table 1: Exemplary oligonucleotide structuresB. Exemplary targeting moieties

[0185] In some embodiments, the conjugate comprises a targeting moiety that is an antibody or antigen binding fragment that binds to the surface of an immune cell (such as an antigen on the surface of an immune cell). In some embodiments, the conjugate comprises a targeting moiety that is an antibody or antigen binding fragment that binds to the surface of a lymphoid cell, such as a B cell or an NK cell (such as an antigen on the surface of a lymphoid cell, such as a B cell or an NK cell). In some embodiments, the conjugate comprises a targeting moiety that is an antibody or antigen binding fragment that binds to the surface of a B-cell (such as an antigen on the surface of a B-cell). In some embodiments, the conjugate comprises a targeting moiety that is an antibody or antigen binding fragment that binds to the surface of an NK cell (such as an antigen on the surface of an NK cell). In some embodiments, the conjugate comprises a targeting moiety that is an antibody or antigen binding fragment that binds to the surface of a myeloid cell, such as a monocyte (such as an antigen on the surface ofa myeloid cell, such as a monocyte). Exemplary monocytes include dendritic cells and macrophages. In some embodiments, the conjugate comprises a targeting moiety that is an antibody or antigen binding fragment that binds to the surface of a dendritic cell (such as an antigen on the surface of a dendritic cell). In some embodiments, the conjugate comprises a targeting moiety that is an antibody or antigen binding fragment that binds to the surface of a macrophage (such as an antigen on the surface of a macrophage).

[0186] In some embodiments, the antibody is a full-length antibody. In some embodiments, the antibody is an antigen-binding fragment of an antibody or an engineered derivative thereof, including, without limitation, a Fab, a F(ab')2, a Fab'-SH, an Fv, an scFv, an Fcab, a single domain antibody, a single light chain antibody, or a single heavy chain antibody. In some embodiments the conjugate comprises an antibody or antigen-binding fragment thereof that is (or is derived from) a human or chimeric (e.g., humanized) antibody. In some embodiments, the conjugate comprises an multispecific (e.g., bispecific) antibody or antibody construct. For example, in some embodiments, the conjugate comprises a bispecific antibody comprising two antigen binding domains that each bind a different antigen expressed on the same immune cell or two different immune cells. For example, in some embodiments, the conjugate comprises a bispecific antibody comprising two antigen binding domains that each bind a different antigen expressed on B cells or two antigen binding domains that each bind a different antigen expressed on dendritic cells. In some embodiments, the conjugate comprises a bispecific antibody comprising two antigen binding sites that each binds a different epitope of a single antigen expressed on immune cells, such as on B cells or on dendritic cells. In some embodiments, the conjugate comprises a bispecific antibody comprising an antigen binding site that binds an antigen expressed on a B cell or on a dendritic cell and an antigen binding site that binds a different antigen, e.g., an antigen expressed on another cell (e.g., another immune cells, such as a myeloid cell (e.g., a monocyte, such as a dendritic cell or a macrophage) or a lymphoid cell, such as a B cell or NK cell).

[0187] In some embodiments, the antibody (or antigen binding fragment thereof) that binds to an antigen expressed on the surface of a B-cell or a dendritic cell is selected from a group consisting of a polyclonal antibody, a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody, and an antibody fragment. In some embodiments, the antibody fragment is selected from the group consisting of Fab, Fab', Fab’-SH, F(ab')2, Fv fragments, scFv, single domain antibody, single heavy chain antibody and single light chain antibody. In some embodiments, the antibody (or antigen binding fragment thereof) comprises a light chainvariable domain (VL) and a heavy chain variable domain (VH). In some embodiments, the antibody (or antigen binding fragment thereof) is a human anti-IgG antibody (or antigen binding fragment thereof). In some embodiments, the antibody is an anti-IgG1, anti- IgG2 or anti-IgG4 antibody. In some embodiments, the antibody is an anti-CD22 antibody (e.g., RFB4, EPRA, 10F4, m971). In some embodiments, the antibody is an anti-human CD22 (hCD22) antibody. Further details regarding exemplary anti-hCD22 antibodies are provided elsewhere herein. In some embodiments, the antibody is an anti-human CD22 (hCD22) antibody. In some embodiments, the antibody is an anti-B cell receptor antibody, such as an anti-CD79b antibody. In some embodiments, the antibody is an anti-human CD79b (hCD79b) antibody). In some embodiments, the antibody is an anti-SIRPα antibody, such as an anti-human SIRPα (hSIRPα) antibody. Further details regarding exemplary anti-hSIRPα antibodies are provided elsewhere herein.

[0188] In some embodiments, wherein the individual has an infectious disease or a proliferative disease, the conjugate targets normal B cells. In some embodiments, wherein the individual has a proliferative disease (e.g., cancer), the conjugate targets an abnormal B cell, e.g., a cancerous B cell.

[0189] Exemplary antigens expressed by B cells that can be targeted by the antibody (or antigen binding fragment thereof) of a conjugate include, but are not limited to, e.g., B220 / CD45R, B7-1 / CD80, B7-2 / CD86, BCMA / TNFRSF17, BLIMP1 / PRDM1, C1q R1 / CD93, CD117 / c-kit, CD11b / Integrin alpha M, CD19, CD1c / BDCA-1, CD1d, CD20, CD21, CD23 / Fc epsilon RII, CD24, CD25 / IL-2 R alpha, CD27 / TNFRSF7, CD34, CD37, CD38, CD40 / TNFRSF5, CD43, CD5, CD69, CD72, CD83, CXCR4, CXCR5, DEP-1 / CD148, EMMPRIN / CD147, FCRL3 / FcRH3, Flt-3 / Flk-2, HLA-DR, IgM, IL-10, IL-12 R beta 2, IL- 12 / IL-35 p35, IL-21, IL-21 R, IL-27 R alpha / WSX-1 / TCCR, IL-27 / IL-35 EBI3 Subunit, IL-3 R alpha / CD123, IL-4 R alpha, IL-6 receptor, IL-7 R alpha / CD127, IRF4, MHC class II (I-A / I- E), Neprilysin / CD10, Pax5 / BSAP, Sca-1 / Ly6, Siglec-2 / CD22, STAT1, STAT3, Syndecan- 1 / CD138, TACI / TNFRSF13B, TGF-beta, TIM-1 / KIM-1 / HAVCR, TLR4. In particular embodiments, B cell specific antigens are selected from CD1, CD2, CD5, CD9, CD11, CD17, CD18, CD19, CD20, CD21 / CD35, CD22, CD23, CD24, CD25, CD27, CD30, CD38, CD40, CD45R / B220, CD69, CD70, CD78, CD79a (Ig^), CD79b (Ig^), CD80, CD86, CD93 (C1Rqp), CD137 / 4-1BB, CD138, CD180, CD252 / OX40L, CD267, CD268 / BAFF-R, CD279 / PD1, CD319, PDL-2, Pax-5, IgD, IgM, Notch 2, and TLR4.

[0190] In some embodiments, B cells can be targeted by a conjugate comprising an anti- CD38, anti-CD79b, anti-CD30, anti-CD22, or anti-CD20, anti-CD19 antibody or antigen- binding fragment thereof or engineered derivative thereof. In some embodiments, a conjugate comprises an immunomodulating oligonucleotide as described herein conjugated to an antibody (or antigen binding fragment thereof) that associates with or binds a B-cell surface antigen described herein (e.g., CD22, etc.).

[0191] Non-limiting examples of anti-CD38 antibodies are daratumumab, SAR650984, MOR202, or any one of antibodies Ab79, Ab19, Ab43, Ab72, and Ab110 disclosed in WO 2012 / 092616, the disclosure of these antibodies is incorporated herein by reference. A non- limiting example of an anti-CD79b antibody is huMA79b v28 disclosed in WO 2014 / 011521. A non-limiting example of an anti-CD22 antibody is 10F4 disclosed in US 2014 / 0127197. A non-limiting example of an anti-CD20 antibody is rituximab. A non-limiting example of an anti-DEC205 antibody is provided in US 2010 / 0098704, the antibodies of which are incorporated herein by reference. Non-limiting examples of anti-CD40 antibodies are lucatumumab and dacetuzumab. A non-limiting example of an anti-CD304 antibody is vesencumab.

[0192] In some embodiments, the antibody is selected from the group consisting of an anti- CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti CD37 antibody, anti-CD38 antibody, anti-CD40 antibody, anti-CD74 antibody, anti-CD79b antibody, anti-CD205 antibody, anti-CD274 antibody, anti-CD303 antibody, anti-CD304 antibody, anti-CD19 antibody, anti-CD1 antibody, anti-CD2 antibody, anti-CD3 antibody, anti-CD5 antibody, anti- CD6 antibody, anti-CD9 antibody, anti-CD11 antibody, anti-CD18 antibody, anti-CD21 antibody, anti-CD23 antibody, anti-CD24 antibody, anti-CD25 antibody, anti-CD26 antibody, anti-CD44 antibody, anti-CD45R antibody, anti-CD49 antibody, anti-CD66 (Carcinoembryonic antigen, CEA) antibody, anti-CD93 antibody, anti-CD52 antibody, anti- CD56 antibody, anti-CD123 antibody, anti-CD138 antibody, anti-CD163 antibody, anti- SLAMF7 antibody, anti-CD180 antibody, anti-DEC205 antibody, and anti-CD206 antibody. In some embodiments, the antibody is an anti-CD20 antibody. In some embodiments, the antibody is an anti-CD22 antibody.

[0193] In some embodiments, wherein the individual has an infectious disease or a proliferative disease (e.g., cancer), the conjugate targets dendritic cells. Exemplary antigens expressed by dendritic cells that can be targeted by the antibody (or antigen binding fragment thereof) of a conjugate include, but are not limited to, siglec-3, siglec 7, siglec 9, siglec 15,CD200, CD200R, LILRB1, LILRB2, LILRB3, LILRB4, LILRB5, M-CSF, CSF-1R, GM-CSF R, IL4 R, arginase, IDO, TDO, MPO, EP2, COX-2, CCR2, CCR5, CCR6, CCR-7, CCR8, CXCR1, CX3CR1, CXCR2, CXCR3, CXCR4, CXCR7, c-Kit, CD244, L-selectin / CD62L, CD11b, CD11c, CD68, CD163, CD204, DEC205 (CD205), IL-1R1, IL1-R2, IL1RAP, IL3RA, CD31, SIRP^, SIRP^, PD-L1, CEACAM-8 / CD66b, CD103, BDCA-1, BDCA2, BDCA-4, CD123, TLR1, TLR2, TLR3, TLR6, TNFRSF1A, TNFRSF1A, ILT-7, FLT3, DC-SIGN, Dectin-2, CLEC1, CLEC12B, CLEC2D, MRC1, and MRC2.

[0194] In some embodiments, the antibody is selected from the group consisting of an anti- siglec-3 antibody, anti-siglec 7 antibody, anti-siglec 9 antibody, anti-siglec 15 antibody, anti- CD200 antibody, anti-CD200R antibody, anti-LILRB1 antibody, anti-LILRB2 antibody, anti- LILRB3 antibody, anti-LILRB4 antibody, anti-LILRB5 antibody, anti-M-CSF antibody, anti- CSF-1R antibody, anti-GM-CSF R antibody, anti-IL4 R antibody, anti-arginase antibody, anti- IDO antibody, anti-TDO antibody, anti-MPO antibody, anti-EP2 antibody, anti-COX-2 antibody, anti-CCR2, anti-CCR5 antibody, anti-CCR6 antibody, anti-CCR-7 antibody, anti- CCR8 antibody, anti-CXCR1 antibody, anti-CX3CR1 antibody, anti-CXCR2 antibody, anti- CXCR3 antibody, anti-CXCR4 antibody, anti-CXCR7 antibody, anti-c-Kit, anti-CD244 antibody, anti-L-selectin / CD62L antibody, anti-CD11b antibody, anti-CD11c antibody, anti- CD68 antibody, anti-CD163 antibody, anti-CD204 antibody, anti-DEC205 (CD205) antibody, anti-IL-1R1 antibody, anti-IL1-R2 antibody, anti-IL1RAP antibody, anti-IL3RA antibody, anti-CD31 antibody, anti-SIRP^ antibody, anti-SIRP^ antibody, anti-PD-L1 antibody, anti- CEACAM-8 / CD66b antibody, anti-CD103 antibody, anti-BDCA-1 antibody, anti-BDCA2 antibody, anti-BDCA-4 antibody, anti-CD123 antibody, anti-TLR1 antibody, anti-TLR2 antibody, anti-TLR3 antibody, anti-TLR6 antibody, anti-TNFRSF1A antibody, anti- TNFRSF1A antibody, anti-ILT-7 antibody, anti-FLT3 antibody, anti-DC-SIGN antibody, anti- Dectin-2 antibody, anti-CLEC1 antibody, anti-CLEC12B antibody, anti-CLEC2D antibody, anti-MRC1 antibody, and anti-MRC2 antibody. In some embodiments, the antibody is an anti- DEC205 antibody. In some embodiments, the antibody is an anti-BDCA2 antibody. In some embodiments, the antibody is an anti-FLT3 antibody. In some embodiments, the antibody is an anti-SIRPα antibody.

[0195] A non-limiting example of an is provided in US 2010 / 0098704, the antibodies of which are incorporated herein by reference. A non-limiting example of an anti-BDCA2 antibody is litifilimab. A non-limiting example of an anti-FLT3 antibody is LY3012218. Non- limiting examples of anti-SIRPα antibodies are described herein.

[0196] In some embodiments, dendritic cells can be targeted by a conjugate comprising an anti-SIRPa antibody, anti-DEC205 antibody, anti-BDCA2 antibody, or anti-FLT3 antibody, or antigen-binding fragment thereof or engineered derivative thereof. In some embodiments, a conjugate comprises an immunomodulating oligonucleotide as described herein conjugated to an antibody (or antigen binding fragment thereof) that associates with or binds a dendritic cell surface antigen described herein (e.g., SIRPα, etc.).

[0197] In some embodiments, which may be combined with any of the foregoing embodiments, the antibody (or antigen binding fragment thereof) comprises an Fc region. In certain embodiments, the Fc region is a human Fc region selected from the group consisting of an IgGl Fc region, an IgG2 Fc region, and an IgG4 Fc region. In some embodiments, the Fc region is a wild-type human IgGl , IgG2, or IgG4 Fc region.

[0198] In some embodiments, an antibody (or antigen binding fragment thereof! that binds to an antigen expressed on the surface of an immune cell, such as a B-cell or a dendritic cell, is attached to a Q-tag described herein. In some embodiments, the Q tag comprises a glutamine residue which is linked to the rest of the conjugate. In still further embodiments of the present aspect, which may be combined with any of the preceding embodiments, each Q tag independently comprises or is a peptide sequence selected from the group consisting of SEQ ID NOs: 39-55 set forth in Table 2. In some embodiments, the Q-tag comprises LLQGG (SEQ ID NO: 172), GGGLLQGG (SEQ ID NO: 173), RPQGF (SEQ ID NO:47), or RPQGFGPP (SEQ ID NO:49). In some embodiments, the Q-tag comprises a peptide sequence RPQGF (SEQ ID NO:47). In certain embodiments, the Q-tag comprising a peptide sequence RPQGF (SEQ ID NO:47) is selected from the group consisting of RPQGF (SEQ ID NO:47), RPQGFPP (SEQ ID NO:48), and RPQGFGPP (SEQ ID NO:49). In some embodiments, the Q-tag comprises a peptide sequence RPQGFGPP (SEQ ID NO:49).Table 2. Exemplary Q-tag Peptide Sequences

[0199] In some embodiments, the Q-tag is attached to the heavy chain of the antibody. In some embodiments, the Q-tag is attached to the heavy chain of the antibody via a linker (e.g., an amino acid or other chemical linker). In some embodiments, the Q-tag is attached to the heavy chain of the antibody (e.g., fused in frame with the heavy chain). In some embodiments, the Q-tag is attached at the C-terminus of the heavy chain of the antibody. In some embodiments, the Q-tag is fused to the C-terminus of the heavy chain of the antibody (e.g., in frame and contiguous with the amino acid sequence of the C-terminus). In some embodiments, the Q-tag is within the Fc domain of the antibody. In some embodiments, the Q tag is naturally occurring. For example, mutation of N297 to N297A exposes Q295 of the antibody, where the conjugation could occur. In certain embodiments wherein the Fc region comprises an N297A substi tution, the conjugate further comprises an immunomodulating oligonucleotide P attached to the Q295 residue, where L is a linker moiety connected to Q295 via an amide bond.Exemplary B-eell targeted conjugates with an anti-CD22 antibody

[0200] In some embodiments of the methods herein, an oligonucleotide of the present disclosure is conjugated to anti-CD22 antibody for use with the immune-honing agent. In some embodiments, CD22 refers to human CD22, and the antibodies bind human CD22. CD22 is also known as Siglec-2, and CD22 gene and polypeptide sequences (e.g., human gene and polypeptide sequences) are known in the art. See, e.g., NCBI Gene ID No. 933 and NCBI Ref. Seq. Accession No. NP_001172028. Any of the anti-CD22 antibodies provided herein may find use in the conjugates and methods of the present disclosure.

[0201] In some embodiments, an antibody or conjugate of the present disclosure comprises a VH domain comprising 1, 2, or 3 CDRs of a single antibody shown in Table 4. In some embodiments, an antibody or conjugate of the present disclosure comprises a VH domain comprising the 3 CDRs of a single antibody shown in Table 4. In some embodiments, an antibody or conjugate of the present disclosure comprises a VL domain comprising 1, 2, or 3 CDRs of a single antibody shown in Table 4. In some embodiments, an antibody or conjugateof the present disclosure comprises a VL domain comprising the 3 CDRs of a single antibody shown in Table 4. In some embodiments, an antibody or conjugate of the present disclosure comprises a. VH domain comprising 1, 2, or 3 CDRs of a single antibody shown in Table 4 and a VL domain comprising 1, 2, or 3 CDRs of a single antibody shown in Table 4. In some embodiments, an antibody or conjugate of the present disclosure comprises a VH domain comprising the 3 CDRs of a single antibody shown in Table 4 and a. VL domain comprising the 3 CDRs of a single antibody shown in Table 4.Table 4. Exemplary Anti-CD22 antibody CDR sequences

[0202] Hie CDR sequences described above are exemplary. In some embodiments, a conjugate used in the methods herein comprises an anti-CD22 antibody that comprises CDRs other than those described herein.

[0203] In certain embodiments, the anti-CD22 antibody is an antibody comprising a VII and VL as shown below in Table 5.Table 5. Exemplary Anti~CD22 Antibody Sequences

[0204] In some embodiments, the anti-CD22 antibody or conjugate comprises a VH domain shown in Table 6 and a VL domain shown in Table 7.Table 6. Anti-CD22 Antibody VH Sequences.Table 7 Anti-CD22 Antibody; VL SequencesL0205] In some embodiments, the anti-CD22 antibody or conjugate comprises a heavy chain comprising a VH domain shown in Table 6 and a heavy chain constant domain sequence shown in Table 8 A. In some embodiments, the anti-CD22 antibody or conjugate comprises a heavy chain comprising a VL domain shown in Table 7 and a light chain constant domain sequence shown in T able 8 A.Table 8A. Antibody constant domain sequences.Exemplary dendritic cell-targeted conjugates with an anti-SIRPtX antibody

[0206] In some embodiments of the methods herein, an oligonucleotide of the present disclosure is conjugated to an anti-SIRPa antibody for use with the immune-honing agent. In some embodiments, SIRPa refers to human SIRPa, and the antibodies bind human SIRPa.SIRPa, as also known as cluster of differentiation (CD)172a or Src homology 2 domain- containing phosphatase substrate- 1, is an inhibitory cell surface receptor expressed predominantly on monocytes, granulocytes, dendritic cells and hematopoietic stem cells. Any anti- SIRPa antibody, including those described herein, may find use in the conjugates and methods of the present disclosure.

[0207] In some embodiments, an anti-SIRPa antibody or conjugate of the present disclosure comprises a VH domain comprising 1, 2, or 3 CDRs of a single antibody shown inTable 9. In some embodiments, an antibody or conjugate of the present disclosure comprisesa VH domain comprising the 3 CDRs of a single antibody shown in Table 9. In some embodiments, an antibody or conjugate of the present disclosure comprises a VL domain comprising 1, 2, or 3 CDRs of a single antibody shown in Table 9. In some embodiments, an antibody or conjugate of the present disclosure comprises a VL domain comprising the 3 CDRs of a single antibody shown in Table 9. In some embodiments, an antibody or conjugate of the present disclosure comprises a VH domain comprising 1, 2, or 3 CDRs of a single antibody shown in Table 9 and a VL domain comprising 1 , 2, or 3 CDRs of a single antibody shown inTable 9. In some embodiments, an antibody or conjugate of the present disclosure comprises a VH domain comprising the 3 CDRs of a single antibody shown in Table 9 and a VL domain comprising the 3 CDRs of a single antibody shown in Table 9.Table 9. Exemplary Anti-SIRPa antibody CDR sequences _CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3TNT230: SHAMS GISAGGSDTYY ETWNHLFDY SGGSYSSYYYA SDDKRPS GGYDQSSYTNPTNT230-VLB; (SEQ. ID PASVKG (SEQ (SEQ ID (SEQ ID (SEQ ID (SEQ IDTNT230-VLC N 0:200) ID N0:201) N0:202) N0:203) N 0:204) N0:205)

[0208] The CDR sequences described above are exemplary. In some embodiments, a. conjugate used in the methods herein comprises an anti-SIRPa antibody that comprises CDRs other than those described herein.

[0209] In certain embodiments, the anti-SIRPa antibody is an antibody comprising a VH and VL as shown below in Table 10. In some embodiments, the anti-SIRPa antibody comprises a VH domain set forth in SEQ ID NO:206 and a VL. domain set forth in SEQ IDNO:2Q7. In some embodiments, the anti-SIRPa antibody comprises a VH domain set forth inSEQ ID NO:206 and a VL domain set forth in SEQ ID NC):208. In some embodiments, the anti-SIRPa antibody comprises a VH domain set forth in SEQ ID NO:206 and a VL domain set forth in SEQ ID NO:209.Table 10. ’C. Linker moieties (L)

[0210] A linking moiety can be attached to an oligonucleotide by forming a bond between an attaching group in the oligonucleotide and a complementary reactive group bonded to the linking moiety. In certain embodiments, die linking moiety, is modified to include a complementary reactive group. Methods of introducing such complementary reactive groups into a linking moiety is known in the art.

[0211] In some embodiments, the oligonucleotide is conjugated to the targeting moiety, such as an antibody (or antigen binding fragment thereof) that binds an antigen on a surface of a B cell via a linking moiety. The length, rigidity, and chemical composition of die linking moiety impact the conjugation reaction rates and the stability of die resulting conjugates. In some embodiments, the linking moiety comprises polyethylene glycol (PEG). In some embodiments, the PEG contains about 10-50 ethylene glycol units. In some embodiments, the linking moiety is an aliphatic chain.

[0212] In some embodiments, the linker L comprises an oligoethylene glycol or polyetiiylene glycol moiety . In certain embodiments, the linker L is a group having the structure, whereinindicates the point of attachment to the oligonucleotideP, and indicates die point of attachment to the glutamine residue of the Q-tag.

[0213] In some embodiments, m is about 3-10, about 10-15, about 15-20, about 20-25, about 25-30, about 5-16, about 15-30, about 15-25 or about 20-30. In some embodiments, in is 20, 21, 22, 23, 24 or 25.I). Exemplary Immune Honing Agents

[0214] In some embodiments, an “immune honing agent (IHA)” refers to a composition comprising, e.g., immunogenic protein(s), peptide(s), polysaccharide(s), nucleic acid(s), or any combination thereof, that can be administered to an individual to induce an immune response in the individual for the purpose of treating, delaying progression, or preventing a proliferative disease or an infectious disease. In some embodiments, an “immune honing agent (IHA)” refers to a composition that is administered (e.g., by injection) to an individual and stimulates an immune response in the individual against a specific infectious agent or disease. In some embodiments, the immune honing agent elicits an immune response in the individual when administered in combination (e.g., simultaneously, concurrently, or sequentially) with an adjuvant. In some embodiments, the immune honing agent does not illicit an immune response in the individual when the immune honing agent is not administered in combination (e.g., simultaneously, concurrently, or sequentially) with an adjuvant. In some embodiments, an “adjuvant” refers to a composition that is combined with or administered with an immune honing agent in order to stimulate an immune response against the antigen in the immune honing agent. In some embodiments, the immune response stimulated after an individual receives the adjuvant and the immune honing agent is than the immune response stimulated after an individual receives the immune honing agent without the adjuvant. In some embodiments, an adjuvant is administered when the immune honing agent is not sufficient to generate a protective immune response by itself. In some embodiments, the adjuvant is selected from the group consisting of Aluminum (Alum), AS01B(MPL), AS04 (MPL), MatrixMTM, and MF59

[0215] In some embodiments, the immune honing agent comprises component(s) (e.g., additional components) that function as preservatives, emulsifiers (such as polysorbate 80) or stabilizers (for example, gelatin or sorbitol). Such components are well known in the art and are described in further detail in, e.g., Modjarrad and Koff (eds) (2016). Human Vaccines: Emerging Technologies in Design and Development (1st ed.). Academic Press; Plotkin, Walter Orenstein, Offit, and Edwards (2017). Plotkin’s Vaccines (7th ed.). Elsevier; Bhatt and Nimesh (2021). The Design and Development of Novel Drugs and Vaccines (1st ed.). Academic Press; Wen, Pujar, and Ellis (2014). Vaccine Development and Manufacturing (1st ed.). Wiley; Kolhe and Ohtake (2021). Practical Aspects of Vaccine Development (1st ed.). Academic Press; and others.

[0216] In some embodiments, the immune honing agent is a cellular immune honing agent, such as a cell vaccine or a “cell-based vaccine”. In some embodiments, the cellular immunehoning agent comprises whole cells or cell lysates as the source of antigens or the platform in which to deliver the antigens to an individual. In some embodiments, individual has a proliferative disease (e.g., cancer), and the cellular immune honing agent comprises an autologous disease cell (e.g., a tumor cell) derived from the individual. In some embodiments, the autologous disease cell has been engineered to express, e.g., granulocyte-macrophage colony-stimulating factor (GMCSF). In some embodiments the autologous diseased cell is attenuated (e.g., irradiated) or inactivated (e.g., killed). In some embodiments, the individual has a proliferative disease (e.g., cancer), and the cellular immune honing agent comprises an allogenic disease cell, e.g., derived from a cell line (such as a human tumor cell line). In some embodiments, the allogenic disease cell is inactivated (e.g., killed). In some embodiments, the cellular immune honing agent is an autologous antigen presenting cell (APC, e.g., a dendritic cell, a macrophage, a Langerhans cell, a B-cell, etc.) that has been loaded with or engineered to express one or more antigens associated with the proliferative disease (e.g., wherein the proliferative disease is cancer. In some embodiments, the microbial cell activates cytokine production in the individual. In some embodiments, the microbial cell is inactivated or attenuated. Methods of administering cellular immune honing agents, and other details regarding cellular immune honing agents, are described in, e.g., Le et al. (2010) Cancer J, 16(4):304-10; Hollingsworth et al. (2019) npj Vaccines 4:7; Pollard et al. (2021) Nat Rev Immunol, 21: 83-100, and others.

[0217] In some embodiments, the immune honing agent is a polypeptide immune honing agent. In some embodiments, the polypeptide immune honing agent comprises a polypeptide (such as an immunogenic polypeptide or fragment thereof) obtained or derived from a diseased cell (e.g., a tumor cell) or an infectious agent (e.g., including, without limitation, an immunogenic polypeptide, or fragment thereof, of a virus, microbe, a parasite, a fungus, a helminth, etc.). In some embodiments, the immunogenic polypeptide (or fragment thereof) is recombinantly produced. In some embodiments the immunogenic polypeptide (or fragment thereof) is obtained (such as purified from) the diseased cell or infectious agent. In some embodiments, the immunogenic polypeptide or fragment thereof is conjugated to a polysaccharide.

[0218] In some embodiments, the immune honing agent is a peptide immune honing agent, such as a peptide vaccine. In some embodiments, the peptide immune honing agent comprises one or more peptide(s) obtained or derived from an antigenic polypeptide associated with a diseased cell (e.g., a tumor cell, such as autologous tumor cell) or an infectious agent (e.g.,including, without limitation, an immunogenic polypeptide, or fragment thereof, of a virus, microbe, a parasite, etc.). In some embodiments, the peptide is about any one of 30, 25, 20, 25, or 10 amino acids in length, including any range between these values. Further details regarding immune honing agents (e.g., peptide vaccines) are described in Hollingsworth et al. (2019) npj Vaccines 4:7; Malonis et al. (2020) Chem Rev. 120(6): 3210–3229; Nelde et al. (2021) Molec and Cell Proteomics, 20:100022, and others.

[0219] In some embodiments, the immune honing agent is a viral immune honing agent, such as a viral vaccine. In some embodiments, a viral immune honing agent comprises a live or attenuated virus. In some embodiments the viral immune honing agent comprises a replication-deficient (i.e., inactive) virus. In some embodiments, the virus comprises a poxvirus vector, an adenovirus vector, an alphavirus vector, or a vector derived from any one of the preceding. Further details regarding immune honing agents (e.g., viral vaccines) are provided in, e.g., Huang et al. (2004) J Infection 49(3): 179-209; Cordosa et al. (2017) Acta Virologica, 61(3):231-239; and others.

[0220] In some embodiments, the immune honing agent is a viral like particle (VLP) immune honing agent, such as a VLP vaccine. In some embodiments, the VLP lacks the genome of a native virus. Further details regarding VLP immune honing agents (e.g., VLP vaccines) are provided in, e.g., Mohsen et al. (2017) Semin Immunol. 34:123-132; Nooraei et al. (2021) Journal of Nanobiotechnology, 19:59; Zeltins, A. (2013) Molecular Biotechnology, 53: 92–107; and others.

[0221] In some embodiments, the immune honing agent is an outer membrane vesicle (OMV) immune honing agent. In some embodiments, the OMV immune honing agent comprises OMVs derived from bacteria (e.g., gram-negative bacteria such as Escherichia, Yersina, Salmonella, Shigella, Pseudomonas, etc.). In some embodiments, the OMV has been loaded with, or is derived from a cell that has been engineered to express an immunogenic polypeptide or fragment thereof associated with a proliferative or infectious disease. Further details regarding OMV immune honing agents can be found in, e.g., Furuyama et al. (2021) Biomed Res Int. 2021: 1490732.

[0222] In some embodiments, the immune honing agent is a nucleic acid immune honing agent, such as a nucleic acid vaccine. In some embodiments, the nucleic acid immune honing agent comprises one or more polynucleotides. In some embodiments, the one or more polynucleotides comprise DNA. In some embodiments, the one or more polynucleotidescomprise RNA. In some embodiments, the nucleic acid immune honing agent is an mRNA vaccine, such as an mRNA vaccine described in Pardi et al., (2018) Nat Rev Drug Discov 17, 261–279. Further details regarding nucleic acid immune honing agents are provided in, e.g., Kutzler et al. (2008) Nature Reviews Genetics 9: 776–788; Plotkin, S. (2011) Clin Infect Dis. 53(3): 296–302; Lee et al. (2018) Front in Immunol 9:1568; Verbeke et al. (2019) Nanotoday 28:100766; Poveda et al. (2019) Vaccines, 7(4), 131; and others.

[0223] In some embodiments, the immune honing agent is cellular immune honing agent comprising a cell that expresses a tumor-associated antigen, an oncogenic viral antigen, or a neoantigen (e.g., a neoantigen that arises from a cancer-specific mutation.), or a fragment of or peptide derived from any of the preceding. In some embodiments, the cellular immune honing agent comprises a cell that has been engineered to express (or overexpress) a tumor-associated antigen an oncogenic viral antigen, or a neoantigen, or a fragment of or peptide derived from any of the preceding. In some embodiments, the immune honing agent is a polypeptide or peptide immune honing agent comprising a tumor associated antigen, an oncogenic viral antigen, or a neoantigen, or a fragment of or peptide derived from any of the preceding. In some embodiments, the immune honing agent is a viral immune honing agent that comprises a viral vector that comprises a nucleic acid that encodes a tumor-associated antigen or an immunogenic fragment thereof, an oncogenic viral antigen, or a neoantigen, or a fragment of or peptide derived from any of the preceding. In some embodiments, the immune honing agent is a VLP immune honing agent or a OMV immune honing agent that comprises a tumor- associated antigen an immunogenic fragment(s) thereof, an oncogenic viral antigen, or a neoantigen, or a fragment of or peptide derived from any of the preceding. In some embodiments, the immune honing agent is a nucleic acid immune honing agent that comprises one or more polynucleotides that encode a tumor associated antigen or an immunogenic fragment thereof, an oncogenic viral antigen, or a neoantigen, or a fragment of or peptide derived from any of the preceding.

[0224] In some embodiments, the immune honing agent is cellular immune honing agent comprising a cell that expresses a pathogen-associated antigen, or an immunogenic fragment thereof or peptide derived therefrom. In some embodiments, the cell has been engineered to express (or overexpress) a pathogen-associated antigen or an immunogenic fragment thereof or peptide derived therefrom. In some embodiments, the immune honing agent is a polypeptide or peptide immune honing agent comprising a pathogen-associated antigen (or fragment thereof) or an immunogenic peptide obtained or derived from a pathogen-associated antigen.In some embodiments, the immune honing agent is a viral immune honing agent that comprises a viral vector that comprises a nucleic acid that encodes a pathogen-associated antigen or an immunogenic fragment thereof or peptide derived therefrom. In some embodiments, the immune honing agent is a VLP immune honing agent or OMV immune honing agent that comprises a pathogen-associated antigen or an immunogenic fragment thereof or peptide derived therefrom. In some embodiments, the immune honing agent is a nucleic acid immune honing agent that comprises one or more polynucleotides that encode a pathogen-associated antigen or an immunogenic fragment thereof or peptide derived therefrom. In some embodiments, the pathogen is a microorganism (e.g., a bacterium, a yeast or other fungus, a protozoan, etc.) a virus, a parasite, a helminth, or a prion.

[0225] In some embodiments, the conjugate and the immune honing agent are administered simultaneously. In some embodiments, the conjugate and the immune honing agent are administered simultaneously as a single composition. In some embodiments, the conjugate and the immune honing agent are administered as separate compositions. In some embodiments, the conjugate and the immune honing agent are administered concurrently. In some embodiments, the conjugate and the immune honing agent are administered sequentially. Exemplary methods of administering a conjugate to an individual in need thereof and exemplary dosage and administration schedules are provided elsewhere herein. Immune honing agents can be administered according to methods of administering vaccines, dosages, administration schedules, and delivery systems thereof. Such methods are well known in the art and are described in, e.g., Pinkbook (see www(dot)cdc(dot)gov / vaccines / pubs / pinkbook / ; Plotkin, Walter Orenstein, Offit, and Edwards (2017). Plotkin’s Vaccines (7th ed.). Elsevier; Milligan and Barret (eds) (2015) Vaccinology: An Essential Guide (1st ed.). Wiley- Blackwell; and others.

[0226] In some embodiments, the conjugate and the immune honing agent are administered with another therapeutic agent. In some embodiments, the another therapeutic agent comprises an antibody-drug conjugate (ADC), a therapeutic antibody, an immunotherapeutic agent, a small molecule drug, a chemotherapeutic agent, a T cell costimulatory molecule, and / or another adjuvant. In some embodiments, the another therapeutic agent is a cancer therapeutic agent selected from T cell agonists, immune checkpoint modulators, STING agonists, RIG-I agonists, other toll-like receptor agonists. In some embodiments, the conjugate and the immune honing agent are administered with another adjuvant. In some embodiments, the another adjuvant comprises an immunostimulatory cytokine, a TLR agonist, an interferonagonist, saponin, a mineral salt, or a lipid (e.g., monophosphoryl lipid A (MPL)). In some embodiments, the another adjuvant is another approved adjuvant. In some embodiments, the approved adjuvant comprises aluminum (e.g., one or more of aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, and potassium aluminum sulfate (Alum)), AS04 (i.e., MPL + aluminum salt)), MF59 (i.e., an oil in water emulsion composed of squalene), AS01B(i.e., MPL + QS21, which is extracted from the Chilean soapbark tree, combined in a liposomal formulation) and CpG 1018. In some embodiments, the another therapeutic agent is an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is a PD-1 / PD-L1 immune checkpoint inhibitor such as an anti-PD-1 antibody or an anti-PD-L1 antibody. In some embodiments, the immune checkpoint inhibitor is an anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.

[0227] Additionally or alternatively, in some embodiments, in relation to a methods of treating, delaying the progression of, or preventing cancer, the conjugate and the immune honing agent are administered in combination with one or more additional therapeutic procedures, for example wherein the additional therapeutic agent or procedure is selected from the group consisting of chemotherapy, a targeted anti-cancer therapy, an oncolytic drug, a cytotoxic agent, an immune-based therapy, a cytokine, surgical procedure, a radiation procedure, an activator of a costimulatory molecule, an inhibitor of an inhibitory molecule, an immune honing agent, a cellular immunotherapy, a cell-based therapy (e.g., CAR-T, TILs, TCR-T, CAR-NK, and CAR-macrophage therapies) and an oncolytic virus therapy. In some embodiments, the antigen-specific IgG titer in an individual who received the immune honing agent and the conjugate is higher than the antigen-specific IgG titer in an individual who received the immune honing agent without the conjugate. In some embodiments, the duration of an IgG2 response in an individual who received the immune honing agent and the conjugate is longer than the duration of an IgG2 response in an individual who received the immune honing agent without the conjugate. In some embodiments, the B-cell response (e.g., memory B-cell response) in an individual who received the immune honing agent and the conjugate is improved as compared to the B-cell response (e.g., memory B-cell response) in an individual who received the immune honing agent without the conjugate. In some embodiments, an improved B-cell response (e.g., memory B-cell response) is characterized by an antigen- specific IgG titer that is higher following antigen challenge in the individual who received the immune honing agent and the conjugate than in the individual who received the immune honing agent without the conjugate.

[0228] In some embodiments, the antigen-specific IgG titer in an individual who received the immune honing agent and the conjugate is higher than the antigen-specific IgG titer in an individual who received the immune honing agent administered or formulated with another adjuvant, such as an unconjugated CpG oligonucleotide. In some embodiments, the duration of an IgG2 response in an individual who received the immune honing agent and the conjugate is longer than the duration of an IgG2 response in an individual who received the immune honing agent administered or formulated with another adjuvant, such as an unconjugated CpG oligonucleotide. In some embodiments, the B-cell response (e.g., memory B-cell response) in an individual who received the immune honing agent and the conjugate is improved as compared to the B-cell response (e.g., memory B-cell response) in an individual who received the immune honing agent administered or formulated with another adjuvant, such as an unconjugated CpG oligonucleotide. In some embodiments, an improved B-cell response (e.g., memory B-cell response) is characterized by an antigen-specific IgG titer that is higher following antigen challenge in the individual who received the immune honing agent and the conjugate than in the individual who received the immune honing agent administered or formulated with another adjuvant, such as an unconjugated CpG oligonucleotide. V. Pharmaceutical Compositions Comprising Conjugates

[0229] Conjugates described herein, or a pharmaceutically acceptable salt of the described conjugates, or any subgroup thereof may be formulated into various pharmaceutical forms for administration with an immune honing agent, e.g., according to a method described herein. In some embodiments, the conjugate and the immune honing agent are formulated as a single composition, e.g., to facilitate simultaneous administration. In some embodiments, the conjugate and the immune honing agent are formulated as separate compositions. In some embodiments, the separate compositions are later combined to facilitate simultaneous administration of the conjugate and the immune honing agent. In some embodiments, the separate compositions remain separate, e.g., for concurrent or sequential administration of the conjugate and the immune honing agent.

[0230] As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the conjugate, optionally in addition salt form, as the active ingredient is combined in admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired foradministration. In some embodiments, the admixture further comprises an immune honing agent. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and / or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. The compounds of the present invention may also be administered via oral inhalation or insufflation in the form of a solution, a suspension or a dry powder using any art-known delivery system.

[0231] It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.

[0232] Administration can be, but is not limited to, intravenous, intraarterial, subcutaneous, intraperitoneal, subdermal (e.g., via an implanted device), and intraparenchymaladministration. In some embodiments, the pharmaceutical compositions described herein are administered by subcutaneous injection.

[0233] The pharmaceutical compositions comprising a conjugate described herein, or a conjugate and an immune honing agent, can be delivered to a cell, group of cells, tumor, tissue, or subject using delivery technologies known in the art. In general, any suitable method recognized in the art for delivering a nucleic acid-protein conjugate (in vitro or in vivo) can be adapted for use with a herein described compositions. For example, delivery can be by local administration, (e.g., direct injection, implantation, or topical administering), systemic administration, or subcutaneous, intravenous, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, oral, rectal, or topical (including buccal and sublingual) administration. In certain embodiments, the compositions are administered by subcutaneous or intravenous infusion or injection.

[0234] Accordingly, in some embodiments, the herein described pharmaceutical compositions may comprise one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical compositions described herein can be formulated for administration to a subject.

[0235] As used herein, a pharmaceutical composition or medicament comprises a pharmacologically effective amount of at least one of the conjugates and one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition or medicament further comprises an immune honing agent. Pharmaceutically acceptable excipients (excipients) are substances other than the Active Pharmaceutical ingredient (API, therapeutic product) that are intentionally included in the drug delivery system. Excipients do not exert or are not intended to exert a therapeutic effect at the intended dosage. Excipients may act to a) aid in processing of the drug delivery system during manufacture, b) protect, support or enhance stability, bioavailability or patient acceptability of the API, c) assist in product identification, and / or d) enhance any other attribute of the overall safety, effectiveness, of delivery of the API during storage or use. A pharmaceutically acceptable excipient may or may not be an inert substance.

[0236] Excipients include, but are not limited to: absorption enhancers, anti-adherents, anti-foaming agents, anti-oxidants, binders, buffering agents, carriers, coating agents, colors, delivery enhancers, delivery polymers, dextran, dextrose, diluents, disintegrants, emulsifiers,extenders, fillers, flavors, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickening agents, tonicity agents, vehicles, water-repelling agents, and wetting agents.

[0237] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0238] Sterile injectable solutions can be prepared by incorporating the conjugate, or the conjugate and the immune honing agent, in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the conjugate, or the conjugate and the immune honing agent, into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0239] Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the conjugate, or the conjugate and the immune honing agent, that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic administration.

[0240] The conjugate, or the conjugate and the immune honing agent, can be prepared with carriers that will protect the conjugate, or the conjugate and the immune honing agent, against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No.4,522,811.

[0241] The conjugate, or the conjugate and the immune honing agent, can be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the disclosure is dictated by and directly dependent on the unique characteristics of the conjugate, or the conjugate and the immune honing agent, and the therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for treating, delaying progression, or preventing a proliferative disease or an infectious disease in an individual.

[0242] A pharmaceutical composition comprising the conjugate, or the conjugate and the immune honing agent, can contain other additional components commonly found in pharmaceutical compositions. Such additional components include, but are not limited to, anti- pruritics, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamine, diphenhydramine, etc.).

[0243] For treating, delaying progression, or preventing a proliferative disease or an infectious disease or for formation of a medicament or composition for treating, delaying progression, or preventing a proliferative disease or an infectious disease, the pharmaceutical compositions described herein including a conjugate, or a conjugate and an immune honing agent, can be combined with an excipient or with a second therapeutic agent including, but not limited to: a second or other conjugates, a therapeutic antibody (or fragment thereof), an immunotherapeutic agent, a small molecule drug, a chemotherapeutic agent, a T cell costimulatory molecule, and / or another adjuvant (e.g., as described elsewhere herein).

[0244] The conjugate, or the conjugate and the immune honing agent, when added to pharmaceutically acceptable excipients or adjuvants, can be packaged into kits, containers, packs, or dispensers. The pharmaceutical compositions comprising the conjugate, or the conjugate and the immune honing agent, may be packaged in pre-filled syringes or vials. VI. Kits

[0245] Also provided herein is a kit comprising a conjugate described herein. In some embodiments, the kit further comprises an immune honing agent.

[0246] In another aspect, the kit further comprises a package insert including, without limitation, instructions for administering the conjugate and the immune honing agent to treat, delay progression, or prevent a proliferative disease or an infectious disease (e.g., a proliferative disease or infectious disease described in further detail elsewhere herein). In some embodiments, the kit further comprises appropriate instructions for administration of the conjugate, the immune honing agent, or formulation(s) comprising the conjugate and / or the immune honing agent), side effects of the conjugate, the immune honing agent, or formulation(s) comprising the conjugate and / or the immune honing agent, and any other relevant information. The instructions may be in any suitable format, including, but not limited to, printed matter, videotape, computer readable disk, optical disc or directions to internet-based instructions. In some embodiments the kit comprises a first container comprising a dosage amount of the conjugate (or of a composition or formulation comprising same). In some embodiments, the first container further comprises a dosage amount of the immune honing agent, e.g., wherein the conjugate and the immune honing agent are formulated as a single composition. The container may be any of those known in the art and appropriate for storage and delivery of intravenous formulation. In certain embodiments, the kit further comprises a second container comprising a dosage amount of the immune honing agent, e.g., wherein the conjugate and immune honing agent are formulated as separate compositions. In some embodiments, the kit further comprises a third container comprising a pharmaceutically acceptable carrier, diluent, adjuvant, etc. for preparation of the formulation to be administered to the individual.

[0247] In another aspect, kits may also be provided that contain sufficient dosages of a conjugate described herein (including pharmaceutical compositions thereof), or sufficient dosages of a conjugate described herein and sufficient dosages of an immune honing agent, to provide an effect (e.g., treatment of, delaying progression of, or prevention of a proliferative disease or an infectious disease) in an individual for an extended period, such as 1–3 days, 1–5days, a week, 2 weeks, 3, weeks, 4 weeks, 6 weeks, 8 weeks, 1 cycle, 2 cycles, 3 cycles, 4 cycles, 5 cycles, 6 cycles, 7 cycles, 8 cycles or more.

[0248] In some embodiments, the kits may also include multiple doses of the conjugate and / or the immune honing agent and may be packaged in quantities sufficient for storage and use in pharmacies, for example, hospital pharmacies and compounding pharmacies. In certain embodiments the kits may comprise a dosage amount of at least one conjugate (or a composition comprising same) as disclosed herein. In some embodiments, the kit further comprises a dosage amount of an immune honing agent (e.g., an immune honing agent described herein). EXAMPLES

[0249] The presently disclosed subject matter will be better understood by reference to the following Examples, which are provided as exemplary of the invention, and not by way of limitation. Example 1: Generation of Reagents

[0250] Oligonucleotides, antibodies, and conjugates were made substantially as described in WO2018189382 and WO2021174091. The amino acid and nucleic acid sequences used in the provided Examples are provided below: Nucleic acid sequence of CpG4523 tucgtcgtgacgtt-c3 (murine CpG, SB-4523) (SEQ ID NO: 121) Nucleic acid sequence of CpG7-7 ucgtcgtgtPS2cgttt-c3 (human CpG, SB-7-7) (SEQ ID NO:210) lowercase: phosphorothioate backbone u: 5’-iodo deoxyuridine u: 5-bromo-2’-deoxyuridine PS2: phophorodithioate backbone t: phosphotriester linker t: 2’-OMe-Thymidine / Cytidine Mouse CD22 antibody Cy34 (TNT28) Amino acid sequence of anti-mCD22 heavy chain:TNT50a Conjugate (CD22TRAAC) anti-mCD22-CpG4523 – DAR:1 Human CD22 antibody RFB4 Amino acid sequence of anti-hCD22 heavy chain variable region:Q ( Q ) Amino acid sequence of anti-hCD22 light chain variable region:TNT126a Conjugate (hCD22TRAAC) RFB4-CpG4523 – DAR:1 Amino acid sequence of Nectin 4 extracellular domain (ECD) (N4; TNT175)Mouse SIRPαantibody (TNT177) Amino acid sequence of anti-mSIRPα heavy chain: (SEQ ID NO:211)Amino acid sequence of anti- mSIRPα light chain:TNT182a Conjugate (SIRPαTRAAC) anti-mSIRPα-CpG4523 – DAR:1 Human SIRPα antibody (TNT230) Amino acid sequence of anti-hSIRPα heavy chain:Amino acid sequence of anti- hSIRPα light chain:TNT233a Conjugate (SIRPαTRAAC) anti-hSIRPα-CpG7-7 – DAR:1 Human CD79b antibody (TNT388) Amino acid sequence of anti-CD79b heavy chain variable domain:Amino acid sequence of anti- CD79b light chain variable domain:TNT389a Conjugate (CD79bTRAAC) anti-CD79b-CpG4523 – DAR:1 TNT176– mouse Nectin 4 Avi tagExample 2: Assessing antigen-specific IgG antibody titer following administration of a B-cell-targeting conjugate in combination with a tumor-associated antigen and adjuvant

[0251] CD22 is a lectin protein present on the surface of mature B cells. In the following experiments, a B-cell-targeting anti-CD22 CpG conjugate, naked CpG and unconjugated anti- CD22 antibody were used. The tumor-associated antigen used in the experiment corresponding the extracellular domain of Nectin 4. The adjuvant used was Monophosphoryl Lipid A (MPL, Sigma).

[0252] Balb / c and FVB mice (aged 7 weeks) sourced from Charles River (Wilmington, MA) were immunized intraperitoneally (IP) and subcutaneously (SC) on day 0, 7 and 14. Day 0 and 14 immunizations included 50 ^g of human Nectin4 (TNT175) and 50 ^g of Monophosphoryl Lipid A (MPL, Sigma). On day 0 and day 14, mice in treatment groups also received either 8^g CpG 4523, 10mg / kg of CD22TRAAC (CD22TRAAC; TNT50a) and anti- mCD22 (TNT28). On Day 7, all mice received a boost of 50 ^g of TNT175 and 50^g of MPL via IP and SC injections. Balb / c mice received a challenge of 50 µg antigen (human Nectin4, TNT175) in Phosphate Buffered Saline (PBS, Gibco) on day 74 via IP injection. Schematics of the immunization and antigen challenge schedules described above are provided in FIG.1.

[0253] Titer assessments were performed as follows: Mice were bled via cheek bleed on days 14, 21, 29, 42, 67 and Balb / c mice were terminally bled on day 77. Serum was separated using Microtainer Serum Separator (BD) according to manufacturers’ instructions and stored in 2-8 °C.

[0254] For titer assessment, ELISA plates (Maxisorp, Nunc) were coated with 1^g / mL of TNT175 in PBS (Gibco) overnight at 2-8 °C. Plates were washed 3X with 300^L ELISA wash buffer (25mM Tris + 150mM NaCl + 0.05% Tween20, Teknova) then incubated one hour at room temperature with mouse serum in diluent (PBS, Gibco + 0.5% Bovine Serum Albumin, Sigma) with dilutions of 1:100 followed by serial dilutions of 1:2 or 1:3. Plates were washed then incubated one hour at room temperature with secondary antibody.

[0255] For total IgG titers, goat anti mouse IgG Fc HRP (Thermo Fisher) was diluted 1:3,000 in diluent. Plates were washed once more, incubated at room temperature for 20minutes with 50 µL / well of ABTS substrate (Invitrogen) and were read at 405nm (SpectraMax I3, Molecular Devices). Data were analyzed via GraphPad Prism (Version 9 for MacOS). Binding was measured as an Optical Density (O.D.) value normalized to background. Isotype titers are plotted as mean with range.

[0256] As shown in FIG. 2 (Day 14), FIG. 3 (Day 21) and FIG. 4 (Days 29 and 42), the CpG conjugated antibody, CD22TRAAC, induced higher antigen specific titers post- immunization in the two mouse strains when compared to the unconjugated CpG oligonucleotide, the unconjugated antibody and the antigen / adjuvant only control. As shown in FIG.5 the B cell-targeted CpG conjugate (CD22TRAAC) induced highest titers across all time points compared to all other treatments. Example 3: B cell targeting CpG improves antigen-specific titers

[0257] Balb / c mice (aged 7 weeks) sourced from Charles River (Wilmington, MA) were immunized intraperitoneally (IP) and subcutaneously (SC) on day 0, 7 and 14 with antigens, antigens combined with treatment or treatment alone as per schedule in FIG. 6. Antigens consisted of 100 ^g of human Nectin-4 (hN4; TNT175) and 100 ^g of mouse Nectin-4 (mN4; TNT176) per dose. Treatment groups were 8 ^g CpG, 10mg / kg CD22TRAAC (TNT50a), 10 mg / kg CD79bTRAAC (TNT389a) or 10 mg / kg anti-CD79b (TNT388). Serum was collected and processed as described previously. Titers were assayed as described previously using 1^g / mL TNT175 or TNT176 to coat microplates.

[0258] As shown in FIG. 7, when combined with N4 antigens, both B cell-targeted CpG conjugates (CD22 and CD79b) induce significantly more robust antigen (human Nectin-4)- specific titers over N4 with unconjugated CpG, N4 only, conjugate only or N4 with non- conjugated anti-CD22 antibody. Statistics analyzed for the data set show significance as compared to free CpG across the first 2-3 titrations depending on the conjugate. The conjugates did not induce titers against self antigens (i.e., mouse Nectin-4) even when these antigens were included in the immunization as per FIG.8.

[0259] Statistics for CpG, CD22TRAAC & CD79bTRAAC from FIG. 7 via 2way ANOVA Tukey’s multiple comparisons test are shown in Table E1, below. Data were analyzed via GraphPad Prism (Version 9 for MacOS). Table E1.Example 4: Assessing IgG2a and IgG2b response following administration of a B-cell- targeting conjugate in combination with a tumor-associated antigen

[0260] Mice from Example 2 were also assayed for titers of IgG1, IgG2a, IgG2b and IgG3 at days 14, 21, 29 and 42. For isotype titers, rat anti-mouse IgG1 HRP, rat anti-mouse IgG2a HRP, rat anti-mouse IgG2b HRP or rat anti-mouse IgG3 HRP (Thermo Fisher) were diluted 1:2,000 in diluent. As in Example 2 for total IgG titers, plates were washed once more, incubated at room temperature for 20 minutes with 501L / well of ABTS substrate (Invitrogen) and were read at 405nm (SpectraMax I3, Molecular Devices). Data were analyzed via GraphPad Prism (Version 9 for MacOS). Binding was measured as an Optical Density (O.D.) value normalized to background. Isotype titers are plotted as mean with range.

[0261] As shown in FIGs.9, 10, 11, and 12 the conjugate CD22TRAAC skews early Th1 response and a more robust IgG2a and IgG2b response as compared to the unconjugated oligonucleotide, unconjugated antibody and antigen / adjuvant control when assayed between Days 14-42. This was observed in both mice strains. Example 5: Assessing memory B cell response following administration of a B-cell- targeting conjugate in combination with a tumor-associated antigen

[0262] Balb / c mice from Example 2 were sacrificed 3 days post antigen challenge, on study day 77. Total IgG titers were assessed as set forth in Example 2 and compared from pre- and post-challenged samples.

[0263] From the sacrificed mice, spleen and draining lymph nodes were collected into RPMI (Gibco) as separate samples and agitated with a sterile syringe plunger on a 701m cell strainer (Thermo Fisher) for single cell suspension. Cells were washed with FACS buffer (Phosphate Buffered Saline, Gibco + 2% Fetal Bovine Serum, Gibco) and centrifuged for five minutes at 400 x g. Cells were plated in 96 well u bottom plates (Thermo Fisher), centrifuged for five minutes at 400 x g and decanted. Cells were stained at 4°C in Fixable Viability Dye eFluor780 (ThermoFisher) diluted 1:4,000 in PBS. Cells were centrifuged and stained at 4 °C in FACS buffer for 30 minutes containing FcR Blocking Reagent (Miltenyi^Biotec), anti-CD19, anti-CD38, anti-IgD, anti-MHCII, anti-B220, anti-CD27, anti-CD40, anti-CD138, anti- CD43, anti-IgM (ThermoFisher, BioLegend) to detect immature, mature and activated B cells. Cells were centrifuged, washed twice in FACS buffer and fixed in 0.5% paraformaldehyde. Cells were analyzed on Attune NxT Flow Cytometer (Thermo Fisher), with subsequent data analysis by Flowjo 10.7 (BD). Dead cells were excluded by gating on the eFluor 780-negative population. Plasma cells were identified as IgM- IgD- CD138+cells. Plasma cell levels were assessed by median fluorescent intensity.

[0264] A comparison of total IgG titers is shown in FIGs 13A and 13B (FIG.13A shows pre-challenged titers and FIG.13B shows post-challenged titers). As shown in FIG 13C, the pre- and post-challenged titers was markedly higher for the conjugate CD22TRAAC as compared to the unconjugated oligonucleotide, unconjugated antibody and the antigen / adjuvant control. The conjugate also resulted in an increase in the number of splenic plasma cells compared to the other treatments. See FIG. 13D. The results demonstrate that mice treated with the antibody-CpG conjugate that targets CD22 (a B-cell antigen) were able to recall antigen specific B cells when challenged with antigen alone 9 weeks post administration. This indicates that the administration of the conjugate provides a more robust memory B cell response to the antigen as compared to the unconjugated oligonucleotide, unconjugated antibody and the antigen / adjuvant control treatments. Example 6: Synergistic induction of an immune response following administration of a B-cell-targeting conjugate in combination with a viral antigen and adjuvant

[0265] An exemplary B-cell-targeting anti-CD22 CpG conjugate was tested for the ability to synergistically enhance IgG titers following immunization with an exemplary viral antigen, the SARS-CoV2 spike protein (SpikeWT).

[0266] Balb / c mice (aged 7 weeks), sourced from Charles River (Wilmington, MA), were immunized by intraperitoneally (IP) and subcutaneously (SC) injecting a total of 25 µg SpikeWT on Days 0, 7 and 14. On Day 0 and Day 14, mice in treatment groups also received either 20 ^g MPL (adjuvant only), 10mg / kg anti-mCD22 (Cy34) CpG conjugate (anti- mCD22TRAAC; TNT50a), 10 mg / kg unconjugated anti-mCD22 antibody (Cy34; TNT28), 10 mg / kg TNT50a and 20 µg MPL, or 2.5 mg / kg anti-hCD22 CpG conjugate (RFB4-CpG 4523; TNT126a).

[0267] Antibody titers were determined by bleeding the mice via cheek bleed on Days 14, 28, 68 and 72. For each animal, the serum was separated using a Microtainer Serum Separator (BD) according to the manufacturer’s instructions and stored at 2-8 °C.

[0268] For titer assessment, ELISA plates (Maxisorp, Nunc) were coated with 1^g / mL of Spike WT in PBS (Gibco) overnight at 2-8°C. Plates were washed 3X with 300^L ELISA wash buffer (25mM Tris + 150mM NaCl + 0.05% Tween20, Teknova) then incubated one hour at room temperature with mouse serum in diluent (PBS, Gibco + 0.5% Bovine Serum Albumin, Sigma) with dilutions of 1:100 followed by serial dilutions of 1:2 or 1:3. Plates were washed then incubated one hour at room temperature with secondary antibody.

[0269] For total IgG titers, goat anti mouse IgG Fc HRP (Thermo Fisher) was diluted 1:3,000 in diluent. Plates were washed once more, incubated at room temperature for 20 minutes with 50µL / well of ABTS substrate (Invitrogen) and were read at 405nm (SpectraMax I3, Molecular Devices). Data were analyzed via GraphPad Prism (Version 9 for MacOS). Binding was measured as an Optical Density (O.D.) value normalized to background. Isotype titers were plotted as mean with range at 1 / 2,700 dilution, and reciprocal titer EC50s were calculated.

[0270] As shown in FIGS.14A and 14B CD22TRAAC in combination with MPL (closed circles, dashed line) induced higher antigen specific titers post-immunization at Day 28 compared to the CD22TRAAC alone (open circle), MPL alone (closed diamonds), or unconjugated anti-mCD22 antibody (TNT28; closed circles, solid line), indicating synergy between the conjugate and MPL. The anti-hCD22 CpG conjugate (NB TRAAC; TNT126a; closed squared, dashed line), which does not recognize mouse CD22, exhibited low antibody titers against the antigen indicating the response was dependent on B-cell binding.

[0271] While administering a high concentration of MPL was able to induce a robust initial response similar to CD22TRAAC, the response was not enduring. On Day 69, mice receiving CD22TRAC exhibited persistent titers that were higher than those observed for MPL, CpG, and anti-CD22 treatments, suggesting a possible long-lived plasma cell (LLPC) deposit for this treatment group. Example 7: Th1 Response following administration of a B-cell targeting conjugate in combination with a viral antigen and adjuvant

[0272] An exemplary B-cell-targeting anti-CD22 CpG conjugate was compared with MPL alone or a combination of the conjugate and MPL to the stimulation of a Th1 response,following immunization with an exemplary viral antigen, the SARS-CoV2 spike protein (SpikeWT).

[0273] Balb / c mice (aged 7 weeks), sourced from Charles River (Wilmington, MA), were immunized by intraperitoneally (IP) and subcutaneously (SC) injecting a total of 25 µg SpikeWT on Days 0, 7 and 14. On Day 0 and Day 14, mice in treatment groups also received either 50 ^g MPL (adjuvant only), 10mg / kg anti-mCD22 CpG conjugate (CD22TRAAC; TNT50a), 10 mg / kg unconjugated anti-mCD22 antibody (Cy34; TNT28) and 50 µg MPL, or 2.5 mg / kg non-binding anti-hCD22 CpG conjugate (NB TRAAC; TNT126a).

[0274] IgG1, IgG2a, IgG2b, IgG3, and IgM antibody titers were measured as described in Example 4 with the addition of rat anti mouse IgG3 (Southern Biotech) used at 1 / 2,000 dilution and anti-mouse IgM (Jackson Immuno) used at 1 / 3,000 dilution in diluent. ELISA was performed as described in previous Example.

[0275] As shown in FIG. 15, at Day 14, mice treated with SpikeWT combined with antibody alone (TNT28) or MPL exhibited higher IgG1 titers compared to their respective IgG2a and IgG2b responses. Conversely, CD22TRAAC and CD22TRAAC with MPL groups had higher IgG2a and IgG2b responses. CpG group had a dominant IgG2a response. IgG3 titers were unremarkable and IgM titers were slightly elevated for groups receiving CD22TRAAC with and without MPL. Similar results were observed at Day 28 (data not shown). The dominant IgG1 response in the SpikeWT and MPL groups demonstrate a Th2 response whereas the groups which received CD22TRAAC alone or in combination with MPL skewed to a Th1 response. High levels of IgG2a and IgG2b in these two groups indicate increased effector function via ADCP and ADCC would occur likely resulting in more profound clearance of antigen. Example 8: Anti-viral immunity in young and elderly mice induced by a B-cell targeting conjugate, viral antigen, with and without adjuvant

[0276] In this Example, an exemplary B-cell-targeting anti-CD22 CpG conjugate was compared with and without a TLR4 agonist, MPL, for induction of COVID-19 immunity in young mice (7-8 weeks old) and elderly mice (12 months old). A. Antibody Titers

[0277] Balb / c mice (aged 7-8 weeks) or (1 year), sourced from Charles River (Wilmington, MA), were immunized on Days 0, 7 and 14 by injecting a split dose (50% intraperitoneally (IP)and 50% subcutaneously (SC)) of 25 µg SpikeWT and PBS, 0.4mg / kg CpG (4523), 1 mg / kg TLR4 agonist MPL emulsified with squalene and TWEEN-80 in 1XPBS, 10 mg / kg anti- mCD22 CpG conjugate (CD22TRAAC; TNT50a) in PBS, or 10 mg / kg TNT50a and 1 mg / kg MPL. The mice were bled and the antibody titers were determined as described in Example 7 on days 14, 29, 59 and 67.

[0278] The IgG titers from Day 29 are shown in FIG. 16A, and SpikeWT-specific IgG titers (fold change over vaccine response) are shown in FIG. 16B. The IgG titer retention in elderly mice as a ratio of the corresponding treatment group in the young mice is shown in FIG. 16C. The mice receiving the conjugate, MPL in addition to the antigen (spikeWT) produced the highest IgG titers (FIG. 16A) and the most SpikeWT-specific IgG. Animals receiving the conjugate in addition to the antigen produced the next highest IgG titers and SpikeWT-specific IgG, followed by MPL, CpG, and then antigen only treatment groups. For each treatment group, the young mice produced more of the measured antibodies than their elderly mice counterparts. Elderly mice receiving the conjugate either with antigen alone or in combination with MPL consistently exhibited higher IgG titers than youth mice receiving CpG or MPL adjuvants. This suggests that the observed rejuvenation of the elderly response is dependent on the B cell conjugate. B. Th1 Response

[0279] The serum from the young and elderly mice from part A was also analyzed for Th1 phenotype as described in Example 7. As shown in FIG. 17, the combination of B-cell- targeting conjugate, spike antigen, and MPL induced the highest levels of IgG2a and IgG2b antibodies. Further, the triple combination restores the IgG2a and IgG2b responses in elderly mice to those observed from the young mice treated with conjugate alone or in combination with MPL. Mice treated with the spike antigen and MPL alone exhibited higher levels of IgG1, in young and elderly mice, than were observed for the spike antigen and B-cell-targeting conjugate or the triple combination. C. Antigen Neutralization

[0280] Day 29 and Day 67 sera were assessed for SpikeWT (SARS-CoV-2 WT) inhibition using the Inhibitor Screening Kit from ACRO Biosystems according to manufacturer’s instruction. Briefly, diluted samples were added to microplates pre-coated with human ACE2 protein followed by the addition of HRP-SARS-CoV-2 Spike RBD. After 1 hour incubation, the wells were washed and 100µL TMB substrate was added for 20 minutes at 37°C. Reactionwas terminated with 50µL stop solution and read at 450nm (SpectraMax I3, Molecular Devices).

[0281] Elderly and youth mice treated with SpikeWT in combination with conjugate and MPL (triple combination) showed most potent neutralization of SARS-CoV2 as demonstrated in FIG.18. The elderly response of mice treated with the triple combination was rejuvenated to that observed for single treatment (conjugate or MPL) youth Spike neutralization levels. Conjugate treated mice consistently had higher neutralization titers compared to CpG and MPL treatment groups in both youth and elderly cohorts. The SpikeWT antigen alone did not provide any neutralization activity in the elderly cohort and minimal activity in the youth cohort.

[0282] Functional characterization of the elderly response reveals synergistic effects in the elderly cohort with the combination of conjugate, MPL and SpikeWT antigen. The potency of this response is restorative to youth levels indicating that this triple combination can provide functional protection to these mice that are known to have otherwise compromised or aged immune system. Triple combination in the youth cohort also demonstrates most potent neutralization titer as evidenced by additive effects between MPL and CD22-CpG conjugate. D. Memory Recall

[0283] On Day 64, the mice from part A were challenged with injection of SpikeWT or 50 µg of the omicron variant of the SARS-CoV-2 spike protein (ACRO Biosystems) to test the memory response following the various treatments. On Day 67, the IgG EC50 responses to the WT spike protein (FIG. 19A) and the Omicron Spike protein (FIG.19B) were determined.

[0284] As shown in FIG.19A, the triple combination generated a robust primary response that resulted in highest levels of long-term titers as well as the most robust memory response to the WT spike protein in young mice. The triple combination also restored the response of the elderly mice to levels similar to those observed for the young mice receiving the conjugate and antigen alone. The persistent titers pre challenge as well as the memory recall generated by treatments employing the B-cell-targeting conjugate were unmet by any of the other treatments, suggesting an essential role for the B-cell engagement of the conjugate for the observed response. As shown in FIG.19B, there was little memory recall to the omicron Spike protein in any of the treatment conditions suggesting that the cross-reactive response is primarily coming from the Long Lived Plasma Cell (LLPC) compartment rather than memory B cells. Groups treated with the conjugate and antigen alone or in combination with MPL maintain enduring titers to both WT spike protein and to omicron spike protein 7 weeks postlast treatment suggesting LLPC compartment is well established in both elderly and youth mice. In the elderly cohort in particular these data indicate rejuvenation of the functional responses of the LLPC’s and memory immune responses. FIG.19C shows an overview of the antibody responses. The overview includes the primary response (Day 14 and Day 29), the LLP signal from persistent titers (Day 59), and the memory recall, post-challenge, observed on Day 67. E. ACE2 inhibition in memory recall

[0285] Serum collected from mice on sacrifice day 67 were assayed for spikeWT inhibition using methods previously described in Section C. As shown in FIG. 20, in elderly mice, only mice receiving the conjugate retained neutralizing activity (left panel). For young mice, mice receiving the conjugate retained superior neutralization activity compared to mice receiving only the SARS-CoV-2 spike protein (right panel). Example 9: Specificity of immune response

[0286] In a further study, young Balb / c mice (aged 7-8 weeks), sourced from Charles River (Wilmington, MA), were immunized and treated with unconjugated anti-mCD22 antibody (TNT28), MPL, anti-mCD22 CpG conjugate (CD22TRAAC; TNT50a), TNT50a and MPL, or non-binding anti-hCD22 CpG conjugate (NB TRAAC; TNT126a) as described in Example 6. On Day 28 of the study, the IgG responses to alpha, beta, gamma, delta, eta, kappa, lambda, omicron, and wild-type (WT) COVID-19 spike variants were measured.

[0287] As shown in FIG. 21, the mice administered the combination treatment of the antigen, B-cell-targeting conjugate, and MPL retained highest IgG titers across various COVID-19 spike variants closely followed by the group treated with antigen and conjugate alone. The triple combination however had the most homogeneous responses between all mice within the cohort as demonstrated by lowest standard deviation. Example 10: Synergistic anti-tumor activity of a B-cell-targeting conjugate in combination with a tumor-associated antigen and adjuvant

[0288] 6-week-old Balb / c mice (Charles River, Wilmington, MA) were implanted with 2 x 106CT26 mouse Nectin-4 transduced cells subcutaneously in the left flank. On day 6 mice were weighed, measured and randomized according to 75mm3average tumor volume per group. On days 7 and 10 mice receiving the N4 were immunized with 50 µg human Nectin-4 (TNT175) and 25 µg mouse Nectin-4 (TNT176). On days 14 and 17 mice receiving the N4were immunized with 100µg human Nectin-4 (TNT175) and 50 µg mouse Nectin-4 (TNT176). On days 7, 10, 14 and 17 N4 immunized mice were also dosed with 2.5µg CpG 4523 (CpG), 50µg MPL or 3mg / kg CD22TRAAC (TNT50a). PBS group was treated with 100µL Phosphate Buffered Saline (Gibco) and CD22TRAAC group received only the conjugate at 3 mg / kg. Mice were measured and sacrificed according to IACUC protocol.

[0289] Mice receiving N4 in combination with suboptimal dosing of CD22TRAAC exhibited best benefit of treatment as evidenced by 40% survival probability as shown in FIG. 22. All other groups including CD22TRAAC without the N4 antigen succumbed to the tumor by day 33. Example 11: Prophylactic anti-tumor activity of a B-cell-targeting conjugate in combination with a tumor-associated antigen

[0290] In this Example, an exemplary B-cell-targeting anti-CD22 CpG conjugate was compared to a TLR4 agonist, MPL, to unconjugated CpG (CpG4523), and to antigen only (tumor-associated antigen human Nectin-4 in PBS) for induction of an antigen-specific immune response and for functional immune memory recall response to the tumor-associated antigen, Nectin-4. In this vaccination model, human Nectin-4 functions as a “mutated” endogenous mouse antigen expressed on the surface of cancer cells. The memory response was challenged twice with syngeneic tumors expressing the human Nectin-4 antigen. The first challenge occurred in young mice (age4 months). When the mice that resisted tumor growth reached 7 months of age (aged mice), the cohort was subdivided into two near equal groups to be re-challenged with a different tumor model, either expressing the same tumor-associated antigen, or the parental cancer cell line. . A schematic of the immunization and implant schedule is shown in FIG.23. A. Tumor Challenge – Youth Memory Recall

[0291] As depicted in FIG. 23, on Days 0, 7 and 14, 7-8-week-old Balb / c mice (Charles River, Wilmington, MA) were immunized with a tumor-associated antigen, human Nectin-4 (N4) by injecting a split dose (50% intraperitoneally (IP) and 50% subcutaneously (SC) of 50 ^g N4 and PBS (n=15), 0.4 mg / kg CpG (4523) (n=15) , 2.5 mg / kg TLR4 agonist MPL emulsified with squalene and TWEEN-80 in PBS (n=15), or 10 mg / kg CD22TRAAC (CD22- CpG4523, TNT50a conjugate) in PBS (n=21).

[0292] On day 70 post first immunization, 6 of the mice dosed with N4 and CD22TRAAC (N4 + CD22TRAAC (1)) were implanted with 0.6 x 106parental murine colorectal carcinoma CT26 cells and 15 of the mice dosed with N4 and CD22TRAAC were implanted with 0.6 x 106CT26 cells transduced to express human Nectin-4 (CT26-N4) (N4 + CD22TRAAC(2)), subcutaneously in the right flank. The other remaining treatment groups (CpG, MPL and controls) were also implanted with CT26-N4. Tumor volumes were measured over time for up to 32 days, and mice that grew tumors were euthanized according to IACUC protocol.

[0293] Tumor growth over time is plotted in FIG. 24. Mice immunized with N4 in combination with CD22TRAAC or CpG exhibited complete tumor growth inhibition in 15 / 15 mice. Mice that received MPL in combination with N4 also exhibited good tumor growth resistance, with 12 / 15 animals eradicating the tumor implant. Meanwhile, 13 of 15 of the mice immunized with N4 only developed tumors and were euthanized as per IACUC protocol. All of the mice that were immunized with CD22TRAAC in combination with N4 but were implanted with parental CT26 tumor cells, also developed tumors. These data suggest that the prophylactic immune response observed was specific against cells expressing the tumor- associated (N4) antigen. B. Tumor Rechallenge – Aged Memory Recall

[0294] On day 176 post first immunization, mice that resisted CT26 Nectin-4 tumor growth in part A were divided into near equal numbers between two subgroups and implanted with 5 x 105of either 4T1 murine mammary gland cancer cells or 4T1 transduced with human Nectin- 4 (4T1N4) cells, subcutaneously in the right flank to measure long-term functional memory recall to the immunized tumor-associated antigen, Nectin-4, now expressed on a different, and more immune suppressive, tumor model. Tumor volumes were measured over time, and mice were sacrificed according to IACUC protocol.

[0295] As shown in FIG.25, mice receiving N4 in combination with CD22TRAAC (N4 + CD22TRAAC) were the only group showing significant tumor growth inhibition specific to the tumor-associated antigen, human Nectin-4, indicated by the inhibition of 4T1N4 tumor growth, but not of parental 4T1 tumor growth. Mice treated with N4 in combination with CpG or MPL did not exhibit any protection from tumor rechallenge by either the parental 4T1 or 4T1N4, as their tumor growth by day 20 post implant was not significantly lower as compared to the control group, age-matched mice for both the 4T1 and 4T1 Nectin-4 tumor implants (FIG. 26). Specificity of the response is also shown in FIG. 27, as a ratio of 4T1N4 vs 4T1tumor volumes, in which the vaccine in combination with CD22TRAAC group averages 50% lower tumor volume of 4T1 Nectin-4 expressing tumors as compared to parental 4T1 across the duration of the study. Administering N4 antigen in combination with CpG showed some specificity on day 6 post 4T1N4 and 4T1 implants with 30% lower tumor volume (FIG.25 and FIG. 27). However, by the end of the study there were no significant differences observed. Lastly, administering N4 antigen in combination with MPL resulted in the least antigen- specific anti-tumor activity, as observed with no significant differences of 4T1N4 and 4T1 tumor volumes across the study (FIG.25 and FIG. 27). Therefore, only CD22TRAAC administration, in combination with the N4 antigen, could maintain antigen-specific tumor growth suppression. These data suggest that durable and functional immune memory recall is achieved, even in aged mice, that are prophylactically treated with the combination of CD22TRAAC and tumor-associated antigen, human Nectin-4. C. Antibody Titers

[0296] As shown in the schematic in FIG. 23, the mice from the above studies were bled on days 21, 68, 84, 152 and 193, and the anti-human Nectin-4 IgG antibody titers were determined as described in Example 2. Titers of anti-human Nectin-4 IgG1, IgG2a, IgG2b and IgM antibody were also measured, on serum samples from study Days 21 and 193, as described in Example 4, with the addition of anti-mouse IgM (Jackson ImmunoResearch) used at 1 / 3,000 dilution in assay diluent. ELISA was performed as described in previous Examples. Antibody titers post-immunization, pre- tumor implantation

[0297] The anti-human Nectin-4 IgG titers from study Day 21, one week after the final immunization boost, are shown in FIG.28. The treatment groups administered with the CD22 TRAAC combined with the N4 antigen (N4 + CD22TRAAC(1) [n=6] and N4 + CD22TRAAC(2) [n=15]) produced the highest IgG titers specific to the tumor-associated antigen, Nectin-4, followed by N4 + CpG, then N4 + MPL and then antigen only (N4) treatment groups.

[0298] Subtype titers from study Day 21 (after immunization and prior to first tumor cell challenge) are shown in FIGS.29A-29D. Mice administered N4 only exhibited basal titers of antigen-specific IgG1 (FIG. 29A; circles), IgG2a (FIG. 29B; circles), IgG2b (FIG. 29C; circles), and IgM (FIG. 29D; circles). Mice treated with N4 combined with MPL exhibited higher IgG1 titers (FIG. 29A; diamonds) compared to their respective IgG2a (FIG. 29B;diamonds) and IgG2b (FIG.29C; diamonds) titers and essentially showed no increase in IgM titers. Conversely, the groups receiving N4 combined with CD22TRAAC (TRAAC (1) and TRAAC (2)) or CpG had higher IgG2a (FIG.29B) and IgG2b responses (FIG.29C) compared to their respective IgG1 titers (FIG.29A). However, the groups receiving CD22TRAAC, exhibited significantly more robust and homogeneous IgG2a and IgG2b responses, and an increased IgM response (FIG.29D), as compared to any other group, including the CpG group (p<0.0001, one-way ANOVA). These trends continued through day 193 as shown in FIGS.32A-32C, with the CD22TRAAC treated mice maintaining a significantly higher IgG2a response as compared to CpG immunized mice (p= 0.0264, one-way ANOVA). These results suggest that N4 + CD22TRAAC treated mice, as compared to all other treatments in combination with the vaccine, were able to sustain the highest levels of IgG2a effector function antibody responses into aged immunological state of 7 months old. IgG2a has the most potent effector function activity of any IgG subclass in mouse (see Collins, Immunology and Cell Biology, 94(10): 949-954, 2016). Antibody titers post- tumor challenge

[0299] In addition to study Day 21, IgG titers specific to human Nectin-4 were assessed on study Day 68 (two days prior to CT26(+ / - N4) tumor cell implant), Day 84 and Day 152 (after CT26-N4 challenge but before 4T1(+ / -N4) challenge), and Day 193 (after 4T1 (+ / -N4) and end of study) to assess ongoing humoral response as well as memory recall. A summary of the anti- human Nectin-4 IgG titers is shown in FIG.30.

[0300] As shown in FIG. 30, mice receiving vaccine in combination with CD22TRAAC exhibited highest long-term antigen specific titers, followed by vaccine in combination with CpG, as observed on study day 152. Mice receiving the vaccine in combination with MPL had low levels of anti-human Nectin-4 specific IgG. This suggests a robust and durable long lived plasma cell response in mice receiving N4 + CD22TRAAC.

[0301] On study Day 193, post exposure to 4T1 and 4T1N4 tumors (and end of study), mice that had received N4 + CD22TRAAC and were implanted with tumors expressing the vaccine antigen, human Nectin-4, (N4 + CD22TRAAC - 4T1N4; FIG.30 and FIG. 31, open squares) had highest levels of circulating IgG to human Nectin-4 as compared to mice implanted with 4T1 (N4 + CD22TRAAC - 4T1; FIG. 30 and FIG. 31, closed squares), followed by mice that had received CpG (FIG. 30 and FIG. 31, open and closed triangles) or MPL (FIG. 30 and FIG. 31, open and closed diamonds). These data suggest robust memoryrecall to the vaccine antigen, human Nectin-4, post exposure in the form of a tumor-associated antigen with highest levels observed in N4 + CD22TRAAC treated animals followed by N4 + CpG respectively. Levels of anti-human Nectin-4 specific IgG for MPL treated group remained low throughout the duration of the study.

[0302] IgG subtype titers were also evaluated on study Day 193 to characterize the functionality of the antibody response post 4T1 and 4T1N4 tumor exposure (FIGS.32A-32C). As shown in FIG. 32A, IgG1 levels were similar across treatment groups. IgG2a titers remained highest in mice receiving CD22TRAAC in combination with N4 (closed and open squares), followed by mice receiving CpG + N4 (closed and open triangles). IgG2a titers were low in mice receiving MPL + N4 (closed and open diamonds) and in age-matched, non- immunized, control (closed and open circles) mice. For IgG2b, both CD22TRAAC + N4 and CpG + N4 treated groups had high levels of antibody; whereas MPL + N4 and age-matched, non-immunized, control groups did not have detectable levels. These data suggest that, in addition to humoral response, a cellular response may be involved in tumor suppression, as both CD22TRAAC and CpG groups in combination with N4 immunization have high levels of the effector function IgG subclasses IgG2a and IgG2b to the tumor-associated antigen, human Nectin-4. However, only administration of CD22TRAAC in combination with N4 immunization was able to inhibit tumor growth. Additionally, the higher IgG2a levels observed in CD22TRAAC + N4 treated mice suggest the involvement of TH1 cells, because interferon- gamma is known to induce class switching to IgG2a, a subclass associated with much stronger Fc gamma receptor activity (see e.g., Collins, Immunology and Cell Biology, 94(10): 949-954, 2016). Example 12: Immune response following administration of a B-cell targeting conjugate in combination with an MHC-I restricted antigen

[0303] An exemplary B-cell-targeting anti-CD22 CpG conjugate (CD22TRAAC) was compared with an unconjugated CpG for the in vivo induction of immune responses and ex vivo post stimulation recall of antigen-specific cellular immune responses.

[0304] Balb / c mice (aged 10-12 weeks), born in-house from pregnant mice sourced from Charles River (Wilmington, MA), were immunized on Days 0, 14 and 28 by injecting a split dose (50% intraperitoneally (IP) and 50% subcutaneously (SC)) of 50 µg KLH conjugated GP2-P4 fusion peptide (GP2-P4-KLH (SEQ ID NO: 218); LifeTein) reconstituted in 0.1 Mammonium bicarbonate then diluted in PBS (Vehicle) alone or in combination with 0.4mg / kg CpG (4523), or 10 mg / kg anti-mCD22 CpG conjugate (CD22-CpG 4523; TNT50a) in PBS. A control group of mice was also injected with vehicle alone. The mice were bled at end of in- life study day 42 and the antibody titers were determined as described in Example 7 with the exception of coating with 2 µg / mL streptavidin (source) then binding 1 µg / mL biotinylated peptide (GP2-P4; CSGSGIISAVVGILSGSGPESFDGDPASNTAPLQPEQLQ SEQ ID NO:216). Spleen and draining inguinal lymph nodes were also collected at end of in-life study day 42 and processed into single cell suspensions as described in Example 5. Splenoyctes were centrifuged, resuspended into 1 mL freeze media (10% DMSO in FBS), and frozen in cryovials at -80 °C. A. Antibody Titer

[0305] Total IgG titer and IgG subtype titers at Day 42 from mice administered vehicle, GP2-P4 antigen, GP2-P4 + CD22TRAAC, and GP2-P4+CpG are shown in FIG. 33A and FIG.33B, respectively. The results demonstrate administration of the CD22TRAAC in addition to the GP2-P4 peptide resulted in robust, increased GP2-P4-specific antibody titers compared to peptide + CpG or the peptide alone. B. Intracellular Cytokines in Draining Lymphocytes

[0306] Lymphocytes were centrifuged and resuspended into complete media (RPMI 1640, supplemented with 10% FBS, 1% Pen / Strep, 1% Glutamax, 1X MEM vitamin solution and 55 µM 2-mercaptoethanol). Lymphocyte cell counts were determined using ViCell Beckman counter and each sample was plated at 1 million cells per well for 24-hour stimulation or 500,000 cells per well for 72-hour stimulation in a 96-well flat bottom plate. Leftover cells were combined, and 4 additional wells plated for each condition to use for staining controls. Cells were then stimulated either with media control containing 25 µg / mL anti-CD28 agonistic antibody (BioLegend) or with 10 µg / mL GP2-P4 fusion peptide (SEQ ID NO: 216) and 25 µg / mL anti-CD28. Cells were incubated for either 24-hours or 72-hours at 37 °C, 5% CO2. Four hours prior to incubation end, GolgiStop (BD Bioscience) was added to the media at a final dilution of 1:1,000. Following incubation, cells were centrifuged, and the media supernatant was collected and stored at -80 °C until analysis.

[0307] Lymphocytes were resuspended in FACS buffer and transferred to a 96-well U- bottom plate. Cells were pelleted then resuspended with 50 ^L Fixable Viability Dye eFluor780 (eBioscience 65-0865-14) diluted 1:4000 in PBS and incubated at 4 ºC for 30 minutes. Cells were washed with FACS buffer then stained at 4 ºC for 45 minutes in 100 ^L FACS buffer containing mouse FcγR Blocking Reagent (Miltenyi Biotec), Brilliant Stain Buffer (BD Biosciences), anti-CD3 FITC (145-2C11), anti-CD4 PerCP-Cy5.5 (RM4-5), and anti-CD8 BV510 (53-6.7). Cells were washed with FACS buffer and fixed with Foxp3 / Transcription Factor Fixation / Permeabilization kit (eBioscience) according to manufacturer’s protocol. Cells were stained for intracellular markers with 1X permeabilization buffer containing anti- Granzyme B APC (AQ16A02), anti-TNFα BV421 (MP6-XT22) and anti-IFNγ PE (XMG1.2) for 30 minutes at room temperature protected from light. Fluorescence minus one control samples received two of the three intracellular stains (anti-TNFα BV421 and / or anti-Granzyme B APC and / or anti-IFNγ PE). Cells were washed twice with permeabilization buffer then resuspended in 100 ^L FACS buffer. Samples were acquired using an Attune NxT Flow Cytometer (Thermo Fisher) and data analyzed utilizing FlowJo®10.10 software. Results were plotted using Prism (Graphpad) software.

[0308] The intracellular IFNγ detected in lymphocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4), are shown in FIG.34A (CD8+ T cells) and FIG. 34B (CD4+ T cells). The intracellular TNFα detected in lymphocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4), are shown in FIG.35A (CD8+ T cells) and FIG.35B (CD4+ T cells). Intracellular Granzyme B in CD8+ T cells and CD4+ T cells, without (baseline) and with ex vivo peptide stimulation (GP2-P4), are shown in FIG. 36A and FIG.36B, respectively. The results show that in vivo administration of GP2-P4 peptide antigen (immune-honing agent) in addition to the CD22TRAAC resulted in a significant increase in T cell activation associated cytokines and enhanced production of cytotoxic Granzyme B in both CD4+ and CD8+ T cells upon ex vivo antigen recall (i.e., ex vivo stimulation with the antigenic GP2-P4 peptide). Mice immunized with the peptide antigen alone or peptide antigen + CpG did not produce increased responses to the antigenic peptide in ex vivo antigen recall. C. Intracellular Cytokines in Splenocytes

[0309] Previously frozen splenocytes were thawed and washed with complete media then passed through a 70 µm cell strainer. Cell counts were determined using a ViCell and plated at one million cells per well for each sample. Cells were stimulated as described above exceptthat both GP2 (CSGSGIISAVVGIL; SEQ ID NO: 217) and GP2-P4 (SEQ ID NO: 216) peptides at 10 µg / mL were used for ex vivo stimulation. Cells were cultured as above for 72- hours. Protein transport inhibitor (eBioscience) was added at a final dilution of 1:50015 hours prior to end of incubation. Cells were stained and cytokines were measured as described above.

[0310] The intracellular IFNγ detected in splenocytes from mice immunized with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with peptide ex vivo stimulation (GP2 + GP2-P4), are shown in FIG.37A (CD8+ T cells) and FIG. 37B (CD4+ T cells). The intracellular TNFα detected in splenocytes from mice treated with peptide only, peptide + CD22TRAAC, and peptide + CpG, without (baseline) and with peptide ex vivo stimulation (GP2 + GP2-P4), are shown in FIG.38A (CD8+ T cells) and FIG. 38B (CD4+ T cells). Intracellular Granzyme B in CD8+ T cells and CD4+ T cells, without (baseline) and with ex vivo peptide stimulation (GP2 + GP2-P4), are shown in FIGS. 39A and 39B, respectively. The results show that administration of GP2-P4 peptide immune-honing agent in addition to CD22TRAAC resulted in a significant increase in T cell activation associated cytokines and enhanced production of cytotoxic Granzyme B, in response to re-administration of GP2 and GP2-P4 antigenic peptides ex vivo, in both CD4+ and CD8+ T cells (i.e., ex vivo antigen recall). Mice immunized with peptide antigen alone or peptide antigen + CpG did not produce increased responses to the antigenic peptides in ex vivo antigen recall. D. Cytokine Response in Media

[0311] Thawed supernatant from lymphocyte and splenocyte cultures, and serum collected from the mice, were used to measure accumulated cytokines using BioLegend LegendPlex kits according to the manufacturer’s protocol. Beads were acquired using the Attune NxT Flow Cytometer (Thermo Fisher) and data were analyzed using FlowJo®10 and Prism (Graphpad) software.

[0312] Total IFNγ, TNFα, IL-17A, and GM-CSF detected in lymphocyte culture media supernatant for each treatment condition, without (baseline) and with peptide ex vivo peptide stimulation (GP2-P4), are shown in FIGS.40A-40D, respectively.

[0313] Total IFNγ, TNFα, IL-17A, GM-CSF, IL-2, and IL-4 detected in splenocyte culture media supernatant for each treatment condition, without (baseline) and with peptide ex vivo peptide stimulation (GP2 + GP2-P4), are shown in FIGS.41A-41F, respectively.

[0314] An overview of the cytokine responses in media following ex vivo antigenic peptide stimulation (i.e., antigen recall) is shown in FIG.42. Example 13: Effect of SIRP^ TRAAC on Dendritic Cell Activation in PBMC Cultures

[0315] PBMCs isolated from 5-9 healthy donors were treated in vitro for 24 hours with 300 nM SIRP^ TRAAC, 300 nM unconjugated anti-SIRP^ antibody, or left untreated (media control). The cell surface expression levels of cell surface markers were analyzed by flow cytometry. CD40, CD86, and HLADR expression on dendritic cells were plotted as median fluorescent intensity, with a single line connecting treatment conditions from a same donor (FIG.43).

[0316] As shown in FIG.43, treatment with SIRP^ TRAAC elicited the maximal observed up-regulation in expression levels of co-stimulatory molecules CD40 and CD86 on total myeloid dendritic cell populations, which include SIRP^- (DC1) and SIRP^+(DC2) subsets, as compared to anti-SIRP^ antibody or media only conditions. Although the expression of HLA-DR is high on these cells, SIRP^ TRAAC induced further increase.

[0317] These data demonstrate that SIRP^ TRAAC efficiently activated human dendritic cells in PBMC cultures and promoted both antigen cross-presentation (signal 1) and up- regulation of co-stimulatory molecules (signal 2) in dendritic cells, thereby increasing their ability to prime / activate T cells. Example 14: Effect of SIRP^ TRAAC on Cytokine Production in PBMC Cultures

[0318] PBMCs isolated from 9 healthy donors were treated in vitro for 72 hours with 300 nM SIRP^ TRAAC, 300 nM unconjugated anti-SIRP^ antibody, or left untreated (media control). The concentration levels of cytokines were quantified in media supernatants using cytokine bead array and flow cytometry. FIG.44 depicts concentration levels (pg / mL) of IL- 12, IFN-γ, and IFN-^2 in cell culture supernatant. Each line represents result from a different donor.

[0319] As shown in FIG.44, SIRP^ TRAAC elicited more production of IFN^2, IFNg and IL-12, as compared to unconjugated anti-SIRP^ antibody or media only control.

[0320] These data demonstrate that SIRP^ TRAAC enhances the production of pro- inflammatory dendritic cell-derived cytokines (IFN^2, IL-12) that activate T cells (signal 3), as shown by increased levels of IFNγ.Example 15: Effect of SIRP^ TRAAC Treatment in Combination with anti-PD-1 Antibody on Inhibition of CT26-Derived Tumor Growth

[0321] The potential for increased tumor control of a combination treatment of SIRP^ TRAAC with an exemplary checkpoint inhibitor (anti-PD-1 antibody) was evaluated in CT26- derived tumors implanted in immune competent syngeneic mice. CT26 murine colorectal carcinoma cells 2x106cells in 100 µL) were subcutaneously injected into the right flank of BALB / c mice. When the tumors reached approximately 110 mm3, the mice were randomized into different treatment groups based on tumor volume and administered phosphate-buffered saline (PBS); anti-PD-1 antibody at 10 mg / kg, two times, three days apart (2q3d); SIRP^ TRAAC at 0.3 mg / kg, 2q3d; or SIRP^ TRAAC at 0.3 mg / kg and anti-PD-1 antibody at 10 mg / kg, 2q3d (n=5 / group).

[0322] As shown in FIG. 45, SIRP^ TRAAC in combination with anti-PD-1 resulted in significant tumor regression (p-value was calculated using a mixed effects analysis) not achieved by either monotherapy. Single agent SIRP^ TRAAC achieved a tumor growth inhibition (TGI) of 10.8% compared to 6.6% with anti-PD-1 monotherapy at Day 27 post- tumor implantation. However, combination therapy enhanced anti-tumor efficacy with a TGI value of 59.5 %. The in vivo activities of SIRP^ TRAAC and anti-PD1 antibody synergistically combine to inhibit CT26 tumor growth in syngeneic mice. This is evidence that SIRP^ TRAAC and anti-PD1 antibody impinge on pathways converging to enhance T cell anti-tumor activity. Example 16: Immune response following administration of a SIRPα targeting conjugate in combination with an MHC-I restricted antigen

[0323] An exemplary dendritic cell-targeting anti- SIRPα CpG conjugate (SIRPαTRAAC) was tested for the in vivo induction of immune responses and ex vivo post stimulation recall of antigen-specific cellular immune responses.

[0324] Balb / c mice (aged 10-12 weeks), born in-house from pregnant mice sourced from Charles River (Wilmington, MA), were immunized on Days 0, 14 and 28, as described in Example 12 with GP2-P4-KLH (SEQ ID NO: 218) (LifeTein) alone or in combination with 0.4mg / kg CpG (4523) or 10 mg / kg anti-SIRPα CpG conjugate (SIRPα-CpG 4523; TNT182a) in PBS. A control group of mice was also immunized with vehicle alone. The mice were bled at end of in-life study, day 42, and the antibody titers were determined as described in Example 7.CSGSGIISAVVGILSGSGPESFDGDPASNTAPLQPEQLQ (SEQ ID NO:218); N-terminal acetylation, KLH conjugation on Cys

[0325] Spleen and draining inguinal lymph nodes were collected at end of in-life study, day 42, and processed into single cell suspensions as described in Example 5. Splenoyctes were centrifuged, resuspended into 1 mL freeze media (10% DMSO in FBS), and frozen in cryovials at -80 °C. A. Antibody Titer

[0326] Total IgG titer and IgG subtype titers at Day 42 from mice administered vehicle, GP2-P4 antigen, GP2-P4 + SIRPαTRAAC, and GP2-P4 + CpG are shown in FIG. 46A and FIG.46B, respectively. The results demonstrate administration of the SIRPαTRAAC in addition to the GP2-P4 peptide resulted in robust, increased GP2-P4-specific antibody titers as compared to the peptide alone or peptide + CpG. B. Intracellular Cytokines in Draining Lymphocytes

[0327] Lymphocytes were isolated, stimulated with media control containing 25 µg / mL anti-CD28 agonistic antibody (BioLegend) or with 10 µg / mL GP2-P4 fusion peptide and 25 µg / mL anti-CD28, stained, and analyzed by flow cytometry as described in Example 12.

[0328] The intracellular IFNγ detected in lymphocytes from mice immunized with peptide only, peptide + SIRPαTRAAC, and peptide + CpG, without (baseline) and with ex vivo peptide stimulation (GP2-P4), are shown in FIG.47A (CD8+ T cells) and FIG. 47B (CD4+ T cells). Intracellular Granzyme B in CD8+ T cells and CD4+ T cells, without (baseline) and with ex vivo peptide stimulation (GP2-P4), are shown in FIG. 48A and FIG. 48B, respectively. The results show that in vivo administration of GP2-P4 peptide antigen (immune-honing agent) in addition to the SIRPαTRAAC resulted in a significant increase in T cell activation associated cytokines and enhanced production of cytotoxic Granzyme B in both CD4+ and CD8+ T cells upon ex vivo antigen recall (i.e., ex vivo stimulation with the antigenic GP2-P4 peptide). Mice immunized with the peptide antigen alone or peptide antigen + CpG did not produce increased responses to the antigenic peptide in ex vivo antigen recall. C. Intracellular Cytokines in Splenocytes

[0329] Previously frozen splenocytes were thawed, stimulated with GP2 (SEQ ID NO: 217) and GP2-P4 (SEQ ID NO: 216) peptides, and assessed for intracellular cytokines as described in Example 12.

[0330] The intracellular IFNγ detected in splenocytes from mice treated with peptide only, peptide + SIRPαTRAAC, and peptide + CpG, without (baseline) and with peptide ex vivo stimulation (GP2 + GP2-P4), are shown in FIG.49A (CD8+ T cells) and FIG. 49B (CD4+ T cells). Intracellular Granzyme B in CD8+ T cells and CD4+ T cells, without (baseline) and with ex vivo peptide stimulation (GP2 + GP2-P4), are shown in FIG. 50A and FIG. 50B, respectively. The results show that administration of SIRPαTRAAC in addition to the antigenic GP2-P4 peptide immune-honing agent resulted in increased levels of IFNγ and Granzyme B in splenic T cells. D. Cytokine Response in Media

[0331] Accumulated cytokines were measured in the thawed supernatant reserved from the lymphocytes and splenocytes as described in Example 12.

[0332] Total IFNγ, IL17A, and GM-CSF detected in lymphocyte culture media supernatant for each treatment condition, without (baseline) and with peptide ex vivo peptide stimulation (GP2-P4), are shown in FIGS.51A-51C, respectively.

[0333] Total IL17A detected in splenocyte culture media supernatant for each treatment condition, without (baseline) and with peptide ex vivo peptide stimulation (GP2 + GP2-P4), are shown in FIG.52.

[0334] An overview of the cytokine responses in media following ex vivo antigenic peptide stimulation (i.e., antigen recall) is shown in FIG.53. Example 17: Specificity of induced cytokine and Granzyme B response

[0335] To test the specificity of the ex vivo cytokine and granzyme B recall response to antigenic peptide observed in Examples 12 and 16, splenocyte samples from Examples 12 and 16 were stimulated with a control peptide (not used in the immunization), AH1 (H - SPS YVY HQF – OH; SEQ ID NO: 219) (Anaspec) at 10 µg / mL with 25 µg / mL anti-CD28 with its own media control groups. Cells were cultured as described above for 72-hours. Protein transport inhibitor (eBioscience) was added at a final dilution of 1:500 15 hours prior to incubation ending. Cells were stained and cytokines were measured as described above.

[0336] As shown in FIGS. 54A-54D, no significant changes were observed in IFNγ, TNFα, IL-17A, or GM-CSF in the media of splenocytes in response to the AH1 peptide. Similarly, no significance changes were observed in intracellular IFNγ or Granzyme B (GZMB) in CD8+ T cells in response to the AH1 peptide (FIGS.55A & 55B). These results indicate the increase in T cell cytotoxic markers observed in Examples 12 and 16 were specific to the immune-honing agent, as they were not observed when the splenocytes were introduced to a different peptide. Example 18: mRNA uptake and antigen presentation of CD22 TRAAC stimulated B cells

[0337] In this Example, purified CD19+ B cells from naïve mouse splenocytes were co- incubated with LNP-encapsulated mRNA with increasing concentrations of CD22TRAAC, CpG, or media only to evaluate changes in expression levels of CD86, CD40, and MHCII and MHC I-restricted presentation of the peptide encoded by the mRNA.

[0338] Full length chicken Ovalbumin (OVA) mRNA (VERNAL Bioscience, VT) was encapsulated into lipid-based nanoparticles using Lipofectamine MessengerMAX (Invitrogen) according to manufacturer’s instructions. Briefly, 6.15 ^L MessengerMAX reagent was diluted in 205 ^L Opti-MEM medium (Gibco) and vortexed 2-3 seconds.8.2 ^g of OVA mRNA was diluted into 205 ^L Opti-MEM medium, mixed well then combined in a ratio of 1:1 with diluted Lipofectamine MessengerMAX reagent and incubated for 5 minutes are room temperature. Ten ^L per well of the resulting mRNA-lipid complex was added to purified B cells from previous section. Negative control wells received 10 ^L Opti-MEM media instead of mRNA-LNP. CD22TRAAC was diluted 5-fold (final concentration of 100-0.00128 nM) and unconjugated CpG (CpG4523) was diluted 5-fold (1000 nM-0.0128 nM). Fifty ^L of either titrated CD22TRAAC, titrated CpG, or media control were added to wells treated with LNP mRNA-OVA. Wells were topped off with 40 ^L media for a final volume of 200 ^L per well. Plates were incubated for 24 or 48 hours at 37 °C, 5% CO2.

[0339] Cells were pelleted by centrifugation, media supernatant was collected and stored at -80 °C. Cells were resuspended in FACS buffer (PBS with 0.5% BSA) and transferred to a 96-well U-bottom plate. Cells were pelleted then resuspended with 50 ^L Fixable Viability Dye eFluor 780 (ebioscience 65-0865-14) diluted 1:4000 in PBS and incubated at 4 ºC for 30 minutes. Cells were washed with FACS buffer then stained at 4 ºC for 45 minutes in 100 ^L FACS buffer containing mouse FcR Blocking Reagent (Miltenyi Biotec), Brilliant Stain Buffer (BD Biosciences), anti-B220 FITC (Clone RA3-6B2), anti-CD86 APC (Clone GL-1),anti-MHC-II BV510 (Clone M5 / 114.15.2), anti-CD40 SB780 (Clone 1C10) and anti-H-2Kb- SIINFEKL PE (Clone 25-D1.16). Cells were washed twice in FACS buffer and fixed overnight at 4 ºC in 100 ^L 0.5% paraformaldehyde (Electron Microscopy Sciences 15710) diluted in PBS. Samples were analyzed utilizing the Attune NxT Flow Cytometer (Thermo Fisher) and FlowJo® 10.10 software.

[0340] CD86, MHCII, and CD40 expression on purified CD19+ B cells from naïve mouse splenocytes at increasing concentrations of CD22TRAAC, CpG or media only are shown in FIGS. 56A-56C, respectively. These results demonstrate CD22TRAAC significantly increased MHCII, CD86 and CD40 expression in B220+ B cells in a dose-dependent manner.

[0341] FIG. 57 shows that CD22TRAAC in combination with the exemplary mRNA immune-honing agent, LNP-mRNA-OVA, induced specific MHC I-restricted antigen presentation in B220+B cells to a greater extent than CpG or media controls.

[0342] The present invention is not intended to be limited in scope to the particular disclosed embodiments, which are provided, for example, to illustrate various aspects of the invention. Various modifications to the compositions and methods described will become apparent from the description and teachings herein. Such variations may be practiced without departing from the true scope and spirit of the disclosure and are intended to fall within the scope of the present disclosure.

Claims

CLAIMS What is claimed is:

1. A method of treatment, comprising administering to a subject: (a) an effective amount of a conjugate comprising a targeting moiety that is capable of binding to the surface of an immune cell covalently linked to one or more immunomodulating oligonucleotides, and (b) an immune-honing agent (IHA).

2. The method of claim 1, wherein the immune cell is a lymphocyte; optionally wherein the lymphocyte is a B cell or an NK cell.

3. The method of claim 1, wherein the immune cell is a myeloid cell.

4. The method of claim 3, wherein the myeloid cell is selected from a monocyte, a dendritic cell, or a macrophage.

5. The method of claim 3, wherein the myeloid cell is a dendritic cell.

6. The method of any one of claims 1-5, wherein the targeting moiety comprises an antibody or an antigen binding fragment thereof.

7. The method of any one of claims 1-6, wherein the IHA comprises an antigen or a nucleic acid encoding an antigen.

8. The method of claim 7, wherein the IHA comprises nucleic acid and the nucleic acid comprises DNA, RNA or a combination thereof.

9. The method of any one of claims 1-6, wherein the IHA comprises a peptide or a cell.

10. The method of any one of claims 1-9, wherein the IHA is derived from a mammalian antigen.

11. The method of claim 10, wherein the IHA induces an immune response against a tumor cell or a cell in the tumor microenvironment.

12. The method of claim 10, wherein the IHA is derived from a tumor cell or a cell in the tumor microenvironment from the subject.

13. The method of claim 10, wherein the IHA is a tumor associated antigen.

14. The method of claim 10, wherein the IHA is derived from a tumor cell line.

15. The method of claim 10, wherein the IHA comprises an amino acid or nucleic acid sequence derived computationally.

16. The method of any one of claims 1-9, wherein the IHA is derived from a pathogen.

17. The method of claim 16, wherein the pathogen is a virus, a bacterium, a protozoon, a worm, a prion or a fungus.

18. The method of claim 16, wherein the pathogen is a virus and the IHA comprises a viral protein, a viral particle or a portion thereof.

19. The method of claim 16, wherein the pathogen is a virus and the IHA comprises a nucleic acid encoding a viral protein, a viral particle or a portion thereof.

20. The method of claim 16, wherein the pathogen is a bacterium and the IHA comprises a bacterial protein or a portion thereof.

21. The method of claim 16, wherein the pathogen is a bacterium and the IHA comprises a nucleic acid encoding a bacterial protein or a portion thereof.

22. The method of claim 16, wherein the pathogen agent is a fungus and the IHA comprises a fungal protein or a portion thereof.

23. The method of claim 16, wherein the pathogen is a fungus and the IHA comprises a nucleic acid encoding a fungal protein or a portion thereof.

24. The method of claim 16 wherein the IHA comprises a metabolite or derivative thereof.

25. The method of claim 16 wherein the IHA comprises a virus, bacterium or fungal cell.

26. The method of claim 25, wherein the virus, bacterial cell, or fungal cell is inactivated, attenuated or replication deficient.

27. The method of any of claims 1-26, wherein the treatment prevents or ameliorates the severity of a disease in the subject.

28. The method of any of claims 1-26, wherein treatment delays or prevents the progression of a disease in the subject.

29. The method of any of claims 1-26, wherein treatment prevents or delays recurrence of a disease in the subject.

30. The method of any of claims 27-29, wherein the disease is an infectious disease.

31. The method of claim 30, wherein the infectious disease is caused by a virus, a bacterium, a protozoon, a worm, a prion, a parasite, or a fungus.

32. The method of any of claims 27-29, wherein the disease is a cancer.

33. The method of claim 32, wherein the cancer is selected from the group consisting of head and neck squamous cell carcinoma (HNSCC), non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), gastric cancer, hepatocellular carcinoma (HCC), esophageal cancer, cervical cancer, cervical squamous cell carcinoma, Merkle cell carcinoma, endometrial cancer, ovarian cancer, pancreatic cancer, melanoma, cutaneous melanoma, sarcoma, colorectal cancer, breast cancer, small cell lung cancer (SCLC), cutaneous squamous cell carcinoma, and urothelial carcinoma, leukemia, lymphoma, myeloma, acute lymphoblastic leukemia (ALL), hairy cell leukemia, and diffuse large B cell lymphoma (DLBCL).

34. The method of claim 32, wherein the cancer is a solid tumor.

35. The method of claim 32, wherein the cancer is a liquid tumor.

36. The method of any one of claims 1-6, wherein the IHA comprises an allergen or portion thereof.

37. The method of claim 36, wherein the treatment induces tolerance to the allergen.

38. The method of claim 36 or claim 37, wherein the treatment reduces or ameliorates a symptom or severity of an allergic reaction of the subject.

39. The method of any one of claims 1-38, further comprising the step of administering one or more therapeutic agent(s) to the subject.

40. The method of any one of claims 1-39, wherein the IHA is administered concurrently with an adjuvant.

41. The method of claim 40, wherein the adjuvant is selected from the group consisting of Aluminum (Alum), AS01B(MPL), AS04 (MPL), MatrixMTM, and MF59.

42. The method of any one of claims 1-41, wherein the conjugate and the IHA are administered concurrently.

43. The method of any one of claims 1-41, wherein the conjugate and the IHA are administered as a single composition.

44. The method of any one of claims 1-41, wherein the conjugate and the IHA are administered separately.

45. The method of any one of claims 1-41, wherein the conjugate is administered prior to the IHA.

46. The method of any one of claims 1-41, wherein the IHA is administered prior to the conjugate.

47. The method of any one of claims 1-46, wherein the conjugate and the IHA are administered multiple times.

48. The method of any one of claims 1-47, wherein the conjugate and the IHA are administered prior to the onset or diagnosis of disease in the subject.

49. The method of any one of claims 1-47, wherein the conjugate and the IHA are administered subsequent to the onset or diagnosis of disease in the subject.

50. The method of any one of claims 1-49, wherein the IHA is re-administered to the subject subsequent to the administration of the conjugate and the IHA.

51. The method of any one of claims 1-50, wherein administration of the conjugate and the IHA produces a higher antigen-specific antibody titer as compared to administration of the IHA without the conjugate.

52. The method of any one of claims 1-51, wherein the duration of an antibody response following administration of the conjugate and the IHA is longer as compared to the duration of an antibody response following administration of the IHA without the conjugate.

53. The method of any one of claims 1-52, wherein a B-cell response is improved following administration of the conjugate and the IHA as compared to a B-cell response following administration of the IHA without the conjugate.

54. The method of claim 53, wherein the B-cell response is a memory B-cell response.

55. The method of any one of claims 1-50, wherein administration of the conjugate and the IHA produces a higher antigen-specific antibody titer as compared to administration of the IHA and an unconjugated immunomodulating oligonucleotide.

56. The method of any one of claims 1-50 and 55, wherein the duration of an antibody response following administration of the conjugate and the IHA is longer as compared to the duration of an antibody response following administration of the IHA and an unconjugated immunomodulating oligonucleotide.

57. The method of any one of claims 1-50, 55 and 56, wherein the B-cell response is improved following administration of the conjugate and the IHA as compared to the B- cell response following administration of the IHA and an unconjugated immunomodulating oligonucleotide.

58. The method of claim 57 wherein the B-cell response is a memory B-cell response.

59. The method of any one of claims 52 or 56, wherein the antibody response is an IgG response.

60. The method of any one of claims 52 or 56, wherein the antibody response is an IgM response.

61. The method of any one of claims 51 or 55, wherein the antibody titer is an IgG titer.

62. The method of any one of claims 51 or 55, wherein the antibody titer is an IgM titer.

63. The method of any one of claims 1-50, wherein the duration or magnitude of an immune cell response following administration of the conjugate and the IHA is increased as compared to the duration or magnitude of an immune cell response following administration of the IHA and an unconjugated immunomodulating oligonucleotide.

64. The method of any one of claims 1-50, wherein the duration or magnitude of an immune cell response following administration of the conjugate and the IHA is increased as compared to the duration or magnitude of an immune cell response following administration of the IHA without the conjugate.

65. The method of claim 63 or claim 64, wherein the immune cell response is mediated by an immune cell selected from the group consisting of T-cell, an NK cell, a dendritic cell, a myeloid cell and any combination thereof.

66. The method of any one of claims 63-65, wherein the immune cell response comprises at least one of activation, maturation, proliferation and cytokine production.

67. The method of any one of claims 63-65, wherein the immune cell response comprises at least one of antigen cross-presentation, up-regulation of a co-stimulatory molecule, enhanced production of a pro-inflammatory dendritic cell -derived cytokine and an increase in interferon γ.

68. The method of claim 67, wherein the co-stimulatory molecule is CD40 or CD86.

69. The method of claim 67, wherein the pro-inflammatory dendritic cell -derived cytokines is IFN^2 or IL-12.

70. The method of any one of claims 1-50, wherein a T-cell response is improved following administration of the conjugate and the IHA as compared to a T-cell response following administration of the IHA without the conjugate.

71. The method of claim 70, wherein the T-cell response comprises an activation or priming of T-cells.

72. The method of any one of claims 1-6, wherein the administration of the conjugate and the IHA to an elderly subject provides a rejuvenated immune response in the elderly subject.

73. The method of any one of claims 1-6, wherein the immune response is improved following administration of the conjugate and the IHA in an elderly subject as compared to the immune response following administration of the IHA without the conjugate.

74. The method of claim 72 or 73, wherein the elderly subject is at least 65 years old.

75. The method of any one of claims 1-6, wherein the administration of the conjugate and the IHA provides a robust immune response in a subject with a compromised or aged immune system.

76. The method of any one of claims 1-6, wherein the immune response is improved following administration of the conjugate and the IHA in a subject with a compromised or aged immune system as compared to the immune response following administration of the IHA without the conjugate.

77. The method of any one of claims 72-76, further comprising administering an adjuvant.

78. The method of any one of claims 1-77, wherein the subject is a mammal.

79. The method of any one of claims 1-77, wherein the subject is human.

80. The method of any one of claims 6-79, wherein the antibody or the antigen-binding fragment thereof is linked to one or more Q-tag peptides (Q) comprising at least one glutamine residue, and wherein each immunomodulating oligonucleotide (P) is linked to a Q-tag peptide via an amide bond with the glutamine residue of the Q-tag peptide and a linker (L) as shown in Formula (A):wherein indicates the point of attachment of each Q to the antibody or antigen binding fragment thereof.

81. The method of claim 80, wherein the Q tag peptide comprises: (a) a sequence selected from RPQGF (SEQ ID NO:47), RPQGFPP (SEQ ID NO:48), or RPQGFGPP (SEQ ID NO:49), (b) a peptide sequence comprising between 5 and 15 amino acid residues, (c) aQ-tag sequence naturally occurring within the antibody or antigen binding fragment, or (d) a sequence selected from the group consisting of SEQ ID NOs:39-55.

82. The method of claim 80 or claim 81, wherein the Q-tag peptide is linked or fused to the C-terminus of the heavy chain(s) of the antibody.

83. The method of any one of claims 80-82, wherein the antibody comprises two antibody heavy chains and two antibody light chains, and wherein one Q-tag is attached to one or both light chain(s) of the antibody.

84. The method of any one of claims 80-83, wherein the Q-tag is within the Fc domain of the heavy chain(s) of the antibody.

85. The method of any one of claims 1-84, wherein the one or more immunomodulating oligonucleotides comprises one or more CpG sites.

86. The method of claim 85, wherein the one or more immunomodulating oligonucleotides comprises at least 3 CpG sites.

87. The method of any one of claims 1-86, wherein the conjugate has a DAR of 1 or 2.

88. The method of any one of claims 1-87, wherein the one or more immunomodulating oligonucleotides comprises the structure of Formula Iwhereinindicate the points of attachment within the oligonucleotide, and wherein† indicates the point of attachment to the linker L; each T1is independently O or S; each T2is S-; T3is a group , wherein † indicates the point of attachment to a linker and wherein # indicates the point of attachment to the rest of the oligonucleotide; Z is O or S; U5’is –H or halogen; R5’is -H or methoxy;Rc1is -H or methoxy; Rg1, Rg2, Rg3, and Rg4are H; R3’is methoxy; R1is -(CH2)3-OH; R2is -H or methyl; and n is an integer from 0 to 2.

89. The method of any of claims 80-88, wherein the linker comprises a polyethylene glycol moiety or has a structure comprisingwherein m is an integer ranging from about 0 to about 50, and wherein † indicates the point of attachment to T3or P, and indicates the point of attachment to the rest of the conjugate.

90. The method of claim 89, wherein Z is S.

91. The method of claim 89, wherein Formula I comprises at least one pair of geminal T1and T2wherein T1is S and T2is S-.

92. The method of any one of claims 1-87, wherein each immunomodulating oligonucleotide independently comprises an oligonucleotide selected from Table 1:

93. The method of any one of claims 6-92, wherein the antibody or antigen binding fragment thereof is a monoclonal antibody or antigen binding fragment thereof.

94. The method of any one of claims 6-92, wherein the antigen binding fragment of the antibody is a Fab, F(ab’)2, Fab’-SH, Fv, scFv, single domain, single heavy chain, or single light chain antibody or antigen binding fragment thereof.

95. The method of any one of claims 6-94, wherein the antibody or antigen binding fragment thereof is a humanized, human, or chimeric antibody or antigen binding fragment thereof.

96. The method of any one of claims 6-95, wherein the antibody or antigen binding fragment thereof comprises an Fc region.

97. The method of claim 96, wherein the Fc region is a human Fc region selected from the group consisting of an IgG1 Fc region, an IgG2 Fc region, and an IgG4 Fc region.

98. The method of claim 97, wherein the Fc region is a wild-type human IgG1, IgG2, or IgG4 Fc region.

99. The method of any one of claims 1-98, wherein the conjugate induces activation of TLR9.

100. The method of any one of claims 6-99, wherein the antibody or antigen binding fragment of the conjugate binds to an antigen expressed on the surface of a B cell selected from the group consisting of B220 / CD45R, B7-1 / CD80, B7-2 / CD86, BCMA / TNFRSF17, BLIMP1 / PRDM1, C1q R1 / CD93, CD117 / c-kit, CD11b / Integrin alpha M, CD19, CD1c / BDCA-1, CD1d, CD20, CD21 / CD35, CD22, CD23 / Fc epsilon RII, CD24, CD25 / IL-2 R alpha, CD27 / TNFRSF7, CD30, CD34, CD37, CD38, CD40 / TNFRSF5, CD1, CD2, CD5, CD9, CD11, CD17, CD18, CD43, CD69, CD70, CD72, CD78, CD79a (Ig^), CD79b (Ig^), CD80, CD83, CD86, CD93 (C1Rqp), CD137 / 4-1BB, CD138, CD252 / OX40L, CD267, CD268 / BAFF-R, CD279 / PD1, CD319, CXCR4, CXCR5, DEP-1 / CD148, EMMPRIN / CD147, FCRL3 / FcRH3, Flt-3 / Flk-2, HLA-DR, IgM, IL-10, IL-12 R beta 2, IL-12 / IL-35 p35, IL-21, IL-21 R, IL-27 R alpha / WSX-1 / TCCR, IL-27 / IL-35 EBI3 Subunit, IL-3 R alpha / CD123, IL-4 R alpha, IL-7 R alpha / CD127, IRF4, MHC class II (I-A / I-E), Neprilysin / CD10, Pax5 / BSAP, Sca- 1 / Ly6, Siglec-2 / CD22, STAT1, STAT3, Syndecan-1 / CD138, TACI / TNFRSF13B, TGF- beta, TIM-1 / KIM-1 / HAVCR, PDL-2, Pax-5, IgD, IgM, Notch 2, and TLR4.

101. The method of claim 100, wherein the antigen expressed on the surface of a B cell is human CD22 (hCD22) or CD79b.

102. A composition for treating, delaying progression, ameliorating or preventing a proliferative disease or an infectious disease in a subject comprising: (a) an effective amount of a conjugate comprising a targeting moiety that is capable of binding to the surface of an immune cell covalently linked to one or more immunomodulating oligonucleotides, and (b) an immune-honing agent (IHA).

103. The composition of claim 102, wherein the immune cell is a B cell.

104. The composition of claim 102, wherein the immune cell is a myeloid cell.

105. The composition of claim 104, wherein the myeloid cell is selected from a monocyte, a dendritic cell, a macrophage, or an NK cell.

106. The composition of claim 104, wherein the myeloid cell is a dendritic cell.

107. The composition of any one of claims 102-106, wherein the targeting agent is an antibody or an antigen binding fragment.

108. The composition of claim 107, wherein the antibody or antigen binding fragment of the conjugate binds to an antigen expressed on the surface of a B cell selected from the group consisting of B220 / CD45R, B7-1 / CD80, B7-2 / CD86, BCMA / TNFRSF17, BLIMP1 / PRDM1, C1q R1 / CD93, CD117 / c-kit, CD11b / Integrin alpha M, CD19, CD1c / BDCA-1, CD1d, CD20, CD21 / CD35, CD22, CD23 / Fc epsilon RII, CD24, CD25 / IL-2 R alpha, CD27 / TNFRSF7, CD30, CD34, CD37, CD38, CD40 / TNFRSF5, CD1, CD2, CD5, CD9, CD11, CD17, CD18, CD43, CD69, CD70, CD72, CD78, CD79a (Ig^), CD79b (Ig^), CD80, CD83, CD86, CD93 (C1Rqp), CD137 / 4-1BB, CD138, CD252 / OX40L, CD267, CD268 / BAFF-R, CD279 / PD1, CD319, CXCR4, CXCR5, DEP- 1 / CD148, EMMPRIN / CD147, FCRL3 / FcRH3, Flt-3 / Flk-2, HLA-DR, IgM, IL-10, IL-12 R beta 2, IL-12 / IL-35 p35, IL-21, IL-21 R, IL-27 R alpha / WSX-1 / TCCR, IL-27 / IL-35 EBI3 Subunit, IL-3 R alpha / CD123, IL-4 R alpha, IL-7 R alpha / CD127, IRF4, MHC class II (I-A / I-E), Neprilysin / CD10, Pax5 / BSAP, Sca-1 / Ly6, Siglec-2 / CD22, STAT1, STAT3, Syndecan-1 / CD138, TACI / TNFRSF13B, TGF-beta, TIM-1 / KIM-1 / HAVCR, PDL-2, Pax-5, IgD, IgM, Notch 2, and TLR4.

109. The composition of claim 107, wherein the antibody or antigen binding fragment of the conjugate binds to human CD22 (hCD22) or CD79b.

110. The composition of claim 107, wherein the antibody or antigen binding fragment of the conjugate binds to human SIRPα.

111. The composition of any one of claims 107-110, wherein the antibody or the antigen-binding fragment thereof is linked to one or more Q-tag peptides (Q) comprising at least one glutamine residue, and wherein each immunomodulating oligonucleotide (P) is linked to a Q-tag peptide via an amide bond with the glutamine residue of the Q-tag peptide and a linker (L) as shown in Formula (A):wherein indicates the point of attachment of each Q to the antibody or antigen binding fragment thereof.

112. The method of claim 111, wherein the Q tag peptide comprises: (a) a sequence selected from RPQGF (SEQ ID NO:47), RPQGFPP (SEQ ID NO:48), or RPQGFGPP (SEQ ID NO:49), (b) a peptide sequence comprising between 5 and 15 amino acid residues, (c) a Q-tag sequence naturally occurring within the antibody or antigen binding fragment, or (d) a sequence selected from the group consisting of SEQ ID NOs:39-55.

113. The composition of claim 111 or claim 112, wherein the Q-tag peptide is linked or fused to the C-terminus of the heavy chain(s) of the antibody.

114. The composition of any one of claims 111-113, wherein the antibody comprises two antibody heavy chains and two antibody light chains, and wherein one Q-tag is attached to one or both light chain(s) of the antibody.

115. The composition of any one of claims 111-113, wherein the Q-tag is within the Fc domain of the heavy chain(s) of the antibody.

116. The composition of any one of claims 102-115, wherein the one or more immunomodulating oligonucleotides comprises one or more CpG sites.

117. The composition of claim 116, wherein the one or more immunomodulating oligonucleotides comprises at least 3 CpG sites.

118. The composition of any one of claims 102-117, wherein the conjugate has a DAR of 1 or 2.

119. The composition of any one of claims 102-118, wherein the one or more immunomodulating oligonucleotides comprises the structure of Formula Iwhereinindicate the points of attachment within the oligonucleotide, and wherein† indicates the point of attachment to the linker L; each T1is independently O or S; each T2is S-; T3is a group , wherein † indicates the point of attachment to a linker and wherein # indicates the point of attachment to the rest of the oligonucleotide; Z is O or S; U5’is –H or halogen; R5’is -H or methoxy;Rc1is -H or methoxy; Rg1, Rg2, Rg3, and Rg4are H; R3’is methoxy; R1is -(CH2)3-OH; R2is -H or methyl; and n is an integer from 0 to 2.

120. The composition of claim 119, wherein the linker comprises a polyethylene glycol moiety or has a structure comprising, wherein m is an integer ranging from about 0 to about 50, and wherein † indicates the point of attachment to T3or P, and indicates the point of attachment to the rest of the conjugate.

121. The composition of claim 119, wherein Z is S.

122. The composition of claim 119, wherein Formula I comprises at least one pair of geminal T1and T2wherein T1is S and T2is S-.

123. The composition of any one of claims 102-118, wherein each immunomodulating oligonucleotide independently comprises an oligonucleotide selected from Table 1:

124. The composition of any one of claims 107-123, wherein the antibody or antigen binding fragment thereof is a monoclonal antibody or antigen binding fragment thereof.

125. The composition of any one of claims 107-123, wherein the antigen binding fragment of the antibody is a Fab, F(ab’)2, Fab’-SH, Fv, scFv, single domain, single heavy chain, or single light chain antibody or antigen binding fragment thereof.

126. The composition of any one of claims 107-125, wherein the antibody or antigen binding fragment thereof is a humanized, human, or chimeric antibody or antigen binding fragment thereof.

127. The composition of any one of claims 107-126, wherein the antibody or antigen binding fragment thereof comprises an Fc region.

128. The composition of claim 127, wherein the Fc region is a human Fc region selected from the group consisting of an IgG1 Fc region, an IgG2 Fc region, and an IgG4 Fc region.

129. The composition of claim 127, wherein the Fc region is a wild-type human IgG1, IgG2, or IgG4 Fc region.

130. The composition of any one of claims 102-129, wherein the IHA comprises an antigen or a nucleic acid encoding an antigen.

131. The composition of claim 130, wherein the IHA comprises nucleic acid and the nucleic acid comprises DNA, RNA or a combination thereof.

132. The composition of claim 131, wherein the IHA comprises an amino acid or nucleic acid sequence derived computationally.

133. The composition of any one of claims 102-132, wherein the IHA is derived from a mammalian antigen.

134. The composition of claim 133, wherein the IHA is derived from a tumor cell or a cell in the tumor microenvironment from the subject.

135. The composition of claim 133, wherein the IHA is a tumor associated antigen.

136. The composition of claim 133, wherein the IHA is derived from a tumor cell line.

137. The composition of any one of claims 102-132, wherein the IHA is derived from a pathogen.

138. The composition of claim 137, wherein the pathogen is a virus, a bacterium, a protozoon, a worm, a prion, a parasite, or a fungus.

139. The composition of claim 137, wherein the pathogen is a virus and the IHA comprises a viral protein, a viral particle or a portion thereof.

140. The composition of claim 137, wherein the pathogen is a virus and the IHA comprises a nucleic acid encoding a viral protein, a viral particle or a portion thereof.

141. The composition of claim 137, wherein the pathogen is a bacterium and the IHA comprises a bacterial protein or a portion thereof.

142. The composition of claim 137, wherein the pathogen is a bacterium and the IHA comprises a nucleic acid encoding a bacterial protein or a portion thereof.

143. The composition of claim 137, wherein the pathogen agent is a fungus and the IHA comprises a fungal protein or a portion thereof.

144. The composition of claim 137, wherein the pathogen is a fungus and the IHA comprises a nucleic acid encoding a fungal protein or a portion thereof.

145. The composition of claim 137, wherein the IHA comprises a metabolite or derivative thereof.

146. The composition of claim 137, wherein the IHA comprises a virus, bacterium or fungal cell.

147. The composition of claim 146, wherein the virus, bacterial cell, or fungal cell is inactivated, attenuated or replication deficient.

148. The composition of any one of claims 102-147, further comprising an adjuvant.

149. The composition of claim 148, wherein the adjuvant is selected from the group consisting of Aluminum (Alum), AS01B (MPL), AS04 (MPL), MatrixMTM, and MF59.

150. The composition of any of claims 102-149 for use in the treatment of a disease, wherein the composition prevents or ameliorates the severity of the disease in the subject.

Citation Information

Patent Citations

  • Immunoregulatory vaccine

    WO2014009209A2

  • A medicament for use in a method of inducing or extending a cellular cytotoxic immune response

    WO2015140175A1

  • Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use

    WO2018189382A1

  • Transglutaminase-mediated conjugation

    WO2021174091A1

  • SIRP-alpha antibodies and conjugates

    WO2023028511A1

Cited By

  • Methods of treating cancer using Anti-CD22 antibody oligonucleotide conjugates

    WO2025081048A1